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ABSTRACT 
Inhibition of Breast and Prostate Cancer Cell Growth by 3,3’-Diindolylmethane 
and Related Compounds.  (December 2006) 
Leela Kotha, B.S., St. Xavier’s College; 
M.S., Bombay University 
Chair of Advisory Committee:  Dr. Stephen Safe 
  
Selective receptor modulators have been developed for steroid hormone 
receptors as a new class of mechanism-based drugs for treatment of hormone 
related diseases.  We investigated an alternative mechanism-based strategy for 
treating various cancers with selective aryl hydrocarbon receptor modulators 
(SAhRMs), such as  diindolylmetane/(DIM), 2,3,7,8-tetrachlorodibenzo-p-
dioxin/(TCDD), and 6-6-methyl-1,3,8-trichlorodibenzofuran/(MCDF) that exhibit 
antiproliferative activity in several cancer cell lines.  MDA-MB-453 and BT-474 
are estrogen receptor/(ER) negative breast cancer cell lines that express a 
functional aryl hydrocarbon receptor/(AhR) and treatment with SAhRMs 
significantly inhibited MDA-MB-453/BT-474 cell proliferation but did not 
significantly affect the percent distribution of cells in G0/G1/S/G2/M phases of 
cell cycle.  TCDD and the SAhRMs had minimal effects on the expression of 
various cellular kinases.  These data coupled with results obtained for other 
activated kinase pathways demonstrate that TCDD and SAhRMs uniquely inhibit 
growth of ER-negative MDA-MB 453/BT-474 breast cancer cells through kinase-
 iv 
independent pathways.  However, the SAhRMs induced  HES-1, an 
antiproliferative transcription factor, in both cell lines and this might represent a 
possible mechanism for the growth inhibitory effects observed with these 
compounds. 
 We proved that ring substituted DIMs exhibit androgenic/antiandrogenic 
activities in androgen receptor/(AR)-positive LNCaP/22RV1 prostate cancer cell 
lines resulting in antiproliferative activities.  These antiproliferative activities were 
accompanied by antiandrogenic activity and structure-dependent down 
regulation of AR.  The ring-substituted DIMs also induced both non-steroidal 
anti-inflamatory drug-induced gene-1/(NAG-1) and activating transcription factor 
3/(ATF-3), two anti-proliferative/apoptotic genes which are responsible in part for 
the inhibitory effects of these compounds on the proliferation of prostate cancer 
cells. 
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CHAPTER I 
 
INTRODUCTION 
 
1.1  Cancer             
1.1.1  Statistical data 
Cancer is the second leading cause of premature death in the world and 
cancer mortality rates are the second only to heart disease.  According to the 
global cancer statistics it is estimated that 10.9 million new cases, 6.7 million 
deaths and 24.6 million people are living with cancer within 5 years of diagnosis 
in the year 2002 (1).  Lung cancer is the main cancer in the world today, both in 
the number of cases (1.35 million) and deaths (1.18 million) and it has the 
highest fatality rate at 0.87 (1).  Breast cancer, the second most common cancer 
overall with 1.15 million new cases annually ranks 5th in mortality since it has 
relatively good prognosis after treatment.  Breast cancer is the most prevalent 
disease of women in the world with an estimated 4.4 million survivors living up to 
5 years after diagnosis and this disease was responsible for 411,000 deaths in 
year 2002  (1).  There are 934,000 cases and 700,000 deaths from stomach 
cancer and 626,000 cases and 598,000 deaths from liver cancer worldwide.  In 
men although lung cancer is the most common cancer worldwide, prostate 
cancer is ranked second with 679,000 cases and 221,000 deaths in 2002 
(Tables 1, 2) (1). 
This dissertation follows the style and format of Cancer Research. 
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Table 1.  Worldwide incidence of cancer by sex and tissue/organ site (1). 
 
 
    
INCIDENCE 
    
    
  
    
Rank CANCER SITE Males Females Total 
       
1 Lung 965,241 386,891 1,352,132 
2 Colo/rectal 550,465 472,687 1,023,152 
3 Stomach 603,419 330,518 933,937 
4 Liver 442,119 184,043 626,162 
5 Esophagus 315,394 146,723 462,117 
6 Bladder 273,858 82,699 356,557 
7 Non-Hodgkin lymphoma 175,123 125,448 300,571 
8 Leukemia 171,037 129,485 300,522 
9 Oral Cancer 175,916 98,373 274,289 
10 Pancreas 124,841 107,465 232,306 
11 Kidney 129,223 79,257 208,480 
12 Brain 108,221 81,264 189,485 
13 Melanoma of skin 79,043 81,134 160,177 
14 Larynx 139,230 20,011 159,241 
15 Thyroid 37,424 103,589 141,013 
16 Multiple myeloma 46,512 39,192 85,704 
17 Nasopharynx 55,796 24,247 80,043 
18 Hodkins lymphoma 38,128 24,111 62,239 
      
  
Female cancers 
   
  Breast  1,151,298 1,151,298 
  Cervix uteri  493,243 493,243 
  Corpus Uteri  198,783 198,783 
  Ovary  204,499 204,499 
  
Male Cancers 
   
  Prostate 679,023  679,023 
  
Testis 
 
48,613 
  
48,613 
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Table 2.  Worldwide mortality of cancer by sex and tissue/organ site (1). 
 
 
 
 
 
 
  
MORTALITY 
  
     
Rank CANCER SITE Males Females Total 
     
1 Lung 848,132 330,786 1,178,918 
2 Stomach 446,052 254,297 700,349 
3 Liver 416,882 181,439 598,321 
4 Colo/rectal 278,446 250,523 528,969 
5 Esophagus 261,162 124,730 385,892 
6 Pancreas 119,554 107,749 227,303 
7 Leukemia 125,142 97,369 222,511 
8 
Non-Hodgkin 
lymphoma 98,865 72,955 171,820 
9 Bladder 108,310 36,699 145,009 
10 Brain 80,034 61,616 141,650 
11 Oral Cancer 80,736 46,723 127,459 
12 Kidney 62,696 39,199 101,895 
13 Larynx 78,629 11,327 89,956 
14 Multiple myeloma 32,696 29,839 62,535 
15 Nasopharynx 34,913 15,419 50,332 
16 Melanoma of skin 21,952 18,829 40,781 
17 Thyroid 11,297 24,078 35,375 
18 Hodkins lymphoma 14,460 8,352 22,812 
     
 
Female cancers 
   
 Breast  410,712 410,712 
 Cervix uteri  273,505 273,505 
 Ovary  124,860 124,860 
 Corpus Uteri  50,327 50,327 
 
Male Cancers 
   
 Prostate 221,002  221,002 
 
Testis 
 
8,878 
  
8,878 
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1.1.2  Stages of carcinogenesis 
All cells undergo complex changes in response to hormones, growth 
factors, cellular regulatory molecules and environmental insults.  Cells divide, 
differentiate, some secrete milk proteins while others secrete hormones 
essential for the maintenance of the homeostasis and eventually  all cells are 
destined to the same common event leading to death or apoptosis.  The etiology 
of any cancer involves a complex interplay of genetic, hormonal and dietary 
factors.  Initiation of a tumor cell is often attributed to irreversible damage or 
mutations caused to the DNA and this DNA damage can be induced by 
carcinogens such as tobacco smoke, synthetic chemicals, endogenous 
biochemicals, ionizing radiation, electromagnetic fields and viruses. 
There are more than 100 distinct types of cancer and they all have 
acquired unregulated proliferative capabilities and the ability to disperse and 
metastasize from the original tumor to distal sites.  Carcinogenesis is a 
multistage, multimechanism, process consisting of a single cell that has been 
irreversibly blocked from terminal differentiation (Figure 1).  The initiation step 
which may be irreversible, can be triggered by a single exposure to a certain 
physical or chemical agent.  Initiated cells may not produce a cancer during the 
lifetime of the organism, but sustained exposure to a non-carcinogenic agent or  
 5 
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Figure 1.  Stepwise malignant progression of human cancer  (2, 3). 
 
 
promoters can give rise to a tumor.  Tumor promotion is potentially reversible as 
DNA damage could be repaired or it could result in clonal expansion of the 
initiated cell by a combination of growth stimulation and inhibition of apoptosis.  
Tumor promotion depends on sustained exposure to noncarcinogenic, and 
nonmutagenic agents or promoters such as phenobarbital, DDT, phorbol ester, 
and polybrominated biphenyls (4-6).  In the promotion stage a single initiated cell 
undergoes clonal expansion and selective proliferation while simultaneously the 
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cell is prevented from undergoing apoptosis.  The expanded initiated cell 
acquires sufficient mutations and epigenetic alterations to become growth 
stimulus independent and resistant to growth inhibitors and apoptosis which 
marks the progression stage of cancer (4, 7, 8). 
 
1.1.3  Physiological alteration of cancer cells 
 Essentially all cancer cell genotypes are due to the manifestation of six 
critical alterations in cell physiology that collectively dictate uncontrolled 
malignant growth (8, 9)  (Figure 2).  These alterations include self-sufficiency in 
growth signals,  insensitivity to growth inhibitory signals, evasion of programmed 
cell death/apoptosis, limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (8, 9). 
 
1.1.3.1  Self sufficiency in growth signals 
 Normal and neoplastic cells differ in their dependence on mitogenic 
stimulation. The proliferation of normal cells requires the presence of 
extracellular growth factors whereas cancer cells have reduced dependence on 
external mitogenic stimulation (8-10).  Cancer cells constitutively over-express 
growth factors and oncogenes that generate  mitogenic signals; for example,  
growth factors like  platelet-derived growth factor (PGDF) and transforming 
growth factor (TGFα ) are  highly expressed in glioblastomas and sarcomas (8, 
9).  In addition, membrane receptors such as epidermal growth factor receptors 
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(EGF-R/erbB2) and HER2/neu are also over-expressed and this enhances 
sensitivity to ambient levels of growth factors that normally would not trigger cell 
proliferation  (2, 8). Tumors of the stomach, brain and breast  over express the 
EGF-R/erbB2 while stomach and mammary carcinomas over express HER2/neu 
receptors(8).  In addition ligand independent activation of growth factor receptors 
is frequently observed due to alterations in the receptors such as the truncated 
version of the EGF-R which  lacks the cytoplasmic domain and is constitutively 
active (8, 9). 
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Figure 2. Acquired capacities of cancer cells (8). 
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Activation of oncogenes also enhances constitutive mitogenic signals.   K-
Ras mutations are highly prevalent in lung pancreatic and colon cancers and 
mutations in B-Raf protein are found in up to 66% of melanomas (11, 12).   Ras 
activates a cascade of serine-threonine kinases like MEK, culminating in the 
activation of mitogen-activated protein kinase (MAPK) which in turn moves to the 
nucleus, and phosphorylates  transcription factors responsible for genes 
involved in cell growth and survival (8, 9). 
 
1.1.3.2  Insensitivity to antigrowth signals 
Antigrowth signals can block proliferation by two distinct mechanisms.  
Cells may be forced out of the active proliferative cycle into the quiescent G0 
state from which they may re-emerge at a later time, or they may enter into a 
postmitotic differentiation state.  Many of the antiproliferative signals are 
regulated by the retinoblastoma (pRB) protein and its two related proteins p107 
and p130.  Hyperphosphorylated pRB blocks proliferation by sequestering E2F 
transcription factors that control expression of genes essential for progression 
from G1 to S phase (13). In many cancers such as retinoblastomas, 
osteosarcomas, cervical carcinomas and breast cancer, the pRB protein is not 
expressed because of mutations that disable the RB gene.  Analysis of 
inactivating mutations in the RB gene indicated that most are the result of C-T 
transitions at CpG dinucleotides (CpG islands).  These recurrent mutations may 
be a result of the deamination of 5-methylcystine within these CpG islands.  
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Many of these mutations result in truncated proteins as a result of premature 
termination of protein synthesis either through introduction of chain termination 
sequences or altered splice sites resulting in changes in  the mRNA processing  
(14, 15).  In cervical carcinomas, the pRB protein is sequestered and tagged for 
degradation by the E7 oncoprotein of type 16 and 18 human papillomaviruses  
(9, 16). 
 
1.1.3.3  Evading apoptosis 
  Resistance to apoptosis can be acquired by cancer cells through a variety 
of changes.  The functions of the p53 tumor suppressor gene which monitors 
stress and directs the cell toward an appropriate repair response are mutated in 
many tumors.   p53 is responsive to many signals  including anoxia, insufficiency 
of nucleotides for DNA synthesis,  inappropriate activation of oncogenes, and 
DNA lesions  such as  single stranded breaks and covalent adducts (17) .   Loss 
of p53 function is observed in more than 70% of all human carcinomas, and 
results in the loss of a key  DNA damage sensor that  induces the apoptotic 
effector caspases (18).  Analysis of p53 mutations has revealed hot spots which 
are localized to exons III, IV, V which encode for regions of the protein involved 
in DNA binding  (17, 19).    Within these exons are hotspot codons  157, 245, 
248 and 273  which harbor CpG sites that are highly susceptible to  DNA adduct 
formation (20-22). 
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1.1.3.4  Limitless replication potential 
The ends of chromosomes, telomeres, act as counting devices for 
determining the number of cell generations.  In 1978, Elizabeth Blackburn, 
working with the ciliated protozoan, Tetrahymena, found that telomeres consist 
of  simple hexameric repeats of nucleotides TTGGGG (23).  These telomeres 
are composed of several thousand repeats of these short 6 base-pair sequences  
and 50-100 repeats are lost every generation resulting in eventual exposure of 
chromosomal DNA due to lack of protection by telomeres. The unprotected 
chromosomal ends give rise to end-to-end chromosomal fusions, yielding the 
karyotypic disarray associated with cellular crises which trigger  apoptosis or 
removal of the damaged cell  (8, 24).  To overcome this flaw, most human 
malignancies have telomerase activity in order to maintain telomerase length.  
Telomerase is an enzyme which adds hexanucleotide repeats onto the ends of 
chromosomes and thus permits unlimited multiplication of cancer cells.  The 
extent of activation seems to be positively correlated with the aggressiveness of 
the disease;  98% of small cell lung carcinomas, 100% of invasive breast 
carcinomas, 70% of ductal carcinomas over-express telomerase activity (17).  
Moreover, ectopic expression of telomerase in presenescent cells renders them 
immortal  (25, 26).  Homozygous knockout mice of the cell cycle inhibitor p16 
are tumor prone, particularly when exposed to carcinogens, and the tumors that 
arise have increased telomerase activity.  However when carcinogens were 
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applied to mice that lacked telomerase activity, tumor incidence was reduced 
(27). 
  
1.1.3.5  Sustained angiogenesis 
 Tumor growth is blocked when it reaches a 2 mm diameter unless 
adequate blood supply is provided.  To overcome this deficit, tumors acquire 
elevated angiogenic activity to achieve greater access to the circulatory system.  
Tumors release many angiogenic signals, which attract and stimulate endothelial 
cells (9). Examples of angiogenesis initiating signals are vascular endothelial 
growth factor (VEGF) and fibroblast growth factors 1 and 2 (FGF1/2) which bind 
to transmembrane tyrosine kinase receptors on the surface of the newly 
recruited endothelial cells.  (8).  The VEGF gene is also under transcriptional 
control of the Ras oncogene, hence activation of the Ras oncogene results in 
up-regulation of the VEGF gene.  Cancer cells express higher levels of 
angiogenic factors such as VEGFs and FGF in combination with down regulation 
of expression of inhibitors of angiogenesis such as thrombospondin-1 than 
compared to normal cells (8, 28, 29). 
 
1.1.3.6  Ability to invade and metastasize 
Primary human tumors acquire the ability to invade to other tissues and 
metastasize to form secondary tumors (2, 8).  Several proteins involved in the 
tethering of cells to their surrounding tissue are altered in cells possessing 
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invasive capabilities.  These affected proteins include cell-cell adhesion 
molecules (CAMs) notably members of the immunoglobulin and calcium 
dependent cadherin families, both of which mediate cell-to-cell interactions 
which link cells to extracellular matrix substances.  The most widely observed 
alteration in cell-to-environment interactions in cancer involves E-cadherin, a 
homotypic cell-to-cell interaction molecule ubiquitously expressed on epithelial 
cells.  Coupling of adjacent cells by E-cadherin conveys anti-growth and other 
signals via cytoplasmic contact with β-catenin to intracellular signaling circuits 
that include the Lef/Tcf transcription factors (8, 30, 31).  Examination of cancer 
cells revels that E-cadherin function is apparently lost in a majority of the 
epithelial cells through mutations of the E-cadherin or β-catenin genes, 
transcriptional repression, or proteolysis of the extracellular cadherin domain.  
Forced expression of these genes in transgenic mouse model of carcinogenesis 
impairs the invasive and metastatic phenotype, whereas interference with these 
genes enhances both capabilities. (8, 30, 31). 
 Alterations in the expression of CAMs in the immunoglobulin superfamily 
also appears to play critical roles in invasion and metastasis.  CAMs can 
undergo a switch in expression from a highly adhesive to poorly adhesive forms 
in Wilms’ tumors, neuroblastoma, and small cell lung cancer and reduction in 
their overall expression is observed in invasive pancreatic and colorectal 
cancers. (32). 
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1.1.4  Environmental and life style contributions to cancer incidence 
The health of an individual and the population is a result of the interaction 
between their genetics and environmental factors. Nutrition is an important 
environmental factor in cancer incidence (33) and it has been estimated that  
nutritional factors contribute  20-60% in development  of all cancers worldwide 
and approximately one third of cancer deaths in Western countries (34, 35) 
(Table 3).  Many studies have been conducted in an attempt to support and 
clarify which specific nutritional factors contributed to cancer incidence.  
However, with the exception of the contributions from obesity, physical inactivity, 
alcohol and lack of dietary folate and calcium, the remaining nutritional factors 
that increase or decrease the risks for human cancers are still largely unknown 
(34).  During the past 50-70 years, there have been major lifestyle changes 
which have lead to increased average body weight and overall obesity.  The 
MONICA project, sponsored by the World Health Organization (WHO) showed 
that  in the 1990s 20% of all individuals  in parts of Western Europe and the USA 
and almost 35% of the population in the Eastern European countries were obese 
(36).  In developing countries, the prevalence of obesity is generally much lower, 
but it has reached 10-15% in some urban areas of Namibia, Zimbabwe, Turkey, 
Guatemala, Honduras, Mexico, and Peru (36). 
 The high prevalence of obesity in developed countries can be explained 
by a lifestyle characterized by over-consumption of energy combined with low 
physical activity.  Obesity is a well known risk factor for cardiovascular disease.   
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Table  3.  Influences of diet and nutrition on various types of cancer (34). 
 
 
++ indicates strong correlation with increase incidence of cancer 
+    indicates slight correlation with increased incidence of cancer 
--  indicates strong correlation with decreased incidence of cancer 
-   indicates slight correlation with decreased incidence of cancer 
 
 
 
 
                
  
Breast Prostate Lung Colon Stomach Esophagus Endometrial 
                
          
Macronutrients/ 
energy balance 
        
Obesity ++ +  ++ + + ++ 
Glycemic index/ 
Load + +  ++   + 
Animal fat       + 
  
        
Foods         
Red/processed  
Meat  +  +     
Fruits - - - - - - - 
Vegetables  -  - - - - 
  
        
Nutrients -        
Folic acid ++  - --     
Alcohol    ++  ++   
Calcium  +  -     
Vitamin D  -  -     
B-Carotene  
supplements   ++  -    
Lycopene- 
containing foods  - -  -    
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and diabetes, and epidemiological studies are providing increasing evidence for  
a link between body weight and cancer risk.  A 16 year study was conducted by 
the American Cancer Society consisting of more than 900,000 US adults 
(404,576 men and 495,477 women) who were free of cancer at enrollment in 
1982, and they reported 57,145 deaths from cancer during the 16 years of 
follow-up.  Death rates were approximately 52% and 62% higher for men and 
women respectively who were obese according to their body-mass index (BMI-   
the weight in kilograms divided by the square of the height in meters) compared 
to individuals with normal weight.  In both men and women body mass index 
was also significantly associated with higher rates of death from cancers of the 
esophagus, colon and rectum, liver, gallbladder, pancreas and kidney, and 
similar results were observed for  non-Hodgkin’s lymphoma and multiple 
myeloma.  Significantly increased incidence of death was observed for cancers 
of the stomach and prostate in men and breast, uterus, cervix, and ovary in 
women.  Based on these  observations, the American Cancer Society estimated 
that current patterns of overweight and obesity in the US could account for 14% 
of all deaths from cancer in men and 20% of cancer deaths in women (37, 38). 
 Body weight modulates metabolic factors that in turn affect cancer risk, 
particularly on circulating levels of growth factors and steroid hormones and their 
binding factors.  These effects vary with gender and the menopausal status in 
women. A linear increase in circulating levels of insulin occurs with increasing 
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BMI in both men and women.  Insulin controls the uptake and use of glucose in 
peripheral tissues.  With increasing caloric consumption and weight gain, tissues 
become insensitive to insulin and this is compensated by production of more 
insulin resulting in hyperinsulinemia. Insulin-like growth factors (IGFs) are 
mitogens that regulate energy-dependent growth processes (39). IGF-1 
stimulates cell proliferation and inhibits apoptosis and has strong mitogenic 
effects in a wide variety of cancer cell lines.  The synthesis of IGF-1 and its main 
binding protein, IGF-1 binding protein-3 (IGFBP-3) are regulated by pituitary 
growth hormone (GH).  More than 90% of IGF-1 is bound to circulating IGFBP-3.  
Obesity and other conditions related to the hyperinsulinemia result in elevated 
blood glucose levels, decreased levels of IGF-binding proteins 1 and 2 and 
higher levels of free plasma IGF-1.  Insulin and free IGF-1 interact with and 
regulate the synthesis and bioactivity of sex steroids that affect the development 
and progression of certain cancers  (Figure  3) (40).  Chronic hyperinsulinemia  
inhibits hepatic synthesis of sex-hormone binding protein/globulin (SHBG), 
resulting in increased levels of bioavailable androgens and estrogens that are 
not bound to SHBG and these free steroid hormones determine the available 
estrogen and androgen levels essential for growth and proliferation of cancer 
cells (37, 38). 
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 Figure 3. Mechanism underlying obesity and cancer (38). 
 
 
1.1.5 Epigenetic contributions to cancer incidence 
 Aberrant DNA methylation of specific gene promoter regions is a key 
mechanism for inactivation of genes that suppress tumorigenesis (Tables 4,5).  
In normal cells, the pattern of DNA methylation is conserved after DNA 
replication and cell division by the methylation of cysteine by a maintenance 
DNA methyltransferase (DNMT1).  DNA methylation of genes occurs primarily in 
the promoter regions that contain CpG islands, which are defined as a 1 kb 
stretch of DNA that contain guanine rich sequences at a higher frequency than 
the rest of the genome.  Genes that are involved in every step of tumor 
formation can be silenced by methylation (41).   Genomic screening of 98 
different primary tumors has revealed that on an average there exists 
approximately 600 aberrantly methylated CpG islands in each tumor (41, 42). 
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Table  4.  Different types of genes silenced by aberrant DNA methylation (41). 
 
 
   
Acquired Capability Gene silenced by Gene function 
 DNA methylation  
   
 
  
Insensitivity to 
antigrowth signals P16CDKN2A Cyclin-kinase inhibitor 
 
 induce differentiation cell 
 
 cycle arrest 
 
  
Self Sufficiency in 
growth signals RASSF1A Regulation of RAS pathway 
 Caspase 8 Initiate apoptosis 
 TMS1 Proapoptotic 
 DAP kinase Proapoptotic 
 p14 ARF Proapoptotic 
 
  
Limitless replicative 
potential Rb Tumor suppressor gene 
 
  
Sustained 
angiogenesis Thrombospondin-1 Angiogenesis inhibitor 
 
  
Increased invasion 
and metastasis E-cadherin Suppress metastasis 
 TIMP3 Inhibit metastasis 
 hMLH1 DNA mismatch repair 
 
  
Genome instability MGMT Repair alkylated guanine 
 BRCA1 Repair DNA damage 
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Table  5.  Epigenetic genes disrupted in human cancer (43). 
    
Function Gene Alteration Tumor Profile 
    
    
DNA 
methyltransferases DNMT1 Overexpression Multiple types 
 DNMT3b Overexpression Multiple types 
 
   
Methyl-CpG binding 
proteins MeCP2 
Overexpression, 
mutations Multiple types 
 MBD1 
Overexpression, 
mutations Multiple types 
 MBD2 
Overexpression, 
mutations Multiple types 
 MBD3 
Overexpression, 
mutations Multiple types 
 MBD4 Inactivating  mutations 
Colon, stomach, 
endometrium 
 
   
Histone 
acetyltransferases p300 Mutations 
Colon, stomach, 
endometrium 
 CBP 
Mutations, homozygous 
deletions 
Colon, stomach, 
endometrium, lung 
 pCAF Rare mutations Colon 
 MOZ Translocations 
Haematological 
malignancies 
 MORF Translocations 
Haematological 
malignancies 
 
   
Histone 
deacetylases HDAC1 Imbalanced expression Multiple types 
 HDAC2 Imbalanced expression Multiple types 
 
   
Histone 
methyltransferases RIZ1 
CpG island 
hypermethylation, 
mutation Multiple types 
 MLL1 Translocations 
Haematological 
malignancies 
 
   
Chromatin 
remodeling factors EMSY 
Gene amplification and 
over expression Breast 
 BRMS1 Loss of expression Breast 
 MTA1 Overexpression 
Breast, Haematological 
malignaincies 
 MTA3 Overexpression 
Breast, Haematological 
malignaincies 
 
   
SWI/SNF family 
proteins PASG Mutations 
Haematological 
malignancies 
 BRG1 
Homozygous deletion, 
mutation Lung 
 HLTF 
CpG island hyper 
methylation Multiple types 
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Although it is unclear which specific molecular events lead to aberrant 
methylation, there are several hypotheses that try to explain this process.   One 
hypothesis is that it could be due to infidelity of DNMT1.  The substrate for this 
DNA methyltransferase is hemimethylated DNA.  Methylation occurs 
immediately after DNA replication with the primary function to ensure that the 
identical methylation patterns of the parental cell are passed on to the next 
generation daughter cell. The DNA methyltransferase methylates genomic DNA 
at very high fidelity, but commits errors at a very low frequency (41, 44).  Other 
DNA methylating enzymes that could be involved in aberrant DNA methylation 
are de novo methyltransferases which include DNMT3a and DNMT3b which use 
unmethylated DNA as their template and play an important role in embryonic 
development (41, 45, 46).  Another possible mechanism responsible for gene 
hypermethylation could be due to a faulty repair mechanism of aberrantly 
methylated DNA.  DNA demethylase is a relatively new enzyme that has the 
potential to function as a repair enzyme, and correct aberrantly methylated CpG 
sequences.  The factors that control the template specificity of DNA 
demethylase have not been identified and  further research is required to clarify 
its role in regulating cell growth and differentiation (41, 47). 
Chromatin remodeling also plays an important role in the regulation and 
expression of certain genes.  Modification of the N-terminal group of lysine in 
histones by acetylation and deacetylation changes the configuration of 
nucleosomes and chromatin structure.  The acetylation of lysine by histone 
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acetyltransferase removes a positive charge on DNA and the compact structure 
of the DNA is lost resulting in opening of the chromatin structure, which 
facilitates gene transcription.  Histone deacetylase (HDAC) removes acetyl 
groups from lysines and reverses  this process and restores the positive charges  
on lysines resulting in a compact chromatin structure  which represses 
transcription and leads to silencing of genes (41).    Aberrant deacetylation of 
histones in nucleosomes is due to dysregulation of specific HDACs and may be 
associated with neoplastic transformation. 
 In summary, it is apparent that many factors merge together to result in a 
malignant phenotype.  There is a fine balance between gene expression and 
environmental and behavioral factors and their interactions which results in 
cellular events that lead to cancer initiation, promotion and progression. 
 
1.2  Breast cancer 
1.2.1  Mammary gland development 
 An understanding of breast development and its morphology is important 
for determining the underlying causes of breast cancer.  The mammary gland is 
a structurally dynamic organ which undergoes changes with age, menstrual 
cycle and reproductive status.  Mammary gland development is initiated in the 
embryo, and major changes occur during the pre-pubertal phase under the main 
stimuli of pituitary and ovarian hormones (48, 49).  The mammary gland first 
appears around day 10 of embryonic development as five pairs of placodes, and 
 22 
by day 15 the placodes have formed epithelial buds surrounded by 
mesenchymal layers.  These structures develop into branching networks of 
ducts terminating in end buds through the signaling between the epithelium, the 
mammary mesenchyme and the stromal fat pad (48, 49).  Mammary gland 
development during the childhood primarily keeps pace with the general growth 
of the body until the approach of puberty or adolescence.  The adolescent period 
begins with the first signs of sexual change at puberty and terminates with 
sexual maturity (48, 49).  Changes in the hormonal environment during puberty 
are the major factors controlling mammary gland development.  In the male, 
further development is inhibited by production of testosterone.  With the 
approach of puberty, the rudimentary mammae begin to show growth activity 
both in the glandular tissue and the surrounding stroma.  Glandular growth is 
due to proliferation and division of small bundles of primary and secondary ducts 
which grow and divide by repeated bifurcations form the main axis and 
successive secondary axes.  The ducts grow and divide to form club-shaped 
terminal end buds which give rise to alveolar buds (49).  Alveolar buds cluster 
around a terminal forming the lobule type 1 or virginal lobule and each cluster is 
composed of approximately 11 alveolar buds.  Alveolar buds and terminal ducts 
are lined by a two-layer epithelium.  Lobule formation in the female breast 
occurs with in 1-2 years after onset of the first menstrual period.  Full 
differentiation of the mammary gland is a gradual process taking many years, 
and in some cases, if pregnancy does not occur, is never fully attained (48-50). 
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 The breast of an adult woman contains three types of lobules, type 1, 2 
and 3.  The breast of nulliparous women is mostly comprised of undifferentiated 
structures, such as the terminal end buds and type 1 lobules, which are potential 
sites for development of preneoplastic lesions which eventually progress into 
invasive carcinomas.  Type 2 lobules are present in moderate numbers during 
the early years but decrease drastically after age 23.  In parous women, type 3 
lobules are the predominant structures during pregnancy until the fourth decade 
of life after which the number of type 3 lobules decrease.  At this stage breasts 
of both nulliparous and parous women are similar and they both have mostly 
type 1 lobules, but the type 1 lobules in parous women are different because 
they are fully differentiated and are therefore less susceptible for development 
into malignant tumors (48-50). 
 The normal mammary gland is composed of two cellular components, the 
mesenchymal component of fatty stroma containing the blood vessels and 
nerves and the epithelial compartment of ducts and lobules.  The epithelial 
component is made up of three distinct cell types, the epithelial cells which line 
the ducts, the alveolar cells which line the alveoli and the myoepithelial cells that 
are between the epithelial cells and the alveolar cells and the basement 
membrane.  Tumors and malignancies in humans and rodent models usually 
occur in the epithelial cells, specifically the undifferentiated terminal end buds, 
whereas benign lesions usually occur in both epithelial and myoepithelial cells 
(48, 49) 
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 Mammary gland development and differentiation is maximal during 
pregnancy when the duct system of the gland branches and enlarges.   There is 
active cell division and increase in size in the epithelial cells of the newly formed 
lobules.  This phase is driven by the hormones 17β-estrodial (E2), progesterone 
and prolactin.  Estrogen mainly acts on the ductal system; progesterone 
promotes alveolar development in the second and third trimester.  At parturition, 
there is a drop in estrogen and progesterone blood levels.   There is an increase 
in prolactin release from the anterior pituitary in response to the suckling 
stimulus from the infant.  As suckling continues, there is large volumes of milk 
produced, and at the end of this period, the epithelial cells are lost due to 
apoptosis and mammary glands reduce in size and return to a resting phase (48, 
49). 
 
1.2.2  Life style and behavioral risk factors for breast cancer 
 The major breast cancer risk factors include obesity, alcohol 
consumption, physical activity, exogenous hormones such as oral 
contraceptives or hormone replacement therapy.  Diet and nutrition are also 
important however the precise contributions of various components of the diet 
are unclear. Reproductive factors such as early menarche (before age 12) 
greater frequency of ovulatory cycles, late age of first birth or multiparity, lack of 
lactation, late menopause, greater number of lifetime ovulatory cycles and 
greater time between menarche and menopause also increase the risk of breast 
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cancer (51-53).  The reproductive risk factors suggest that a woman’s overall 
lifetime exposure to estrogens enhances breast cancer incidence.  The Nurses’ 
Health Study  reported that women who were engaged in an average of 7 or 
more hours per week of physical activity had an 18% lower chance of 
developing breast cancer than women who engaged in less than 1 hour per 
week of such activities (54).  Increased breast cancer risk is associated with 
alcohol use, obesity, increased meat (red) intake, diets rich in fat and low in 
fiber.  Epidemiological data suggest that consumption of soy products is 
associated with a lower risk of breast cancer (51, 55, 56).  However, recent 
evidence suggests that one component of soy, genistein, may promote the 
growth of some estrogen-sensitive tumors and reduce the efficiency of 
antiestrogen tamoxifen (51, 57, 58).  Phytoestrogens can act as weak estrogens 
and as antagonists depending on the hormonal status of the host.  High 
phytoestrogen intake can compete with endogenous estrogens in 
premenopausal women and reduce overall estrogen exposure of the target 
tissue; phytoestrogens can also increase estrogenic response  in women with 
low endogenous levels of estrogens in post-menopausal women (51, 52).   
Specific micronutrients have been associated with reduced risk of breast cancer 
and these include carotenoids, folate, calcium, vitamin D, lycopene and vitamin 
C (51, 54).  Many of these studies on micronutrients give variable results and 
may not be conclusive. 
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1.2.3 Genetic risk factors 
Approximately 10-15% of all breast cancers are thought to be familial, 
with about one third of these cases attributed to inherited cancer-susceptibility 
genes, designated BRCA1 and BRCA2 (59).  BRCA1 gene was identified by 
linkage analysis in 1990 and linkage was established to the long arm of 
chromosome 17 at region q21 with the help of polymorphic markers.  Familial 
breast cancer, characterized by frequent occurrence of male breast cancer is 
linked to the BRCA2 locus located on 13q.  Along with BRCA1 and BRCA2 a 
third gene, p53 located on 17p13, when inherited in a mutated from can confer 
high lifetime risks for developing breast cancer (59-61). 
Germ-line mutations of BRCA1 and BRCA2 genes account for  
approximately 40% of inherited breast cancer cases.  It is estimated that in 
families that have mutations in BRCA1 or BRCA2 , the cumulative risk of 
developing breast cancer is 71% up to the age of 70, which corresponds to 10-
20 fold increased risk compared to women who do not have the familial gene 
mutations (59, 60).  Mutations in BRCA1 and BRCA2 are associated with very 
early-onset of breast cancer.  As many as 33% of women under the age of 29 
with breast cancer carry a mutation in BRCA1 or BRCA2.  These individuals  
also have a 44% greater chance for developing ovarian cancer by age 70 (59). 
BRCA1 protein is expressed in a wide range of tissues, including the  
breast.  It is highly expressed in tissues containing rapidly proliferating cells that 
are involved in differentiation.  The BRCA1 gene consists of 24 exons and the 
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size of the mRNA is 7.8 kb and expression is increased during G1 to S phase. 
The gene product of BRCA1 is a phosphorylated protein that consists of 1863 
amino acids and has a molecular weight of 220 kDa.   A ring finger structure is 
present at the N-terminal region and a binding site for RAD 51 has been 
identified in the central part of the primary structure.  Two BRCT domains are 
present at the C-terminal region and take part in DNA repair and may be 
involved in transcriptional activation and chromatin remodeling.  BRCA1 has 
many functions, including repair of oxidative DNA damage and BRCA1 is also 
involved with homologous recombination and repair in combination with RAD51 
(62).  BRCA1 regulates gene expression as a co-activator in a p53 dependent 
manner and as a co-repressor of estrogen induced transcription.   BRCA1 
mediates ligand-independent transcriptional repression of the estrogen receptor 
(ER) and acts as a ligand reversible barrier to transcriptional activation by 
unliganded ER.  BRCA1 deficient cells exhibit decreased cell growth and 
hypersensitivity to ionizing radiation, giving rise to DNA damage associated with 
chromosomal abnormalities including breaks in DNA and aneuploidy in the 
successive daughter cells.  Therefore it is believed that BRCA1 contributes to 
the maintenance of chromosomal stability (62-64). 
 BRCA2 gene has a total length of 70 kb and consists of 27 exons and has 
a transcriptionally active product of approximately 11.5kb.  The BRCA2 gene is 
highly expressed in the thymus, testis, mammary tissue and the ovaries (62, 65) 
and the expression of BRCA2 is cell-cycle dependent.  The protein is 378 kDa 
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and has 3418 amino acids with no homology to BRCA1 protein although it 
shares similar structural features and expression patterns.  BRCA2 also has a 
RAD51 binding site and contributes to the maintenance of chromosomal stability 
and homologous recombination (62, 66). 
 Since BRCA1 and BRCA2 are expressed in the same tissue and cell 
types they interact with each other and RAD51 along with other proteins 
involved in DNA repair and recombination.  BRCA1 is phosphorylated by a 
protein kinase called ATM (ataxia-telangiectasia)  as a result of DNA damage 
and the hyperphosphorylated BRCA1 co-localizes with BRCA2 and RAD 51 
protein in the nuclear foci at S-phase of the cell cycle(59, 66-68).  
 Breast cancer is also found in rare genetic syndromes, such as Li-
Fraumeni syndrome (LFS).  The spectrum of cancers in LFS families include soft 
tissue sarcomas, brain tumors, osteosarcomas, leukemia, and adenocorticol 
carcinomas and characteristically develop at very early age with presence of 
multiple tumors (59, 62, 66).  Genetic analysis shows that families at risk have a 
50% probability of developing invasive cancers by age 30 and more than a 90% 
chance by age 70.  The tumor suppressor gene p53 is often reported to be 
mutated in the LFS families.  Germline mutations in the p53 gene account for up 
to 1% of breast cancer cases diagnosed under the age of 35 (59). 
 Carriers of homozygous or compound heterozygous mutations in the 
ATM gene suffer from the rare recessive disorder ataxia-telangiectasia (AT).  AT 
is a degenerative disorder that is characterized by progressive cerebral ataxia, a 
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weakened immune system, high sensitivity to ionizing radiation, distinctive 
dilated blood vessels in the eyes and skin and increased susceptibility to cancer.  
ATM is a protein kinase that phosphorylates BRCA1, activating its DNA repair 
response upon DNA damage.  Heterozygous carriers of ATM mutations exhibit a  
five-fold increased risk for breast cancer (66-68). 
 
1.2.4 Environmental risk factor 
There are well known geographical variations in breast cancer rates 
suggesting a role for the environment in the etiology of breast cancer.  Breast 
cancer incidence in the US are among the highest in the world and rates in 
Western industrialized countries are as much as five-to-eight fold higher than 
rates in Asia and Africa (69).  Studies indicate that as populations migrate from 
the low to high-risk geographical areas the incidence of breast cancer in these 
individuals approaches that of the host country within one or two generations 
suggesting that environmental factors play a major role in determining incidence 
of breast cancer (69-71) .  Female age, reproductive cycles, inheritance patter of 
breast cancer susceptibility genes (BRCA1 and BRCA2), and other known 
factors explain only about 40% of breast cancer cases in the US and it is 
estimated that up to 60% of breast cancer cases have an environmental etiology 
(69). 
Most scientists believe that breast cancer is the result of complex 
interactions of internally and externally introduced factors that occur over long 
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periods of time.  A number of environmental chemicals induce mammary cancer 
in rodents and similar effects in humans, and these genotoxic agents are broadly 
classified as tumor initiators or tumor promoters.  These compounds act at many 
junctions during the development of breast cancer and some of them act by 
modulating endocrine pathways.  These chemicals and other endocrine 
disruptors have industrial origins and enter the environment as industrial by-
products/wastes or through their use in production of pesticides and other 
industrial chemicals (Tables 6,7) (69). 
 Some chemicals are present both in the environment and workplace.  
These chemicals may be used in manufacture of glues, paints, varnishes, 
solvents and many other products.  Band and coworkers (2000) have noted  
increased incidence of breast cancer linked to occupations involving exposure to 
solvents used in the printing and publishing, laundry and dry cleaning industries, 
mechanics, aircraft workers,  automotive repair workers, gasoline service station 
workers are all exposed to solvents and exhibit increased rates of  breast cancer 
(72).  Only one case control study assessing breast cancer risk found an 
increased risk for post-menopausal breast cancer among those working in the 
laundry and dry cleaning industries (72).  A cohort study of women employed in 
coiling and wire drawing in the manufacture of light bulbs where methylene 
chloride and trichloroethylene were used had an excess of breast cancer 
incidence among those who worked for more than 5 years (73).   In another 
study increased rates of breast cancer were observed in pre and 
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postmenopausal women working in the publishing and printing industry (72). It 
should be noted that all these studies suffer some shortcomings since the 
occupational studies rely on historical assessment of exposure to organic 
solvents which are short-lived in the body  (69). 
Exposure to metals may also be associated with breast cancer risk.  
Martin and coworkers (2003) demonstrated that in MCF-7 breast cancer cells, 
divalent cadmium, copper, cobalt, nickel, lead, mercury, tin, chromium, arsenic, 
selenite and vanadate activated responses mediated by ERα .  In addition, the 
metalloestrogen-induced activation of ERα  was more potent than 
phytoestrogens, and  most  other environmental estrogenic compounds (74).   
Cadmium in particular was shown to induce estrogenic responses along 
with increased uterine weights, hyperplasia, hypertrophy of the endometrial 
lining and increased mammary epithelial density in female rats (74).  However, 
the effects of heavy metals on breast cancer rates in humans has not been fully 
determined. 
Viral exposure may be involved in the genesis of breast cancer. Two  
possible viral candidates are the Epstein-Barr virus (EBV) and mouse mammary 
tumor virus (MMTV) (69).  The EBV is a ubiquitous human γ herpes virus that 
infects and establishes a mostly asymptomatic life-long infection in B 
lymphocytes.  The EBV genome has been detected in subset of breast tumor 
specimens and in a study by Yasui and colleagues (2001) it was noted that 
breast cancer rates were higher in individuals who had a history to 
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Table 6.  Chemicals associated with increased incidence of mammary gland 
      tumors in rats and mice tested by US National Toxicology program 
      (75). 
 
 
    
Chemical Use 
    
    
Benzene Gasoline solvent 
2,2'-bis(Bromomethyl)-1,3-
propanediol Flame retardant 
1,3-Butadiene 
Auto exhaust, rubber manufacturing, 
gasoline 
C.I. acid red 114 Dye for jute, silk , leather 
C.I.basic red 9 monohydrochloride Dye for paper, textiles, leather 
2-chloroacetophenone Flame retardant 
Chloroprene Neoprene manufacture 
Clonitralid Molluskicide 
Cytembena Pharmaceuticals 
2,4-diaminotoluene Intermediate in dye industry 
1,2-Dibromo-3-chloropropane Soil fungicide and pesticide 
1,2-Dibromoethane Soil fungicide, lead scavenger in gasoline 
2,3-Dibromo-1-propanol Flame retardant 
1,1-Dichloroethane Solvent 
1,2-Dichloroethane 
Solvent and intermediate in insecticide 
manufacture 
Propylene dichloride Solvent in dry cleaning fluids, fumigant 
1,2-Dimethoxybenzidine 
dihydrochloride Dye intermediate 
3,3-Dimethoxybenzidine 
dihydrochloride Dye intermediate 
2,4-Dinitrotoluene Dye intermediate, explosives, propellants 
Ethylene oxide Sterilizing gas for medical equipment 
Furosemide Pharmaceuticals 
Glycidol 
Intermediates in pesticides and fragrances, 
plastic stabilizers 
Hydrazobenzene 
Dye intermediates, tobacco pesticides, 
motor oil 
Isophosphamine Pharmaceuticals 
Isoprene By-product of ethylene production 
Methylene chloride Solvent, furniture stripper, adhesives 
Nitromethane 
Rocket and engine fuel. Solvent, mining 
explosive 
1,2,3-trichloropropane 
Chemical intermediate, solvent for paint 
remover 
Sulfallate Herbicide 
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Table 7.  Endocrine disruptors (75). 
 
    
Compound Exposure / Uses 
    
    
Pesticides 
  
Atrazine Selective herbicide 
Chlordane Insecticide, acaricide, veterinary pharmaceutical 
Chlorpyrifos Insecticide, acaricide 
Cypermethrin Insecticide 
Lindane Insecticide 
Malathion Insecticide 
Methoxychlor Insecticide Veterinary pharmaceutical 
Pentachlorophenol Insecticide and wood preservative 
Permethrin Insecticide 
Toxaphene Insecticide 
Tributyl tin Biocide, rodent repellant 
Vinclozolin Agriculture fungicide 
Organochlorines and 
PAHs 
  
PAHs Industrial air pollutants, smoke from coal/coke-burners, tobacco tar 
Polybrominated biphenyls Flame retardants 
polybrominated diphenul 
ethers Flame retardants 
PCBs (Aroclor 1254) Transformers and electrical equipment (NO LONGER IN USE) 
Dioxins  and furans Products of incineration, paper manufacturing and herbicides 
Phenols and akkylphenols 
  
Biphenol A Polycarbonate and polyester-styrene resins 
4-tert-butylphenol Intermediates in manufacture of varnish and lacquer resins, soap, antioxidants 
Nonylphenol polyethoxylate Surfactants, detergent, defoaming agents, pesticide formulation, rubber industry 
Phthalates 
  
Butyl benzyl phthalate Commercial plasticizer for polyvinyl chloride polymers 
Di/n-butyl/ethyl phthalate Personal care products such as nail polish, perfume, hair spray, inks, adhesives 
Parabens 
  
Butyl, ethyl, methyl, propyl 
paraben 
Pharmaceutical aid (antifungal),  preservative in foods, creams, lotions, 
ointments 
Other organics 
  
Amsonic acid Dyes, bleaching agents,  optical brighteners or fluorescent whitening agents 
Styrene Manufacturing of plastics, synthetic rubber, resins, insulator 
Vinyl acetate Production of polymers, adhesives, paints, food packing 
Metals 
  
Cadmium, lead Batteries, plastic stabilizers, pigments 
Mercury Thermometers, dentistry, pharmaceuticals, agricultural chemicals 
Phytoestrogens 
  
Genistein, Coumestrol, 
Zearalenone Soy, grains,  grain molds 
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mononucleosis, (caused by EBV) (76).   In one study, MMTV-like envelope 
protein gene sequences were detected in 37% of human breast tumors, but not 
in normal breast tissue   Future work may involve the use of vaccines to prevent 
or modify the primary infection to reduce breast cancer risk (77). 
Organochlorines (OC) are a group of synthetic chemicals that are 
abundant in the environment as pesticides or industrial by-products. The most 
abundant of the OCs are dichlorodiphenyltrichloroethane (DDT) and 
polychlorinated biphenyls (PCB), which were introduced in the US in 1945 and 
then were banned in the 1970s (69, 78).  DDT was widely used in the US as an 
insecticide in forestry and agriculture from 1945 until the early to mid 1960s.   
PCBs were used in dielectric fluids in transformers and capacitors, as 
plasticizers, lubricants and heat transfer fluids and in manufacture of paper and 
paint until they were banned in 1977 (69). OCs degrade slowly as they 
accumulated in the food chain due to their chemical stability and they are found 
in human adipose tissue, blood and breast milk.  The most prevalent OC residue 
found in human tissues is dichlorodiphenyltrichloroethylene (DDE) which is the 
major metabolite of DDT (69).  A case control study conducted in 1993 by Wolff 
and colleagues in New York showed that there was a two to four-fold increase in 
the occurrence of breast cancer among women with the highest serum levels of 
DDE and PCBs compared to women with the lowest levels (79).  However, 
many studies conducted since then did not find an increased risk of breast 
cancer with exposure to OCs (80-84). 
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1.2.7  Role of  ER in breast cancer 
 Estradiol (E2) is a steroid hormone that exhibits important biological 
functions in target tissues such as the female and male reproductive tract.  The 
growth of the mammary gland and uterine endometrium during pregnancy and 
menstrual cycle is dependent on estrogen.  E2 is also important in the 
functioning of other tissues, such as bone, liver, brain and the cardiovascular 
system.  In addition to its role as a proliferative agent in normal cells, E2 has 
also been linked to the initiation, promotion and progression of breast and 
endometrial cancers.(85).  .  One of the earliest studies showing a relationship 
between breast cancer and ovarian hormones was the observed regression of 
breast cancer after removal of ovaries, the major site of estrogen production in 
premenopausal women  (86).  The classical scheme of ER action involves ligand 
(E2) binding to the ER, dissociation of heat shock proteins from the ER and 
receptor dimerization.  The dimer then binds to DNA sequences called estrogen 
response elements (ERE) that are located in the regulatory regions of 
responsive target genes which recruit coactivators and other transcription factors 
to activate gene expression (87) 
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1.2.8. Expression of the Estrogen Receptor (ERα) in breast cancer 
 Breast cancers can be divided into two subtypes based on their 
expression of ERα. The ER status of breast tumors is important because 
circulating estrogens can bind ER and stimulate cell division and tumor growth 
where as ER-negative breast tumors are resistant to the effects of estrogens 
(88). 
 Most invasive breast cancers (IBCs) are derived from premalignant breast 
lesions, which in turn arise from normal epithelial cells lining the terminal duct 
lobular units (TDLU)  (88, 89).  All epithelial cells or their ancestors must express 
ER at some time during their lifecycle.  Immunochemical examination of a 
normal adult woman would show that nearly all TDLUs contain ER positive cells, 
but only 30% on average are ER positive at any given time.  These ER positive 
cells are mostly non-dividing.  In the 30%, the fraction of cells that are dividing 
only account for less than 5% of the overall population (88).   A normal breast 
consists of largely ER negative non-dividing cells and they may arise from ER 
positive or other wise estrogen-responsive stem cells that have differentiated in 
diverse directions (88) 
ER expression and growth of breast cancer are closely correlated.  IBCs 
contain on average 75% ER positive cells, but this can vary from less than 1% to 
100%.  In ER positive IBCs, the proportion of dividing cells that are ER positive 
also varies from less than 1% to nearly 100%.  The remaining 25% of the cells 
which are ER negative exhibit estrogen independent proliferation (88, 90). 
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 ER-negative IBCs are histologically high grade, rapidly proliferating 
tumors derived from ER-negative ductal carcinomas in situ (DCIS) and the two 
types of cells share many similarities.  Most DCIS have evolved from atypical 
ductal hyperplasias (ADH) in which nearly all cells are ER-positive, however ER-
negative cells are present in all premalignant lesions including ADH and they 
may be involved as progenitor cells in the development of ER-negative DCIS.  
Human mammary epithelial cells show gene expression patterns similar to basal 
IBCs, which are also ER-negative, suggesting that they may represent a stem 
cell population for ER-negative breast cancer (91, 92)  
 
1.2.9  Treatment and prevention of breast cancer 
Surgical removal of cancerous tissue is a very highly effective method of 
treatment for node negative breast cancer, however this does not affect distal 
metastasis where the cancer has spread to surrounding tissues such as the 
lymph nodes.  Treatment of gross micrometastasis and multifocal isolateral and 
contralateral breast cancer requires a mastectomy, adjuvant and radiation 
therapy.  Depending on the extent of cancer, two types of surgical procedures 
are available.  Breast conserving surgery involves complete removal of 
neoplastic tissue and a small amount of normal tissue and the cosmetic effects 
can be addressed with post reconstructive surgery.  This initial option is limited 
to patients with early stage breast cancer.  The second procedure is a total 
mastectomy, which involves the complete removal of the mammary gland, 
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axillary lymph nodes and fascia of the underlying pectoral muscle and this is the 
primary option for patients with late stage breast cancer as well as for women 
with a high genetic/familial risk of breast cancer (93, 94). 
Endocrine therapy is another method for managing breast cancer.  
Normal breast tissue is hormonally regulated and mammary neoplasia 
progresses from a state of hormone-responsiveness (dependent) to hormone-
nonresponsiveness (independent).    Neoplastic cells initially  take advantage of 
the growth hormones of the endocrine system to rapidly proliferate in a 
hormone-dependent manner and endocrine therapy eliminates the production of 
or antagonizes the effects of these growth/steroid hormones (95). 
The most primitive form of hormone ablation is removal of endocrine 
glands namely the ovaries, adrenals and pituitary (96).  More than 100 years 
ago, George Beatson showed that metastatic breast cancer could be forced into 
remission by bilateral removal of the ovaries, as it is the primary site of estrogen 
production and this surgery increases the lifespan of premenopausal breast 
cancer patients. The decrease in E2 production can be as much as 20-fold 
(200pg/ml to 10 pg/ml) (97, 98).  Since androgens are precursors of E2 that are 
primarily produced in the adrenal cortex, adrenalectomy prevents androgen 
production and their conversion into E2.  The pituitary gland secretes LH and 
FSH to induce E2 and progesterone production in the adipose tissue.   Hence a 
hypophysectomy stops production of LH and FSH so they are no longer able to 
stimulate production of E2 in the adipose tissue.  A hypophysectomy is usually 
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recommended for postmenopausal women as the adipose tissue is still a source 
of E2 production (96).   Although surgical techniques are effective against 
hormone-responsive tumors, these procedures are both invasive and 
irreversible; hence they have been replaced by specific antiestrogenic drugs. 
Chemotherapeutic treatment of cancer has made significant advances in 
the past three decades.  This was made possible due to the increased 
knowledge and understanding of the roles of membrane receptors, signal 
transduction pathways and transcription factors involved in the tumorigenic 
process. 
 
1.2.10  Selective estrogen receptor modulators (SERMs)  
 
The ER is essential for normal breast development and for mammary 
carcinogenesis.  This receptor has been an important target for drug 
development.  SERMS play a key role in breast cancer chemotherapy.  These 
agents antagonize the effects of estrogens in some tissues and mimic their 
action in others (99).    The introduction of the antiestrogen tamoxifen in the 
early 1970s represented a landmark in the treatment of breast cancer.  Over the 
past three decades tamoxifen has been proven to be effective for  treatment of 
early and advanced breast cancer and has been successfully used for 
chemoprevention of breast cancer in high risk pre and postmenopausal women 
(100-102). 
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Before the breakthrough discovery of tamoxifen, in the early 1950s two 
antiestrogenic drugs namely Mer-25 and clomiphene were introduced.  This was 
followed by the development of a series of triarylethylene derivatives with alkyl 
substitutes for chlorine in the clomiphene molecule for treating hormone 
dependent tumors.  However animal studies revealed that clomiphene and 
related compounds lead to formation of cataracts due to accumulation of 
desmosterol, a cholesterol precursor (102-104). 
Tamoxifen was first used in a clinical trial in 1969 consisting of 46 
premenopausal patients with advanced breast cancer.  When patients were 
administered 10-20 mg tamoxifen daily for 3 months, a remission rate of 22% 
was achieved and this was comparable to that seen with stilboestrol (the drug 
used at that time), but with reduced toxicity.  Thirty-five randomized clinical 
studies involving 5160 patients comparing tamoxifen with other endocrine 
therapies, showed that tamoxifen had clear therapeutic advantages (102, 105). 
The antitumorigenic effects of tamoxifen are mediated by its anti-
estrogenic activity.  E2 binds ER and initiates a sequence of events that lead to 
activation of gene transcription and enhanced cell proliferation.  Tamoxifen 
competitively inhibits binding of estrogen to the ER and the tamoxifen-ER 
complex homodimerizes leading to attenuation of estrogen responsive gene 
expression.  This results in decrease of cell proliferation by arresting cells in 
G0/G1 phase of cell cycle (102, 106).  Tamoxifen can affect malignant breast 
epithelial cells indirectly by modulating level of cytokines in a local and systemic 
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manner.  It stimulates production of transforming growth factor β (TGFβ) which is 
an inhibitory growth factor which acts on breast carcinoma cells in a negative 
paracrine manner.  Tamoxifen also decreases the production of IGF-1   a potent 
mitogen for breast cancer and tamoxifen also induces apoptosis in both ER-
positive and ER-negative breast cancer cells (101, 102, 107, 108).  Tamoxifen, 
although the leading drug of choice for breast cancer treatment, has adverse 
side effects which include hot flashes, endometrial cancer, abnormal bleeding 
and pain, rare reports of thromboembolic events, stroke, deep vein thrombosis, 
and pulmonary embolisms.  However, it has been concluded that its benefits in 
saving lives by far exceeds the incidence and severity of the in side effects 
(102). Raloxifene is another SERM with estrogen antagonist action in both 
breast and uterus and agonist action in bone.  It is potentially less hazardous 
than tamoxifen, as it has not been associated with increased risk of endometrial 
cancer (99).   
Unfortunately, most patients who respond well to treatment with SERMs 
such as tamoxifen will eventually have a reoccurrence of resistant tumors.  
These tumors may express a functional ER and their resistance may be due to 
numerous mechanisms including increased local metabolism of tamoxifen to 
unstable or less potent metabolites, mutations in ER, variations in co-regulator 
expression and recruitment or interaction with other signaling pathways.  The 
precise mechanism of tamoxifen resistance is still unknown and requires further 
research (99, 109). 
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1.2.11  Aromatase inhibitors in breast cancer 
Estrogen depravation is an effective treatment for breast cancer and 
introduction of tamoxifen, the antiestrogen, as first-line treatment has markedly 
improved breast cancer survival.  However tamoxifen also exhibits partial ER 
agonist activity, and may also be involved in the later development of tamoxifen 
resistance.  Hence there is a pressing need to find alternatives to tamoxifen for 
treatment of this disease.  A promising alternative for decreasing E2 has been 
the development of inhibitors of aromatase, the enzyme that converts 
androstenedione and testosterone to estrone and E2.  This enzyme is a member 
of the cytochrome P450 class and is highly expressed in the placenta and in 
granulosa cells of the ovarian follicles, but is also present in smaller amounts in 
peripheral tissues such as adipose tissue, liver, muscle, brain and breast tissue 
(96, 101, 110). 
Aromatase inhibitors can be classified into two subtypes, steroidal and 
nonsteroidal or type 1 and type 2 agents respectively.  Steroidal inhibitors 
include formestane and exemestane which are analogues of androstenedione 
(substrate) and irreversibly bind aromatase at the substrate binding side, and 
are known as enzyme inactivators.    Nonsteroidal inhibitors such as fadroxole, 
anastrazolem and letroxole reversibly bind the heme group of the enzyme.  Thus 
different types of aromatase inhibitors can be used sequentially in order to 
prolong their clinical response.  However the clinical significance of these 
different mechanisms of action on aromatase inhibitors is not yet completely 
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understood. Several clinical trails have shown that aromatase inhibitors as 
second-line treatment are effective for the treatment of breast cancer in 
postmenopausal women who have experienced disease progression while on 
tamoxifen. (96, 101, 110) 
The treatment of breast cancer has come a long way since its beginning.  
Endocrine therapy and antiestrogen treatment regimens provide the latest 
therapeutic methods for treating ER-positive breast cancer.  However there are, 
as yet no mechanism based drugs for treatment of ER-negative breast cancers 
which are primarily treated with cytotoxic drugs and the overall prognosis is very 
poor.  Hence research leading to the discovery of mechanism-based drugs for 
treatment of these cancers is essential and some of these aspects will be 
discussed later in this dissertation. 
 
1.2.12  The aryl hydrocarbon receptor (AhR)   
 The AhR is a ligand activated nuclear transcription factor that was 
first identified by Poland and coworkers (1976) in the hepatic cytosol of mice 
using 3H labeled 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) as a radioligand 
(111).  The AhR  belongs to the periodicity/AhR nuclear translocator 
(ARNT)/single-minded (PAS) and basic helix-loop-helix (bHLH) protein family  
(112-115).   Members of the  PAS family include the hypoxia responsive genes 
such as hypoxia inducible factors (HIF1-α , HIF2-α/HLF) which are involved in 
oxygen sensing and angiogenesis, proteins involved in neurogenesis  such as 
 44 
single minded protein(Sim), transcription factors such as steroid receptor 
coactivator 1 and transcriptional intermediate factor 2 (SRC-1, TIF2) and 
circadian rhythm proteins such as CLOCK, BMAL1 and ARNT (113, 114, 116, 
117).    
 
1.2.13  Molecular structure of AhR  
The AhR and ARNT proteins are transcription factors that contain several 
domains that are responsible for DNA binding, ligand binding, and interactions 
with other proteins that are required for ligand-induced transactivation (Figure 4). 
The N-terminal region of these proteins contains a bHLH motif which is also 
shared by the family of transcription factors which include the protooncogenes 
Myc and MycD.  Adjacent to the C-terminal region of the bHLH domain is a 
sequence of 250 amino acids termed PAS.  This is a consensus region which 
was originally identified as a conserved region between Drosophila period (per), 
human ARNT, and Drosophila Sim.  Within this 250 amino acid sequence are 
two imperfect repeats of 50 amino acids PAS-A and PAS-B which functions as 
interactive surfaces for hetero or homo dimer formation with the Hsp 90 complex 
(unliganded form) and binding of receptor ligands.  The HLH region is mainly 
responsible for dimerization with the ARNT and DNA binding (113, 114, 118-
120). 
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Figure 4. Structure domains of AhR and ARNT (121). 
 
 
1.2.14  Mechanism of AhR mediated transactivation 
 The AhR is the only member of PAS family activated by a ligand (Figure 
5).  The unliganded AhR is a cytosolic protein complexed with heat-shock 
protein (Hsp) 90, the co-chaperone protein p23 and the immunophilin-like 
AIP/ARA9/XAP2 protein.  Binding of Hsp90 to the AhR at the PAS-B domain 
masks the nuclear localization signal resulting in the cytoplasmic localization of 
the AhR in many cells.  Ligand binding results in conformational changes and 
exposure of the nuclear translocator sequence; the liganded AhR translocates 
into the nucleus where it switches partners from Hsp90 to ARNT.  In its 
transcriptionally active form, the AhR is a hetero dimer of the AhR and the ARNT 
proteins, which interacts with the genomic cis-acting dioxin-response elements 
(DREs) in the promoter regions of the Ah-responsive genes such as CYP1A1.  
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The AhR is a transcription factor that binds a diverse group of natural and man-
made compounds; however the endogenous ligand has not been identified. 
(121-124)  
The physiological role of the AhR-ARNT hetero dimer has been 
investigated in AhR transgenic knockout mice. These mice typically have 
problems in liver development, they exhibit poor fecundity and weight loss, 
suggesting that the AhR-ARNT complex regulates constitutive functions in the 
absence of exogenous ligand, and this is consistent with the biochemical studies 
showing that AhR-ARNT alone may act as a transcription factor (125, 126).  In 
addition, the AhR influences the cell cycle since mouse embryonic fibroblast 
from AhR deficient mice exhibit a prolonged doubling time compared to wild type 
cells.  Analysis of these fibroblast cells by flow cytometry showed that the slow 
growth rate of these AhR deficient cells was due to prolonged G1 phase of the 
cell cycle (127-129).  There is also a significant increase in TGF-β  expression 
and down-regulation of mitotic kinases such as Cdc2 and other cell cycle 
kinases responsible for proper timing of cell division (112, 127, 130) .   
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Figure 5.  Mechanism of AhR action (121). 
 
 
1.2.15  Toxic responses mediated by AhR 
The AhR was initially identified in the mouse liver cytosolic extracts as the 
intracellular receptor that bound the environmental toxicant TCDD with high 
affinity and subsequently activated the CYP1A1 gene which is one of the most 
widely characterized AhR-dependent biochemical responses which 
subsequently activates a battery of genes which catalyze the oxidative 
metabolism of diverse substances (131-133).  The AhR also binds structurally 
related polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) 
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which contain 3 or 4 lateral chlorine substituents (2, 3, 7, and 8) and these 
compounds are also environmental contaminants formed as byproducts of 
combustion and sewage treatment during production of pesticides and various 
industrial chemicals and during the chlorine-dependent bleaching process in 
paper production (134-136).  TCDD and other AhR agonists are  toxic in 
laboratory animals and in mammalian cell culture and  their toxic effects include 
carcinogenicity and tumor promotion, teratogenicity, immunosuppression, 
neurotoxicity, hepatotoxicity, a wasting syndrome, chloracne and associated 
dermal effects as well as disruption of the endocrine and reproductive pathways 
(115, 131, 137).    In cells, TCDD induces cytokines, hormones and growth 
factors and their receptors as well as phase I and phase II drug-metabolizing 
enzymes such as CYP1A1, CYP1A2, CYP1B1, glucuronosyltransferase and 
glutathione-S-transferases (137, 138).  The AhR also binds with moderate 
affinity to chemoprotective phytochemicals such as indole-3-carbinol (I3C), 
flavonoids, and carotenoids, which exhibit agonist/antagonist activities in rodent 
mammary tumors (112, 139, 140). 
 
1.2.16  Inhibitory AhR-ER crosstalk 
 The ligand-activated AhR complex inhibits estrogen-induced gene 
expression and their derived proteins or dependent activities and also inhibits 
growth of estrogen-dependent mammary tumors in rodent models. TCDD and 
related compounds have been used to study the AhR-mediated responses in 
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ER-positive and ER-negative human breast cancer cells.  ER is a ligand 
activated transcription factor that is a member of the nuclear receptor family.  As 
mentioned earlier, the ER plays an important role in normal female physiological 
development and has also been associated with the promotion of breast and 
endometrial cancer.  Drugs used for treatment of early stage ER-positive breast 
cancer target the ER and these include antiestrogens such as tamoxifen, that 
block estrogen action in mammary tumors.  Several studies also show that 
ligands for the AhR inhibit multiple estrogen-induced responses including the 
inhibition of mammary tumor growth in cells expressing AhR.  AhR-dependent 
inhibition of E2 induced responses has been observed  in the  rodent uterus and 
mammary tumors as well as in breast cancer cell lines (119, 130, 141).
 Kociba and co-workers (1978) reported the effects of long term dietary 
exposure to TCDD on tumor development in both male and female Sprague-
Dawley rats.  There was an increase in hepatocellular carcinomas and 
keratinizing squamous cell carcinomas in female but not male rats.  In contrast, 
several age-dependent spontaneous tumors in the endocrine organs and the 
female reproductive tract were decreased in rats exposed to TCDD in the diet for 
up to two years.  The incidence of both mammary and uterine tumors were 
decreased in female rats exposed to TCDD suggesting that ligand-dependant 
activation of the AhR inhibits formation/ and or growth of E2 dependent tumors.  
These initial observations gave rise to the idea of inhibitory AhR- ER crosstalk 
(121, 142).           
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 Gierthy et al (1993) demonstrated that TCDD at 5 µg/kg/week inhibited 
tumor growth in B6D2F1 immunosuppressed mice bearing MCF-7 cells as a 
xenograft and an implanted E2 pellet (143).  In MDA-MB-231 cells which are 
ER-negative and have a nonfunctional AhR, crosstalk is restored between the 
two receptors upon transient transfection of human ER.  This also demonstrates 
that cross-talk occurs between the two receptors.  (144).  Moreover, in breast 
cancer cells expressing a functional AhR and ER, TCDD significantly inhibits E2-
induced cell proliferation, cathepsin D secretion and mRNA levels, pS2, prolactin 
receptor and mRNA, secretion of tissue plasminogen activator, and 
progesterone receptor (PR) and mRNA.  (143, 145-153).  Inhibitory AhR-ER 
crosstalk activated by TCDD inhibits E2 induced MCF-7 cell proliferation and 
multiple hormone induced cell cycle enzymes and these include cyclin D1 and 
E2F1 protein and mRNA, cyclin dependent kinase-2 (cdk-2), cdk-4 and cdk-7 
activities, cdc25 phosphatase protein and RB protein phosphorylation  (154-
156).          
 Studies have shown that TCDD and related compounds are 
antiestrogenic in rat and mouse uterus.  Treatment of ovariectomized or 
immature rats and mice with E2 increases uterine wet weight and DNA 
synthesis.  Cotreatment with TCDD inhibits E2-induced increase in uterine wet 
weight,  DNA synthesis, EGFR binding and mRNA, progesterone receptor (PR)  
binding,  peroxidase activity, and c-fos mRNA levels (154, 155, 157-161).  
Studies have also shown that incidence of spontaneous mammary and uterine 
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tumors in female Sprague-Dawley rats administered TCDD in the diet for up to 2 
years showed that TCDD inhibited tumor formation and tumor growth.  
Subsequent studies have demonstrated that treatment with TCDD inhibits E2 
dependent mammary tumor formation and growth in carcinogen-induced mice 
and athymic nude mice bearing human breast cancer cell xenografts (143, 162).  
This confirms the finding in Seveso, Italy where women accidentally exposed to 
high levels of TCDD exhibited a decreased incidence of mammary cancer.(163) 
 
1.2.17  Mechanism of inhibitory AhR-ER cross-talk 
 There are several possible mechanisms proposed for inhibitory AhR-ER 
crosstalk and one of these involves enhanced metabolism of E2.  Several 
studies have demonstrated that TCDD and other AhR agonists induce CYP1A1 
and CYP1B1 in breast cancer cells resulting in enhanced metabolism of E2 and 
thereby depleting  intracellular hormone levels resulting in decreased hormone-
responsiveness (164-166).  However, there is evidence to support that 
alterations in E2 metabolism are insufficient to mediate AhR mediated 
antiestrogenic response.  For example, TCDD inhibits cathepsin D mRNA levels 
in MCF-7 cells with in 30-60 min and this precedes induction of CYP1A1 protein 
and E2 metabolism (148, 150, 167).  Furthermore, rodents treated with TCDD 
do not show altered E2 levels, and several selective AhR agonists do not induce 
CYP1A1 protein in breast cancer cells or rodent models but these compounds 
inhibit tumor growth (150, 168).                                                                      
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 Another mechanism of inhibitory AhR-ER crosstalk involves direct 
interaction of the AhR with inhibitory DREs (iDREs).  In most cases where genes 
such as CYP1A1 are activated by the AhR, the AhR/ARNT complex interacts 
with a DRE located in the gene promoter.  Binding of the AhR/ARNT hetero 
dimer complex to DREs induces remodeling of chromatin structure enabling the 
association of transcription factors in the gene promoter and enhancer region 
resulting in gene transcription.  Studies in this laboratory have identified iDREs 
that would account for the inhibitory effects of AhR-ER cross-talk on some genes 
(121).  Cathepsin D is one such gene with an iDRE in the promoter region.  The 
Cathepsin D gene promoter contains an estrogen responsive ERE1/2(N23) Sp1 
motif that is estrogen responsive and this response is inhibited by cotreatment 
with TCDD.  Closer examination of the sequence between the ERE half-site and 
the GC rich Sp1 binding sites revealed the presence of an overlapping core 
inhibitory DRE motif.  Mutation of the DRE motif did not effect reporter gene 
activity induced by E2, however cotreatment with TCDD did not affect E2-
induced responses (169-171). Subsequent studies have identified iDREs in the 
5’ flanking region of the c-fos, pS2, and Hsp 27 genes (172).   
 A third mechanism by which AhR agonists such as TCDD may inhibit 
estrogen-responsive gene expression is by ligand-activated degradation of ER 
resulting in limiting levels of ERα expression.  Initial reports by Harris and 
coworkers (1990) demonstrated that for a series of AhR agonists, their potency 
to induce degradation of ER in MCF-7 cells correlated with their binding affinity 
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for the AhR (172).  Wormke et al.  (2003) showed that both E2 and TCDD 
activated proteasome-dependent degradation of ERα and AhR proteins in MCF-
7 and T47D cells respectively (130). In addition TCDD induced degradation of 
ERα protein, where as E2 did not activate proteasome dependent degradation 
of the AhR.  Thus, TCDD not only activates protease dependent down-regulation 
of its own receptor, but also induces degradation of ERα protein via proteasome 
dependent pathways  and the combined effects of E2 plus TCDD may result in 
limiting levels of ER α for activation of some genes (130).  It is also possible 
that the ligand bound AhR may compete with ER for cofactors leading to 
decreased E2-induced transactivation (173-175).  Studies in this laboratory and 
others have shown that the AhR interacts with ERα coactivators, namely SRC-1, 
RIP 140 and ERAP140 and corepressor SMRT.  These interaction may also 
contribute to inhibition of ER-mediated responses by AhR agonists (131, 137, 
173-175). 
 
1.2.18  Selective AhR modulators (SAhRMs) for treatment of breast cancer  
As discussed above, the AhR is a potential target for breast cancer 
therapeutics.  Alkylated PCDFs and substituted diindolylmethanes (DIMs) 
represent two classes of SAhRMs (Figure 6) which exhibits relatively low toxicity 
but induces antiestrogenic responses.  The toxicity associated with TCDD and 
related compounds is due to their coplanar structure and substitution with 
 54 
chlorine groups at the lateral (2,3,7,8) positions resulting in high AhR binding 
affinities and long term occupation of the AhR (131, 137).  PCDDs or PCDFs 
with chlorine substitutions at only  2 lateral positions exhibit decreased AhR 
binding affinity and toxicity (176).  Moreover, substitution of chlorine with  alkyl 
groups such as a methyl substituents  slightly decrease AhR binding however 
these alkyl PCDFs exhibit decreased toxicity and decreased activity as inducers 
of hepatic CYP1A1 in rats (177-181). 
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Figure 6. Selective AhR modulators 
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1.2.19  Alkyl-substituted polychlorinated dibenzofurans 
 6-Methyl-1, 3, 8 trichlorodibenzofuran (6-MCDF) and other 6-alkyl 
substituted analogs were developed as AhR antagonists and in a series of 
studies this compound was shown to be relatively non-toxic. The 2,4,6,8- or 
1,3,6,8- substituted PCDFs  with at least one alkyl group bound the AhR with 
moderate affinity, exhibited minimal toxicity and partial AhR antagonist activity.   
Cotreatment studies with TCDD and 6-MCDF showed that 6-MCDF inhibited 
TCDD-induced CYP1A1 gene expression in various cell lines and in rat liver 
(177-179).  6-MCDF also inhibited immunotoxicity, cleft plate and hepatic 
porphyria induced by TCDD in mice.  Thus 6-MCDF was shown to be an AhR 
antagonist. (177-179, 182). 6-MCDF competitively binds to the AhR and in gel 
mobility shift assays this complex appears to be distinct from that of the TCDD-
AhR complex, indicating that 6-MCDF may induce a different conformation of the 
AhR compared to the AhR bound to TCDD.  This may explain the reason why 6-
MCDF does not readily induce the gene cascades associated with AhR-
mediated toxicity (179, 182-184).      
 Results in the Safe laboratory have shown that AhR agonists such as 6-
MCDF and 8-MCDF inhibit  carcinogen induced (7,12-
dimethylbenz[a]anthracene-DMBA) mammary tumor growth in  female Sprague 
Dawley rats by 6-MCDF and 8-MCDF (168).   Both compounds cause a dose 
dependent decrease in mammary tumor growth at does of 5, 10 and 25 
mg/kg/week and there was no induction of hepatic CYP1A1 in the treated 
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animals.  The effects of 6-MCDF, TAM and their combination were also 
extensively studies in the rat mamnmary tumor model.  6-MCDF and TAM alone 
inhibited mammary tumor growth at doses of 100 and 50 g/kg/day respectively, 
where as cotreatment with 100, 50, 25 g/kg/day of each compound resulted in 
complete inhibition of mammary tumor growth in all cotreatment groups and in 
some groups the final tumor volumes were less than the initial volumes 
indicating growth stasis.  Data analysis showed that 100, 50 µg/kg doses are 
additive and the interaction at 25 µg/kg is synergistic.  Body and organ weights 
were unchanged in all treatment groups, and there was no induction of CYP1A1-
dependent  EROD activity indicating absence of any AhR mediated effects on 
the liver (168).         
 The effects of TAM, 6-MCDF and their combination were determined in 
ovariectomized female Sprague Dawley rats using TAM (400 µg/kg/day) for 20 
days in combination with 6-MCDF at 800 µg/kg/day.  Results showed that TAM 
significantly induced uterine wet weight, peroxidase activity, and levels of PR 
binding.  However, 6-MCDF at the given dose significantly inhibited uterine 
peroxidase activity and did not induce wet weight or PR binding.  In the 
cotreatment studies, there were minimal changes in uterine wet weight 
compared to treatment with TAM alone.  In addition cotreatment studies showed 
significant inhibition of TAM –induced peroxidase activity and PR binding.(185-
188). These results suggest that 6-MCDF in combination with TAM will act 
synergistically to inhibit mammary tumor growth and block the potential 
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endometrial effects of TAM in the endometrium where the prolonged used of 
TAM is a risk factor for endometrial cancer (168). 
 
1.2.20 I3C and DIM 
Diets enriched in cruciferous vegetables have been associated with 
protection against multiple cancers, including breast cancer in women (34, 185, 
189, 190)  and there has been research on the chemoprotective mechanisms 
associated with phytochemicals produced by these plants. I3C is  found in 
cruciferous vegetables as a cyanogenic glucosinolate which can be hydrolyzed 
by myrosinase to give the free indole derivative(191, 192).   I3C is known to 
inhibit carcinogen-induced initiation and spontaneous tumor formation in various 
cancers such as breast, lung and endometrium (193).   I3C is an  unstable 
compound and rapidly undergoes acid-catalyzed condensation reactions in the 
human gut  to give a complex mixture  of products including DIM, 
5,6,11,12,17,18-hexahydrocyclononal [1,2-β:4,5-β’:7,8-β ‘’] triindole, [2-(indole-3-
ylmethyl)-indole-3-yl] indol-3-ylmethane, 3,3’-bis(indole-3-ylmethyl)  indolenine, 
cyclic and linear tetramers of I3C and  indole (3,2-β) carbazole (ICZ)    (140, 
191, 192, 194). I3C binds weekly to the AhR and the higher molecular weight 
condensation products exhibit increased binding affinity for the AhR (140, 195).  
 The effects of consumption of I3C have been extensively studied.  Initial 
reports showed that high doses of I3C fed in the diet or administered by oral 
intubation to rodents greatly decreased the incidence of spontaneous and 
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carcinogen induced tumors of mammary gland, endometrium, lung, colon, skin, 
liver and cervix (196-199).  Studies have shown that treatment with I3C prevents 
the formation of DMBA-induced mammary tumors in rats, and dietary 
supplementation with cabbage or broccoli both of which are good sources of 
I3C, also resulted in decreased mammary tumor formation in DMBA-treated rats 
(199).  Furthermore, dietary administration of DIM at 5 mmol 20 h prior to 
treatment with DMBA inhibits tumor formation in the carcinogen induced rat 
mammary tumor models (193).       
 The antiproliferative effects of DIM were examined in human breast 
cancer cell lines by examination of incorporated 3H and flow cytometry.  Cell 
proliferation was inhibited up 90%  and also resulted in a G1 arrest (193). . The 
G1 cell cycle arrest of human breast cancer cells by DIM was a result of 
interactions with specific proteins that subsequently control the transcription of 
critical cell-cycle genes.  Cell cycle arrest in MCF-7 cells is accompanied by 
downregulation of Cdk6 and stimulation of p21 gene expression.  Similar results 
are also observed in prostate cancer cells (LNCaPs) (193, 200). DIM also 
caused breast cancer cells to undergo programmed cell death as monitored by 
DNA fragmentation and chromatin condensation.  Apoptosis was accompanied 
by decrease in the apoptosis inhibitory protein Bcl-2 and increase in the levels of 
the  proapoptotic protein Bax (201, 202).  In summary, the transcriptional control 
of cell cycle gene expression is mediated by a combination of the specific effects 
of I3C and DIM. 
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1.3. Prostate cancer 
1.3.1 Statistics 
 
Prostate cancer is the fifth most common cancer worldwide and second 
most common in men.  There were 679,000 new cases of prostate cancer 
diagnosed worldwide in 2002.  The prognosis is relatively good, hence has a 
less prominent cause of mortality with 221,000 deaths worldwide in 2002.  
Approximately 75% of all cases are in men aged 65 or more and mortality rates 
are relatively high in the Carribean, Southern and Central Africa, Northern and 
Western Europe, Australia/New Zealand and North and South America and low 
in Asian populations and in North Africa.  Variations in mortality rates and 
incidence between China and the US are 16-fold and approximately 80-fold 
respectively (1). 
 
1.3.2 Prostate structure and development 
The development of the male reproductive system is dependent upon 
many factors.  The development starts at the embryonic stage where there 
interaction of the mesenchymal-epithelium and the fetal androgens first begins 
(203, 204).  In the fetus, testosterone stimulates budding of the prostate 
epithelium from the urogenital sinus which then produces growth factors such as 
sonic hedgehog to activate the underlying mesenchyme (204).  This is followed 
by branching and morphogenesis of the prostate and the urogenital 
mesenchyme which express very high levels of the androgen receptor (AR).  
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The AR is however undetectable in the epithelium at this time during 
development.  The mesenchyme produces paracrine growth factors that aid in 
glandular morphogenesis and epithelial cell growth in the developing prostate.  
During the maturation process, the AR can be detected in the secretory cells 
layer and in the adult prostate in the stromal and secretory epithelial cells (205). 
A normal adult prostate is composed of a glandular epithelial and a 
fibromuscular stromal component and a balance of proliferation and cell death is 
maintained in these two compartments.  The concept of zonal anatomy of the 
prostate suggested by McNeal in the 1980s forms the current basis for 
describing the location of the neoplastic cells in the prostate.  According to this 
concept, the glandular part of the prostate is composed of a small central zone 
surrounded by a large peripheral zone which make up 95% of the gland.  The 
remainder is composed of the transition zone and the peri-urethral glands.  
About 70% of prostate cancers occur in the peripheral zone and 20% in the 
transition zone and the remaining fraction of the cancers originate in the central 
zone.  Benign prostatic hyperplasia (BPH) develops mainly from the peri-urethral 
stroma and glands of the transition zone (205). 
Most prostate cancers originate from the glands of the peripheral zone 
and hence are classified as adenocarcinomas.  Carcinogenesis occurs in a 
multistage process involving progression from a low-grade small, latent 
carcinoma to high grade metastatic disease (Figure 7).  Normal  prostate 
epithelial cells undergo multiple cellular, biochemical, and genetic alterations, 
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elevated levels of androgens such as testosterone and dihydrotestosterone 
(DHT) leading to neoplastic changes characteristic of prostate cancer (206). 
 
 
Figure 7. Steps in progression of prostate cancer (207).  
 
 
 
1.3.3 Environmental risk factors associated with prostate cancer 
Prostate cancer occurrence differs markedly across different populations 
varying from approximately 1 per every 100,000 reported for China, to 45-65 per 
100,000 Caucasians in the US; rates for people of African descent are as high 
as 100 per 100,000.  Prostate cancer incidence in Western Europe is 20-30 per 
100,000 with some variations among the countries.  The rates of clinical prostate 
cancer vary geographically whereas latent prostate cancer is still equally 
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distributed in areas with high and low prostate cancer.  This strongly suggests 
that environmental factors may be important for the progression from latent to 
clinical prostate carcinoma (208, 209).  It has been reported that among 
migrants moving from countries with a low prostate cancer incidence, such as 
Japan, to North America, their incidence rate approaches incidence rates 
observed among Caucasian Americans within a generation.  Men from the same 
ethnic group but raised in different environments have a risk of prostate cancer 
comparable to the incidence of their residing country rather than their country of 
origin (189). 
It is estimated that 40% of prostate cancers can be explained by genetic 
factors, and there is strong evidence from migration studies that lifestyle and 
environmental factors also have a major influence on development of this 
neoplasia (210). Among the environmental factors, the diet plays a major role in 
the initiation, promotion and progression of prostate cancer.  Several studies 
have identified dietary substances with antioxidant properties that have an 
inhibitory effect on development and progression of prostate cancer.   Many of 
these substances such as carotenoids and lycopenes, retinoids and vitamin A, 
vitamin E, vitamin C, selenium (Se), and phenol containing substances have 
effects that extend beyond just their antioxidant properties (211-213). 
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1.3.3.1 Carotenoids and lycopenes. 
Approximately 600 carotenoids are found in nature and some of these are 
pure hydrocarbons (carotenes) while others may contain oxygenated functional 
groups (xanthophylls).  The major carotenoids include α/β-carotene, β 
crypotoxanthin, lutein, and lycopene (Figure 8).  Carrots, winter squash, and 
pumpkin are a major source of α-carotene while fruits such as mangoes, 
apricots, cantaloupe and vegetables such as carrots, red peppers, pumpkin, 
sweet potatoes, broccoli and leafy green vegetables are a rich source of β -
carotene.  β -Cryptoxanthine is found primarily in mangoes, apricots, sweet 
potatoes, broccoli and leafy green vegetables and lutein is found predominantly 
in green vegetables such as brussels sprouts, green beans, peas, zucchini and 
corn.  Main sources of lycopene are tomatoes, water-melon, and pink grapefruit 
(214-216). 
 The chemical structure of carotenoids enables them to absorb UV light 
and act as antioxidants.  In addition, β-carotene inhibits cancer cell growth in a 
cell cycle-independent manner and also induces apoptosis (214, 215). In 
addition to acting as quenchers for reactive oxygen species, carotenoids also 
interfere with free radical-initiated reactions such as lipid peroxidation. (217). 
 The link between lycopene intake and development or progression of 
prostate cancer has been extensively investigated.  Several studies have 
reported a significant inverse association between the dietary intake of tomatoes 
and blood lycopene levels, and the risk of prostate cancer (218). A population 
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based case-control study conducted in New Zealand showed a link between 
lycopene consumption and prostate cancer revealed that increased intake 
resulted in decreased prostate cancer, however no correlation was observed for 
β-carotenoids (219). Another randomized, placebo-controlled study by Gann and 
colleagues (1999) compared plasma lycopene levels in 578 men with prostate 
cancer with 1294 age and smoking status matched controls and observed an 
inverse correlation between plasma lycopene levels and prostate cancer risk. 
(220).  Similar results were observed in a Chinese population by Binns and 
colleagues who noted an odds ratio (OR) of 0.18 (95% CI0.08-0.41) for lycopene 
in a questionnaire-based case-control study (221).  Some studies have 
demonstrated an inverse correlation between dietary lycopene intake and both 
serum IGF-1 levels and risk of prostate cancer.  Lycopenes may exert protection 
against prostate cancer, particularly early in the disease process by decreasing 
plasma IGF-1 levels by an unknown mechanism (222-224).  In vitro studies 
using prostate cancer cell lines namely PC-3, DU145, LNCaP by Kotake and co-
workers (2001) demonstrated the antiproliferative effects of carotenoids found in 
tomatoes.  They discovered that both  monoethoxy and acyclic carotenoids 
significantly reduced prostate cancer cell viability and in addition they 
demonstrated that the reduced viability was mediated by apoptosis.(225). 
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Figure 8. Lycopene and β-carotene 
 
 
1.3.3.2  Retinoids and vitamin A 
Retinoids include retinal (vitamin A) retinoic acid, and retinol (Figure 9).  
Vitamin A or retinal is a conversion product of β-carotene in the gut but its main 
sources are derived from foods of animal origins such as liver and fish oil, 
whereas β-carotene found in carrots, and green vegetables is chemically 
converted into retinol in the gut (226).  Vitamin A exhibits anti-oxidant activity; 
however the compound alone is unable to quench singlet oxygen species but 
rather exerts its effects by affecting tissue levels of other antioxidants such as a-
tocopherol and Se.  Retinoids are classified as antiproliferative biomolecules 
which may also induce apoptosis (227, 228) These compounds also act as 
transcriptional regulators by inhibiting DNA polymerase activity in G1 phase of 
the cell cycle in some cell types.  (229, 230). 
 66 
Studies by Sharp and co-workers (2001) using the synthetic retinoid N-(4-
hydroxyphenyl)-retinamide (4-HPR) showed that in vitro  cell growth was 
inhibited in 4 different prostate cell lines (DU145, RWPE-1, WPE1-7, WPE1-10) 
and histological staining revealed that this was achieved by a mechanism in 
which both  tumor suppressor protein p53 and pRB were downregulated.  This 
suggests that inhibition of prostate cancer cell proliferation is achieved at several 
stages of disease progression(231).   Epidemiological studies in men older than 
70 years demonstrated an inverse relationship between dietary vitamin A intake 
and prostate cancer (212, 232).  Men with BPH had plasma vitamin A levels five 
to eight fold higher than those men with prostate cancer.  A study by Rohan et 
al.(1995) comparing the diets of 207 men with prostate cancer and 207 
randomly selected men with BPH revealed that higher dietary retinol intake was 
associated with a reduced risk of prostate cancer.  Thus, increased dietary 
intake of vitamin A may be beneficial in reducing the incidence of prostate 
cancer in older men who already have a higher age-related risk of developing 
prostate cancer (233). In addition, treatment with retinoids appears to increase 
the expression of prostate-specific membrane antigen, a marker that is 
associated with more differentiated histology in prostate cancer tissues (234).  
Also, Slawin et al. (1993) demonstrated that mice fed a diet enriched with 
synthetic retinoid, fenertinide, had a 49% reduction in prostate tumors and 52% 
reduction in tumor mass as compared to mice whose diet lacked fenretinide 
(235). 
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Figure 9. Vitamin A 
 
 
1.3.3.3  Vitamin E 
Vitamin E refers to eight structurally related compounds found in 
vegetable oils, nut oils, egg yolk, various cheeses, whole grain products and 
vegetables like carrots, sweet potatoes and tomatoes.  These compounds are 
fat soluble and are absorbed efficiently from the gut.  The antioxidant properties 
of vitamin E are due to the chemical structure and the reactivity of the phenolic 
hydrogen ion and C6 hydroxyl group which provides the unpaired electron that 
stabilize various free radical species  (236). The major forms of vitamin E are α, 
β, δ and γ-tocopherol (Figure 10).  α-Tocopherol has the greatest antioxidant 
activity followed by β-tocopherol and γ-tocopherol (both are roughly equal) 
followed by δ-tocopherol which has the least activity (236).  Vitamin E scavenges 
free radicals, inhibits peroxidation of lipid membranes and reduces carcinogen-
induced DNA damage.  In addition α-tocopherol binds highly reactive genotoxic 
electrophiles such as hydroxyl, superoxide, lipid peroxy, hydroperoxyl and 
nitrogen oxide derived free radicals and these interactions protect against DNA  
and biological membrane damage by free radicals (237).  In a large study of 
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smokers, both incidence and mortality from prostate cancer were significantly 
lower in men who were given 50 mg of vitamin E (a-tocopherol)  for 5-8 
years(238).  The United States Health Professional Study (USHPS) conducted 
on 47,780 healthy male health professional, including smokers and non smokers 
who were administered a dietary lifestyle questionnaire followed by 11 years of 
monitoring for prostate cancer showed no association between dietary vitamin E 
supplementation and decreased prostate cancer.  However there was an inverse 
association between dietary vitamin E supplementation and a decrease of 
metastatic and fatal cases of prostate cancer among the smokers in this group 
of professionals(239). 
  
 
Figure 10. γ-tocopherol 
 
 
1.3.3.4  Vitamin C  
Vitamin C also known as ascorbic acid is present in foods of both plant 
and animal origin (Figure 11).  Some sources include potatoes, fruits, vegetables 
and organ meats such as kidney and liver.  Vitamin C is thought to protect 
cytoplasmic and membrane components of cells from oxidative damage by 
scavenging free radicals generated during cellular metabolism as well as from 
free radical induced damage.  It does so by donating one or two of its electrons 
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during a redox reaction resulting in production of an ascorbate free radical (AFR)  
(240, 241). In addition, vitamin C inhibits cellular DNA synthesis, growth, and 
viability by inhibition of G1 phase of cell cycle and by triggering DNA degradation 
(242). In vitro studies using prostate cancer cell lines namely LNCaP and DU145 
cells have shown that vitamin C causes a dose and time dependent  decrease in 
cell number, viability and DNA synthesis (242).   Epidemiological results 
however have shown mixed results about the beneficial role of dietary vitamin C 
in prostate cancer.  Most studies found no association between increased serum 
and dietary vitamin C content and reduced risk of prostate cancer.  The study by 
Deneo-Pellegrini et al. (1999) however, has demonstrated that the beneficial 
effects of vitamin C in reducing risk of prostate cancer are dose dependent, 
hence raising the possibility that studies showing no association may have not 
included individuals with adequate vitamin C levels to demonstrate such an 
association (213, 243, 244).  The European Prospective Investigation into 
Cancer and Nutrition (EPICN) which evaluated plasma vitamin C levels and 
cancer mortality in both males and females whose diet was augmented with low 
and high doses of vitamin C showed an inverse relationship to cancer mortality 
in both the sexes (245). 
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Figure 11. Vitamin C 
 
 
1.3.3.5  Selenium (Se) 
 Plants are major source of Se and its concentration varies according to 
geographic region and soil content.  The major dietary sources of Se are bread 
products and meats (246).   Se is a constituent of the enzyme glutathione 
peroxidase (GPO) and in concert with glutathione (GSH) GPO plays a crucial 
role in preventing harmful effects of free-radical induced lipid membrane 
damage.  The multi-complexed enzyme system along with GSH prevents free 
radical formation by converting hydrogen peroxide to harmless water.  Se also 
induces apoptosis and inhibits cell growth by arresting or blocking various steps 
in the cell cycle (247).  In prostate cancer DU145 cells, Se induces apoptosis by 
activation of multiple caspases such as caspase-3, -7,-8, and -9, along with the 
release of mitochondrial cytochrome c accompanied by DNA laddering (248).  In 
vivo studies by Hardell et al. (1995) have shown that average plasmas levels of 
Se were significantly higher in patients with BPH than those with prostate 
cancer.  In a similar study by Criqui et al. (1991)  plasma Se levels were higher 
in patients of the control group than those who died of prostate cancer whose 
plasma was stored under similar conditions of time and temperature. (249, 250).  
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However in one prospective study, it was found that increased Se levels in men 
who later developed prostate cancer correlated with reduced risks of advanced 
disease (251) although it was not observed in another study (252).  In addition, a 
placebo controlled study by Clark et al (1998) reported  that geographical areas 
of the US with low Se soil content, exhibited a significantly lower incidence of 
prostate cancer among men receiving dietary supplements enriched with Se 
(253, 254). 
 
1.3.4 Lifestyle risk factors associated with prostate cancer 
Among the lifestyle factors that play a substantial role in development of 
prostate cancer are obesity and smoking.  Obesity is often associated with a 
more sedentary life style and decreased frequency of physical activity.  Obesity 
caused an increase in circulating estrogen levels and decreasing androgen 
levels since they are aromatized to form estrogens in adipose tissue.  This 
results in an increase of prostate cell sensitivity to androgens and hence 
increases the risk of prostate cancer (255). 
Andersson and colleagues (1997) discovered that BMI was positively 
associated with increased mortality from prostate cancer, and similar results 
were observed by Rodriguez and coworkers (2001) upon examination of 1590 
deaths from prostate cancer in two cancer prevention studies.  Another study 
(Hsing et al. 2000) among a Chinese male population cohort showed that the 
highest quartile of waist-to-hip ratios among the subjects conferred a 2.71 times 
 72 
greater risk of prostate cancer compared to lowest quartile.  In contrast, other 
studies (Health Professionals Follow-up Study, Baltimore Longitudinal study of 
Aging and Swedish Twin Registry) showed that there was not a statistically 
significant excess risk of prostate cancer associated with BMI or other measures 
of obesity.  Thus it appears to be that obesity confers an excess risk of prostate 
cancer mortality rather than incidence (256-258).  
The role of smoking in prostate cancer is not clear, however most of the 
studies that used incident prostate cancer cases in their analyses observed no 
strong association between smoking and risk of  prostate cancer development.  
However there are some studies for example one among the Swedish 
construction workers which consisted of 135,000 subjects of which 2300 
subjects developed prostate cancer during 20 years of follow-up which indicate a 
significantly increased risk for prostate cancer.  In two other studies conducted in 
Iowa and California there was a significant positive association between 
smoking and risk for prostate cancer.  In addition there was a dose-response 
relationship observed in the Swedish and the Iowa cohort studies (259-262).  
Also the Health Professional Follow-Up Study found that men who had smoked 
15 or more pack-years of cigarettes within the preceding 10 years were at a 
higher risk of metastatic prostate cancer and fatal prostate cancer relative to 
non-smokers, and they also noted a dose-response relation between smoking 
and prostate cancer. (263). 
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1.3.5 Genetic risk factors for prostate cancer 
1.3.5.1.  Hereditary risk factors in prostate cancer 
Prostate cancer can be divided epidemiologically into hereditary and 
sporadic forms.  Some of the important hereditary risk factors for prostate cancer 
can be attributed to the following genes:  ELAC2, CHEK2, RNASEL, BRCA1 and 
BRCA2.  The first hereditary prostate cancer gene to be discovered was the 
ECLA2 gene located on chromosome 17p.  Although the entire function of this 
gene is not clearly known it has been proposed as a metal dependant 
hydrolyase, and its overall role in prostate cancer seems to be minimal (264, 
265).   This gene consists of 24 exons coding for a protein of 826 amino acids, 
which displays 98.9% homology with the chimpanzee gene.  Mutational analysis 
of this gene revealed a frame shift mutation that segregates with prostate cancer 
in a high risk pedigree. Analysis of another large pedigree revealed another 
missense mutation, Arg781His, which occurs in a very highly charged stretch of 
amino acid residues near the C terminus of the protein which also segregates 
with the disease (265).  Upon extensive screening two more missense variants 
were identified namely Ser217Leu and Ala514Thr which lie at the border of a 
histidine motif and thus may affect the protein function (265) An extensive study 
by Rebbeck et al (2000) consisting of 359 prostate cancer cases and 266 male 
controls matched for age and race revealed that the Leu217 and Thr541 had a 
mutation frequency of 31.6% and 2.9% respectively and the relative risk of 
prostate cancer was increased in men carrying the Leu217/Thr541 allele (266). 
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 The CHEK2 gene is an upstream regulator of p53 in the DNA damage 
signaling pathway.  CHEK2 mutations have been identified in both sporadic and 
familial cases of prostate cancer (264, 265).  This gene is located on 
chromosome 22q and encodes for cell-cycle checkpoint kinase2 (chk2) a 
mediator of cells’ response to DNA damage.   Upon DNA damage chk2 
phosphorylates several substances such as p53, BRCA1, Cdc25A and Cdc25C 
which are involved in DNA repair and apoptosis. It has been suggested that 
germ-line CHEK2* 1100delC resulting in truncated protein along with other 
CHEK2 mutations confer susceptibility to prostate cancer (267).  In a Swedish 
study by Wagenius and co-workers (2005) CHEK2* 1100delC mutation was 
found at a frequency of 1.6% in sporadic cases diagnosed before the age of 55 
and similar results were observed for hereditary prostate cancer.  The CHEK2* 
1100delC mutation was found at a greater frequency in a study conducted 
among Finnish patients with hereditary prostate cancer (268).  
 Many important features are shared between breast and prostate cancer.  
They both share hormone dependency and a tendency for bone metastasis and 
epidemiological studies have shown evidence to link these two cancers in 
inheritance.  The tumor suppressor gene BRCA1 has been linked to a subset of 
hereditary breast cancers.  In some studies, a slight increase in risk of prostate 
cancer was detected in individuals carrying known BRCA1 truncating mutations, 
especially those who were younger in their age at diagnosis (68).  However 
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several other studies have found no association between BRCA1 mutations and 
prostate cancer risk (269). 
 The BRCA2 gene, however, has been consistently shown to play a 
significant role in prostate cancer.  Germ-line mutations in the BRCA2 gene 
account for 30-35% of familial breast cancers and an association between 
BRCA2 mutations and prostate cancer has been noted in breast-ovarian cancer 
families with BRCA2 mutations.  A common founder mutation (6174delT) which 
has been identified in an Ashkenazi Jewish population has been significantly 
associated with increased risk of prostate cancer.  Another founder mutation, a 
5-bp deletion among Icelandic population has been associated with increased 
risk of prostate cancer.  An estimated 5% of prostate cancer in familial clusters 
have been linked to germ-line mutations in BRCA2 and hence these mutations 
are significant in prostate cancers diagnosed at a younger age (270). 
 RNASEL is a ribonuclease that degrades viral and cellular RNA resulting 
in cellular apoptosis upon viral infection (264).  The RNASEL gene    is located 
on chromosome 1q25 and with the help of positional cloning and candidate gene 
methods a non-sense mutation and a mutation in an initiation code have been 
shown to segregate independently in hereditary prostate cancer.  A founder 
frame shift mutation 471delAAAG has been identified in Ashkenazi Jews, at a 
relatively high frequency (4%) and in the model human prostate cancer cell line, 
LNCaP.  The frequency of this mutation was higher among prostate cancer 
patients (6.9%) as compared to (2.4%) in unaffected elderly men in this group of 
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population (270, 271). The role of RNASEL in prostate cancer was strongly 
supported by a Finnish study consisting of 116 families with hereditary prostate 
cancer. A truncating mutation, E265X was found at a significantly higher 
frequency 4.3%, in hereditary prostate cancer than in the control cases (1.8%).  
In addition the frequency of the E265X mutation increased with the number of 
affected members per family such that families with four or more affected 
individuals have a frequency of E265X of 9.5%.  There was no significant 
increase in the frequency of E265X in  unselected prostate cancer patients 
compared to controls(271). 
 
1.3.5.2  Sporadic prostate cancer 
The genomic alterations in prostate cancer that are responsible for 
sporadic cancer are mostly somatic changes.  A role for a number of genes has 
been identified for their role in sporadic prostate cancer.  For hereditary cancer, 
the relevant mutations are mainly at the sequence level, but for sporadic cancer, 
the relevant mutations include alterations in both sequence and copy number 
(270). 
Early stage prostate cancer often remains euploid and numerical and 
structural chromosomal alterations accumulate at advanced stages.  Deletion of 
chromosomal segments predominate, while gains of chromosomal segments 
and amplifications become more frequent in advanced prostate cancer (205). 
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 Mutations of a substantial number of tumor suppressor genes have been 
identified in all human cancer cells.  Among the established tumor suppressor 
genes, p53 and PTEN are clearly involved in the progression of prostate 
carcinoma.  Losses of chromosome 17p and 10q corresponding to p53 and 
PTEN respectively, occur with moderate frequency in advanced cancers.  Loss 
of one allele is accompanied by point mutation in the remaining copy of p53 
leading to its functional inactivation(272).  In the case of PTEN, point mutations 
have been identified in one allele and the other copy is transcriptionally silenced.  
PTEN is one of the few genes that is implicated in prostate cancer by frequent 
somatic mutations in aggressive prostate cancer.  PTEN is more frequently 
mutated in prostate cancer metastases indicating its role in progression of 
prostate cancer (270). 
 KLF-6 is another tumor suppressor gene and its gene product acts as a 
zinc finger transcription factor and has a role in cell proliferation and 
differentiation.  Somatic mutations of KLF-6 in prostate cancers have been 
confirmed in many studies, and in addition loss of KLF-6 expression by 
regulatory mechanisms also occurs in prostate cancer.  In addition a germline 
SNP in KLF-6 has been confirmed in a tri-institutional study of 3411 men there 
was a significant association of this mutation with an increased relative risk of 
prostate cancer (273). 
 The altered expression of several prominent oncogenes also contributes 
to prostate cancer development and progression.  A very consistent finding in 
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metastatic cancers is over-expression of MYC which is due to increased copy 
number by chromosomal gains or amplification.  Comparative genome 
hybridizing studies have shown that gain of 8q, including 8q24 involving MYC 
and 8q21 is one of the most frequent alterations in prostate cancer (274). In vivo 
studies using transgenic mouse models over-expressing MYC in the prostate 
leads to prostatic intraepithelial neoplasia and induction of prostate carcinomas.  
Moreover, over-expression of MYC, can also immortalize human prostatic 
epithelial cells (275). 
 In addition to altered oncogenes and tumor suppressor genes, prostate 
cancer has been shown to harbor deregulated expression of several growth 
factors including tyrosine kinase receptors EGFR, FGFR2c and ErbB2.  
Chromosomal gain may contribute to over-expression of many of these growth 
factors/receptors (276).  Although examination in finer detail will reveal a much 
larger number of genes that are responsible for the initiation, progression and 
promotion of prostate cancer, the genes mentioned above are some of the 
critical genes involved in the disease. 
 
 1.3.6  Treatment of prostate cancer 
 Treatment of prostate cancer is highly dependent on the stage and 
advancement of the cancer (Table 8).  There are multiple treatment options 
based on individual diagnosis and progression of the disease.   Management 
options for clinically localized prostate cancer include radical prostatectomy,  
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Table 8.  Staging of the primary tumor and regional lymph nodes (277). 
 
 
radiotherapy and cancer surveillance.  Adjuvant therapy in the form of androgen 
deprivation, radiotherapy and hormone therapy is available for patients with 
more advanced cancers.  Current treatment options for early prostate cancer 
include radical prostatectomy, radiotherapy and hormone therapy consisting of 
androgen ablation(278). 
   
T- Primary 
tumor 
  
ABCD 
   
   
TX Primary tumor cannot be assessed  
T0 No evidence of primary tumor  
T1 Clinically unapparent tumor not palpable or visible by imaging  
T1a Tumor incidental histological finding in 5% or less of tissue resected A1 
T1b Tumor incidental histological finding in more than 5% or less of tissue 
resected 
A2 
T1c Tumor identified by needle biopsy B0 
T2 Tumor confined within the prostate  
T2a Tumor involves one lobe B1 
T2b Tumor involves both lobes B1 
T3 Tumor exceeds through the prostatic capsule  
T3a Extracapsular extension (unilateral or bilateral) C1 
T3b Bilateral extracapsular extension C1 
T3c Tumor involves seminal vesicles C2 
T4 Tumor invades bladder neck, external spincter, rectum, levator 
muscles and/or pelvic wall 
C2 
N Regional lymph nodes  
NX Regional lymph nodes cannot be assessed  
N0 No regional lymph node metastasis D 
N1 Regional lymph node metastasis  
   
 80 
 Radical prostatectomy is a curative procedure intended for treatment of 
localized prostate cancer, which consists of surgical removal of the prostate and 
the seminal vesicles.  It was first discovered by H. H. Young in 1905.  Since then 
many advancements have been made in this technique which enables the 
patients to maintain their quality of life, in terms of urethral control and erectile 
function.   Radical retropubic prostatectomy (RRP) is  offered to men with 
clinically localized prostate cancer (T1-3a, Nx/0, M0) and a life expectancy of 10 
years or longer (279).  In general PSA levels serve as a good method for 
monitoring the tumor free status following RRP.  A few long term (15 years) 
follow-up studies have shown that PSA progression-free survival has been 
reported to be 40-60% after 15 years (279). 
 Radical radiation therapy is currently used to treat more than 60,000 men 
each year in achieving total tumor eradication in these men who are presented 
with early prostatic carcinoma (280)..   There are no randomized studies that 
compare the outcome of surgery (prostatectomy) with either radiotherapy or 
brachytherapy for patients with clinically localized low-risk prostate cancer.  
However there is substantial documentation from large single-institutional and 
multi-institutuional studies of patients with this disease category (PSA < 10, 
gleason score  6,  T2b) showing that the outcome of external beam 
radiotherapy is similar to those of surgery (277).  A successful outcome requires 
a patient to have no PSA-based evidence of relapse with long-term follow-up of 
10 years or more(280). 
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1.3.6.1  Antiandrogen hormone therapies 
 Androgen deprivation by hormone therapy has been the mainstay of 
treatment for managing advanced prostate cancer.  Castration-based therapy is 
the predominant form of androgen deprivation therapy; however it is associated 
with adverse side effects such as decreased muscle mass, loss of bone mass 
and osteoporosis along with quality of life issues such as maintenance of sexual 
activity and physical ability.  Hence alternative hormone therapies that are both 
effective and better tolerated are essential (281, 282). 
 Androgen blockade for the treatment of prostate cancer has significantly 
improved since its inception in the 1930 where the methods used were 
irradiation of the testis or radiotherapy.  Androgen blockade can now be 
achieved by pharmacological means with the introduction of luteinizing hormone 
releasing hormone (LHRH) analogs.  LHRH analogs are equally effective as 
castration and have the advantage of being reversible.  Leuprolide (Lupron®, 
Viadur ®) and Goserelin (Zoladex ®) are the two most commonly used for 
treatment of prostate cancer in the US (283, 284).  However, LHRH analogs are 
associated with many disadvantages such as  initial transient “flare” of 
symptoms during therapy, loss of sexual potency, hot flashes  fatigue, anemia 
and osteoporosis (283). 
Antiandrogens are a class of drugs with a different mechanism of action 
to castration therapies.  Antiandrogens compete with circulating androgens for 
binding sites on their receptors with in the prostate cell, thus promoting 
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apoptosis and inhibiting prostate cancer growth (Figure 12) (283). Antiandrogens 
are classified into two structurally distinct classes namely steroidal 
antiandrogens which include cyproterone acetate (CAP) and non steroidal 
antiandrogens which include bicalutamide [Casodex], flutamide, nilutamide.  
Both classes of chemicals act as competitors of androgens at the receptor level.  
While this is the main mechanism of action for non-steroidal antiandrogens, 
steroidal antiandrogens also have progestational activity that decreases serum 
testosterone levels, leading to loss of libido and sexual function (282, 285).  In 
contrast, the non-steroidal antiandrogens do not suppress testosterone and 
estrogen levels, allowing sexual potency to be retained (282). 
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Figure 12. Structures of available antiandrogens (282). 
 
 
 Comparative studies of non-steroidal antiandrogen monotherapy versus 
castration alone in patients with locally advanced disease have been carried out 
with bicalutamide only.  A study pooling two open-labeled, multicenter studies of 
identical design has evaluated efficiency of bicalutamide monotherapy to 
castration.  The study consisting of 480 patients with T3-4 upto N0 disease 
stages received either 150 mg of bicalutamide or castration.  After a follow-up of 
6.3 years, mortality was 56% with no significant difference between the two 
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groups in terms of overall survival or time of progression for bicalutamide relative 
to castration (286).  The early prostate cancer program (EPC) conducted 3 
randomized double-blind, placebo controlled studies to compare bicalutamide as 
an adjuvant to therapy of curative intent in men with locally advanced disease.  
The study consisted of 8,113 men with localized or locally advanced prostate 
cancer who were randomized to bicalutamide 150 mg or placebo, in addition to 
standard care of radiotherapy, radical prostatectomy, or watchful waiting.  The 
follow-up analysis (7.5 years) revealed that 150 mg of bicalutamide significantly 
improved progression-free survival compared with radiotherapy or radical 
prostatectomy alone.  In addition, bicalutamide 150 mg adjuvant to radiotherapy 
was associated with a significant improvement in overall survival, largely 
because of a reduced risk of prostate cancer-related deaths (16% in 
bicalutamide group vs. 24.3% with standard care alone) (287).  In a randomized 
trial evaluating flutamide at 750 mg adjuvant to radical prostatectomy compared 
with radical prostatectomy alone in patients with lymph-node negative prostate 
cancer there was a significantly increased progression free survival.(288). 
 One of the most important advantages of non-steroidal antiandrogens is 
that they allow patients to maintain serum testosterone and estrogen levels, thus 
offering potential benefits on quality of life when compared with castration based 
therapies (282). In an Italian study comparing bicalutamide 150 mg monotherapy 
with combined androgen blockade (CAB) using flutamide 750 mg plus goserelin 
3.6 mg (LHRH analog), significantly fewer patients in the bicalutamide group 
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reported erectile dysfunction  (69.2% vs. 93.3% respectively) or loss of libido 
(59.6% vs. 85.5 respectively) compared with CAB alone.(289).  Hence it is clear 
that non-steroidal antiandrogens are an effective treatment option with locally 
advanced prostate cancer and are advantageous over castration based 
regimens. 
 
1.3.7  The androgen receptor (AR)  
 The AR gene is a member of the steroid hormone receptor gene family 
which includes the glucocorticoid receptor, progesterone receptor, 
mineralocorticoid receptor and s(290).  The AR is located on chromosome Xq11-
12 and its genomic organization is conserved throughout mammalian evolution 
from rodents to man.  The AR gene spans approximately 90 kb of DNA 
containing eight exons that code for 2757 base pair open reading frame with a 
10.6-kb mRNA (Figure 13) (291, 292).   The first exon codes for the N-terminal 
domain that is the transcriptional regulatory region of the protein, also known as 
the activation function 1 (AF1) domain.  Exon 2 and 3 code for the central DNA-
binding domain (DBD) and exons 4-8 code for the C-terminal steroid 
hormone/ligand binding domain (LBD) (291, 292). 
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Figure 13.  AR structural organization  (293). 
 
 
 The AR is a phosphoprotein that mediates the action of testosterone and 
dihydrotestosterone (DHT) by acting as a transcription factor.  The AR is found 
in many tissues of both sexes but is most abundant in male sex tissues.  The AR 
has a pivotal role in growth and differentiation of the male urogenital structures 
and is also essential for the initiation and maintenance of spermatogenesis 
(294). 
 
1.3.7.1  Molecular mechanism of AR action 
 The AR is a large multi-protein complex comprised of heat shock proteins 
bound to the ligand binding domain in its transcriptionally inactive form.  Many 
unliganded steroid hormone receptors reside in the cytoplasm where they are 
sequestered by such chaperone molecules.  Ligand binding induces 
conformational changes in receptors, which leads to shedding of the chaperones 
and translocation into the nucleus (295-299).  However in the case of the AR 
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there is evidence showing that the major portion of the receptor is located in the 
nucleus (292) and localization of the AR may also be cell type specific (300, 
301).  In the absence of ligand, the LBD represses AF-1-mediated activation and 
agonist binding phosphorylates the AR at  three or more sites and one of these 
is required for transactivation (292). 
 Like other nuclear receptors, AR activity is also modulated by coactivator 
and corepressor complexes.  Agonist binding results in recruitment of 
coactivators to the AF1 regions resulting in formation of a protein complex which 
then interacts with other transcriptional mediators and cofactors as well as the 
basal transcriptional machinery to modulate target gene transcription(302, 303).  
There are mainly two types of coactivators; type 1 coactivators function by 
influencing chromatin remodeling, or recruitment of general transcription factors 
associated with the RNA polymerase II holocomplex.  The p160 family of 
coactivators, which include steroid receptor coactivator 1 (SRC-1), SRC-2, also 
known as glucocorticoid receptor interacting protein (GRIP/TIF2), SRC-3, cyclic 
AMP response element  binding protein/p200 (CBP/p300) act as transcriptional 
coactivators for AR and are included in type 1 coactivators (304, 305).  Type II 
coactivators act by influencing appropriate folding of the AR or promoting 
between the N- and C-terminal domain interactions.  A number of AR associated 
proteins including ARA70, ARA 55, ARA54 which stabilize ligand-bound AR are 
included in this category.(306).  The cell cycle regulatory proteins such as cyclin 
E and the RB also function as coactivators of AR in its transactivation regulatory 
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activity, and this may be a factor linking the growth promoting activity of AR 
signaling with  regulators of cell cycle progression (293, 306, 307). 
 
1.3.7.2  AR and prostate cancer 
The AR and prostate cancer are closely linked since the prostate gland 
depends on androgens for its development and maintenance.  Congenital 
dysfunction or deficiency mutations of the 5-a-reductase in genetic males 
causes minimal development or absence of the prostate gland (308).   Mice that 
have been castrated for less than a week will experience involution of the 
prostate due to epithelial cell apoptosis (309).  The role of AR in promotion of 
prostate cancer is evident in transgenic mice engineered for elevated AR 
expression in the prostate since they show very high turnover of prostatic 
epithelial cells and develop prostatic intraepithelial neoplasia later in life (310).  
Although it is evident that androgens are important in the development of 
prostate cancer, it is difficult to correlate relative levels of serum androgens with 
prostate cancer risk since many other factors may  play an equally important role 
in prostate cancer promotion (292). 
 The AR gene is normal and expressed in primary prostate carcinomas, 
but following androgen deprivation therapy, a number of AR gene alterations 
occur.  These alterations cause the receptor to be more sensitive to low levels of 
circulating androgens and also affect the receptor’s ability to recognize a wider 
spectrum of ligands that activate the AR (292, 294).  Prostate cancer cells adapt 
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to hormone deprivation therapy by amplifying AR gene copy number.  
Approximately 25-30% of patients who experience disease reoccurrence exhibit 
this phenomenon.  Experiments have shown that gene amplifications are not 
found in pretreated tissue from patients in whom AR gene amplification occurred 
following hormone ablation therapy.(311-313).  AR amplification was associated 
with increased mRNA expression and patients harboring AR amplifications had 
longer response duration to initial hormone therapy and a longer median survival 
after recurrence (313).  Also, patients with AR amplifications had an increased 
likelihood of responding to second-line hormone therapy than patients lacking 
amplification (313). 
 Point mutations in the AR lead to altered responses to antiandrogens and 
binding affinities to a larger number of agonists.  The first AR mutation in 
prostate cancer was discovered in the well-characterized LNCaP cell line which 
harbors a point mutation at codon 877 of the hormone-binding domain.  The 
mutant cell lines recognize the antiandrogens cyproterone acetate and 
hydroxyflutamide, the active metabolite of flutamide as agonists (314, 315).  
Since then, point mutations have been reported in hormone sensitive prostate 
cancers and more frequently from androgen-independent tumors (316, 317).  
Marcelli et al. (2000) reported that AR point mutations occurred in 8 of 38 (21%) 
regional lymph nodes from hormone-sensitive patients (318).  Tilley et al. (1996) 
reported AR mutations in 11 of 25 (44%) of prostate gland tumor samples from 
hormone-sensitive patients (319). 
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 AR mutations in prostate cancer cluster in three regions of the gene.  In 
the LBD, mutations cluster in the loop between helices 3 and 4 which is common 
to many steroid hormone receptors.  Mutations in this regions enables the AR to 
bind to a greater spectrum of steroid hormones and pharmacological  
antiandrogens(317, 320, 321).  A second cluster is located in the region 874 to 
910 that flanks AF-2, and affects binding of p160 coactivator molecules and the 
AR NTD (322).  Mutations are also found in the hinge region that borders the 
DBD and the LBD.  Mutations in this region affects AR interactions with 
corepressors resulting in diminished efficacy of antiandrogens and this may 
explain the sensitization of the AR to ligand interactions in late-stage prostate 
cancer (323). 
 There have also been several studies showing that the AR in prostate 
cancer cell lines can be activated in the absence of androgens or by decreased 
levels of androgens.  Initial studies in LNCaP cells showed the growth factor 
interactions with IL-6 and the IGF-1, keratinocyte growth factor(KGF), and EGF  
stimulated AR transactivation function in the absence of androgen (293, 324).  
These results correlate with the observation that IL-6 levels are elevated both in 
the serum as well as tissue extracts of patients with prostate cancer.  Also KGF, 
IGF-1, and EGF are produced and secreted by fibroblasts of prostatic stoma 
tissue and these growth factors are known to affect paracrine regulation of 
prostate epithelial cells via their cognate cell surface receptors expressed in 
epithelial cells.  The ligand dependent interaction causes activation of receptor 
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tyrosine kinase activity of the cell surface receptors in epithelial tissue which 
leads to activation of a cascade of kinase-driven intracellular signaling pathways.  
With the help of pharmacological inhibitors , it was demonstrated that the Ras-
Raf-MEK-ERK pathway of MAP kinase signaling is a major pathway in the 
crosstalk of AR with IL-6/IGF/EGF/KGF (293, 324).  High grade prostate 
carcinomas are frequently exhibit activated PI3K/Akt signaling (325).  Activation 
of Akt triggers antiapoptotic signals by phosphorylation and induces inactivation 
of the proapoptotic proteins Bad and Caspase-9 (326, 327). 
 Like androgens, estrogens can also promote growth of the hypertrophic 
prostate tissue and prostate adinocarcinomas.  The b form of ER (ERβ) is the 
primary mediator of estrogen action in the prostate (328).  The normal human 
prostate epithelium shows significant expression of the ERβ and E2 stimulates 
proliferation of LNCaP prostate cancer cells.  Exposure of  LNCaP cells to 
estrogen or androgen triggers association of AR and ERβ to the cytoplasmic 
tyrosine kinase Src and the AR-Src-ERβ ternary complex  activates the Src/Raf/-
1/ERK-2 pathways, causing S-phase entry and prostate cancer cell proliferation 
(329). 
 With all the molecular knowledge available  at hand about the many 
pathways active in prostate cancer progression and metastasis,  combined with 
the ongoing research commitments in this field,  new methodologies and new 
drugs will become available to the growing demands of the disease. 
 92 
1.4  Research objectives  
 
The AhR is a ligand activated nuclear transcription factor that mediates 
responses to toxic halogenated aromatic compounds such as TCDD, 
polynuclear aromatic hydrocarbons, combustion products and phytochemicals 
such as flavonoids and I3C. The AhR complex is a heterodimer containing AhR 
and ARNT which bind genomic DREs in regulatory regions of Ah-responsive 
genes (122, 132). SAhRMs are relatively non-toxic AhR agonists that inhibit E2-
induced signaling pathways and growth of E2-dependent mammary tumors in 
rodent models.   
 
1.4.1  Objective 1 (breast cancer study) 
 The first objective is to investigate the potential growth inhibitory actions 
of SAhRMs in ER-negative breast cancer cells that express a functional AhR.  
This study has identified two new Ah-responsive ER-negative breast cancer cell 
lines namely BT-474 and MDA-MB-453 cells.  Preliminary results from these cell 
lines show that the SAhRMs-6-MCDF and DIM inhibit growth of these cells and 
TCDD induces CYP1A1 and DRE-dependent activities (330).  This study 
describes the growth inhibitory effects of SAhRMs in ER-negative breast 
cancers and investigates their mechanism of cell growth inhibition. A major 
objective in this laboratory is to develop new mechanism-based treatments for 
later stage ER-negative breast cancers, since these tumors are now treated with 
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cytotoxic drugs which exhibit adverse toxic side effects in multiple tissues and 
organs. 
 
1.4.2  Objective 2 (prostate cancer study) 
Epidemiological studies show that high consumption of cruciferous 
vegetables such as cauliflower, broccoli and brussels sprouts are associated 
with decreased risks for several cancers and I3C is highly expressed in these 
vegetable and the this compound induces several anticarcinogenic activities 
(185, 188, 190, 331-333).  At low pH in the gut, I3C is converted into structurally 
diverse condensation products including DIM and both compounds  induce 
many of the same responses in vitro (140, 194, 334).  Research in this 
laboratory has focused on using DIM as a building block for synthesis of both 
ring- and methylene-substituted DIMs (C-DIMs) as a novel class of anticancer 
drugs. 
 The major objective of this study will be to determine the structure-
dependent antiandrogenic activities of a series of ring-substituted DIMs and 
identify potentially new antiandrogens for treatment of prostate cancer.  A series 
of symmetrical, dichloro and dibromo DIM isomers will be investigated as 
antiandrogens and androgens in AR-responsive LNCaP and 22Rv1 prostate 
cancer cells transfected with the androgen-responsive pPB construct, which 
contains the probasin gene promoter linked to the luciferase gene.  We expect to 
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see structure dependent activation with the series of DIM compounds under 
investigation. 
The antiandrogenic/androgenic responses of few model ring substituted 
DIM compounds will be  further investigated by determining their effects on AR 
levels and expression of androgen-responsive proteins such as PSA and 
FKBP51 in LNCaP cells since these proteins play a major role in the prognosis 
of prostate cancer treatment (335).    We expect some of these compounds will 
act by decreasing AR levels and mechanism of this response will be 
investigated. 
 
1.4.3  Objective 3 (prostate cancer study) 
The second objective of the prostate cancer study will be to determine the 
mechanism of action of the ring-substituted DIMs.   Preliminary results show that 
ring-substituted DIMs inhibit growth of prostate cancer cells lines (LNCaP and 
22Rv1 cells).  It has previously been shown that overexpression of non-steroidal 
anti-inflammatory drug-induced gene-1 (NAG-1) in breast cancer cells results in 
growth arrest and apoptosis. And similar results were observed in colon cancer 
cells (336-338).  In addition to NSAIDs, other agents that induce NAG-1 include 
phorbol esters, cyclooxygenase inhibitors, genistein, plant polyphenolics, diallyl 
disulfide, retinoids, I3C, DIM, and peroxisome proliferator activated receptor 
γ(PPARγ) agonists (336, 337, 339-341).  Several mechanisms of NAG-1 
induction have been described and these are dependent not only on the 
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structure or class of inducing agent but also on cell context.   We propose to 
examine the effects of ring substituted DIMs on induction of NAG-1 induction in 
prostate cancer cells. 
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CHAPTER II 
 
 
INHIBITION OF ESTROGEN RECEPTOR NEGATIVE BREAST CANCER 
CELL GROWTH BY ARYL-HYDROCARBON RECEPTOR AGONISTS 
 
2.1  Introduction 
 
 The aryl hydrocarbon receptor (AhR) was initially identified as a receptor 
that bound the environmental toxicant TCDD with high affinity and studies with 
AhR knockout mice have confirmed a role for this protein in mediating TCDD-
induced toxicity (111, 115, 124-126, 131, 133, 137).  The mechanism of AhR 
action is similar to that described for other ligand-activated receptors and was 
derived from early studies on AhR mediated induction of CYP1A1 gene 
expression (reviewed in (115, 124, 133, 342)).  The unbound AhR is associated 
with heat shock protein 90 (Hsp90) and, in the presence of a ligand, the bound 
receptor forms a hetero dimeric nuclear AhR complex containing the AhR and 
AhR nuclear translocator (ARNT) proteins.  The complex binds DREs in target 
gene promoters to induce transcriptional activation. 
 TCDD modulates an increasing number of biochemical, toxic and 
endocrine responses suggesting that this signal transduction pathway should be 
useful for developing SAhRMs for treating various diseases.  The linkage of the 
AhR with toxic halogenated aromatics hindered development of SAhRMs; 
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however, an increasing number of studies have shown that the AhR binds 
structurally-diverse naturally-occurring compounds including phytochemicals that 
exhibit multiple chemoprotective and anticarcinogenic activities (139, 140, 195, 
343-348).  Some of these phytochemical compounds that bind the AhR include 
I3C and related condensation products, various carotenoids, flavonoids, and the 
antioxidant resveratrol (found in wine and grape juice). 
 Research in this laboratory has focused on one of the most intriguing AhR 
mediated responses, namely the tissue specific inhibition of estrogen-induced 
responses (183, 349-351).  Kociba and coworkers (352) initially reported that 
dietary administration of TCDD to female Sprague Dawley rats inhibited age 
dependent spontaneous mammary and uterine tumor formation.  Subsequent 
research in several laboratories has demonstrated that TCDD inhibits 17β-
estradiol (E2)-induced uterine wet weight and uterine peroxidase activity, 
progesterone receptor (PR) binding,  (ER) binding, epithelial growth factor 
receptor (EGFR) binding, c-fos and EGFR mRNA in female rodents (154, 155, 
157-161) .  Moreover, TCDD also inhibited E2-regulated endometriosis (353)  
and mammary tumor formation or growth in rodent (mice or rats) models (143, 
162, 354) .  TCDD has been used to investigate AhR-responsiveness and 
inhibitory AhR-ERα crosstalk in  ERα-positive breast cancer cell lines  (145, 146, 
148, 150-152, 167, 169, 170, 172, 355-367).TCDD inhibited E2 induced breast 
cancer cell growth, cell cycle progression as well as a number of E2 responsive 
genes/proteins including PR mRNA/protein, pS2 mRNA/protein, cathepsin D 
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mRNA/protein, prolactin receptor mRNA, vitellogenin A2, cyclin D1, creatine 
kinase B gene, and phosphorylation of RB protein, cyclin-dependent kinase 
(cdk) 2 and cdk4.  Recent studies also show similar inhibitory  AhR-ERα 
interactions in Ishikawa and ECC1 human endometrial cancer cell lines (141, 
368, 369).  Mechanistic studies show that AhR-mediated inhibition studies of 
ER-mediated gene expression is complex and may involve multiple pathways 
(183, 349-351). Studies in this laboratory and others have identified inhibitory 
dioxin response elements (iDREs) GCGTG, as genomic targets for direct 
interaction with the nuclear AhR complex, and functional iDREs have been 
characterized in promoter regions of cathepsin D, c-fos, pS2 and Hsp 27 genes  
(150, 169, 170).  Mutation of these sequences results in loss of inhibitory AhR-
ER crosstalk for these genes, and this represents a unique model for 
interactions between two ligand-activated signaling pathways.  In addition, AhR 
ligands induce proteasome-dependent degradation of ERα  (370) and the AhR 
complex may also directly sequester DNA-bound ER (371). 
 Most research on the effects of TCDD and other AhR agonists in breast 
cancer cells has focused on inhibitory AhR-ERα crosstalk in E2-responsive 
breast cancer cell lines (167, 358-360).  It was initially reported that ER-negative 
breast cancer cells are Ah-nonresponsive (365) and this is typified by MDA-MB-
231 cells that express both AhR and ARNT, however, TCDD does not induce 
CYP1A1 in this cell line.   This was later shown to be due, in part, to over 
expression of Hsp90 which prevented TCDD induced transformation and 
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activation of the cytosolic AhR receptor complex (372).  One study reported the 
TCDD inhibited growth of ER-negative MDA-468 breast cancer cells and this 
was the first example of ER-negative cell line that expressed the AhR and was 
Ah-responsive  (369). 
 In this study we have investigated the Ah-responsiveness of two ER-
negative breast cancer cell lines MDA-MB-453 and BT474 cells that overexpress 
the oncogene epidermal growth factor receptor 2 (EGFR2/ErbB2).  The results 
show that the AhR is expressed in both cell lines and treatment with TCDD 
induces CYP1A1 protein and ethoxyresorufin-O-deethylase (EROD) activity.  
TCDD and related compounds inhibit MDA-MB-453 and BT474 cell growth and 
analysis of several proteins and kinases have identified hairy and enhancer of 
split homologue-1 (Hes-1) as a TCDD inducible protein associated with AhR 
dependent inhibition of cell proliferation in these cell lines. 
 
2.2  Materials and methods 
 
2.2.1 Cell lines and reagents 
 
MB-453 and BT474 breast cancer cells were obtained from American 
Type Culture Collection (Manassas, VA).  Fetal bovine serum was obtained from 
JRH Biosciences, Lenexa, KS.  Cells were maintained in RPMI 1640 (Sigma 
Chemical St. Louis, MO) supplemented with 0.22% sodium bicarbonate, 0.011% 
sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS, and 10 mL/L of 
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100x antibiotic antimycotic solution (Sigma).  Cells were maintained at 37°C in 
the presence of 5% CO2.  Antibodies for AhR, CYP1A1, Sp1, pERK, ERK, pAkt, 
CD1, p27, pErbB2 and ErbB2 were purchased from Santa Cruz Biochemicals 
(Santa Cruz, CA).  TCDD was prepared in this laboratory.  DIM was prepared by 
dimerization of I3C and 6-MCDF was synthesized in this laboratory and was 
greater than 98% pure.   
 
2.2.2   Western blot analysis 
 MDA-MB-453 and BT474 breast cancer cells were seeded in 100 mm 
plates in DMEM: Ham’s F-12 media containing 2.5% charcoal-stripped FBS and 
allowed to attach overnight.  The next day, cells were treated with DMSO, 
different concentrations of TCDD, DIM 6-MCDF or other chemicals for different 
time points as indicated.  For experiments where MG132 or calpain were used, 
cells were pretreated for 30 min. Whole cell lysates cells were scraped in 500 µL 
of lysis buffer [50 mM HEPES, 0.5 M sodium chloride, 1.5 mM  magnesium 
chloride, 1 mM EGTA, 10% v/v glycerol, 1% Triton X, and 5 µL/ml of Protease 
Inhibitor Cocktail (Sigma)].  The lysates were incubated on ice for 1 - 1.5 hr with 
intermittent vortexing followed by centrifugation at 40,000 g for 10 min at 4°C.   
Protein levels were estimated using Bradford reagent; equal amounts of protein 
were diluted with loading buffer and boiled for 4 min, and loaded onto 10% SDS-
polyacrylamide gel.  After electrophoresis, gels were transferred to 
polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) using an 
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electroblotting apparatus overnight at 4°C in transfer buffer containing 48 mM 
Tris-Cl, 29 mM glycine, and 0.025% SDS.  The membranes were blocked with 
TBS [10 mM Tris-HCl (pH 8) and 150 mM sodium chloride] plus 5% milk (blotto-
buffer) for 1 hr, and then incubated in primary antibodies (AhR, Sp1, CYP1A1, 
pERK, ERK,  p27, pAkt, CD1, pErbB2, PARP, Hes-1).  at 1:1000 dilution in 
blotto buffer at 4°C  overnight, followed by one min washes (2X) and incubation 
with secondary antibody for 3 - 5 hr at 4°C.  Membranes were then rinsed with 
water and incubated in enhanced chemiluminescence (ECL) reagents (Perkin 
Elmer, Boston, MA) for 1 min, removing excess ECL with paper towelette.  The 
membrane was sealed in plastic wrap and photographed for immunoreactive 
bands using ECL hyperfilm.    
 
2.2.3  Cell proliferation assays 
 Breast cancer cells were maintained in RPMI media with phenol red and 
were seeded into 6-well plates at a density of 50,000 cells/well in DME-F12 plus 
5% FBS stripped with dextran treated charcoal.  After allowing 24 hr to attach, 
cell were treated with test compounds in DMSO (1% final volume) or DMSO  
alone every 48 hr in fresh media.  Cells were harvested every 48 hr by 
trypsinization and counted using a Coulter Z1 cell counter (Coulter Electronics, 
Hialeah, FL).   
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2.2.4  Ethoxyresorufin-O-deethylase (EROD) analysis of breast cancer cells 
 Trypsinized cells were plated into 48-well tissue culture plates allowed to 
attain 70% confluency and treated with DMSO, TCDD, DIM or 6-MCDF for 24 hr.  
Cells were then washed with PBS, 200 µl PBS was added to each well and cells 
were incubated in a 370  C water bath for 2 min.  The reaction was started by 
addition of 50 µl of ethoxyresorufin (1 mg/40 ml methanol) and incubated in 370 
C water bath for 10 min.  The reaction was stopped by addition of 100 µl 
fluorescamine.  Protein activity was measured at 400/460 excitation/ emission 
and EROD activity was measured immediately afterward at 530/590 excitation 
emission using a cytoflor 2350 fluorescence measurement system. 
 
2.2.5  Statistical analysis 
 Statistical differences between different groups were determined by  
 
ANOVA and Scheffe’s test for significance.  The data are presented as mean ±  
 
SE for at least three separate determinations for each treatment. 
 
  
2.3  Results 
 MDA-MB 453-and BT474 breast cancer cell lines are highly aggressive 
cells that over-express ErbB2 and this study investigates the Ah-responsiveness 
of these cells and the effects of AhR ligands on their proliferation.  Figure 14A 
summarizes the effects of 10 nM TCDD, 1, 2, and 5 µM 6-MCDF on proliferation 
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of MDA-MB-453 cells and growth inhibition was observed at all concentrations.  
In a parallel study the growth inhibitory effects of 10 nM TCDD, 1, 5 and 10 µM 
DIM were also determined  ( Figure 14B) and growth inhibition was observed at 
all concentrations of DIM demonstrating that 3 prototypical AhR agonists  
inhibited growth of an ER-negative breast cancer cell line.  MDA-MB-453 cells 
exhibit constitutively activated kinase activities which are responsible in part, for 
their enhanced proliferation (373-375).  The results in Figure 14C show that the 
MAPK and PI3K inhibitors UO126 and LY 274002 respectively also inhibit 
growth of MDA-MB-453 cells and both compounds are more potent than TCDD.  
Results in Figure 15A show 10 nM TCDD, 10 and 20 µM DIM inhibited growth of 
BT474 and similar results were observed for 2 and 5 µM 6-MCDF, 5 µM UO126 
and 10 µM LY294002  (Figure 15B). 
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Figure 14. Cell proliferation assays with SAhRMs in MDA-MB-453 cells.   
MDA-MB-453 cells were treated with (A) TCDD and 6-MCDF (B) TCDD and 
DIM.  
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Figure 14.  (continued) (C) MDA-MB-453 cells were treated TCDD, UO126 
and LY and cell numbers were determined after 2,4 and 6 days as 
described in Materials and methods. Data presented as means of three 
replicate determinations for each treatment group.  Significant inhibition 
(p<0.05) of cell proliferation ± SE (to DMSO) is indicated as “*” in figures (6 
day point). 
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Figure 15. Cell proliferation assays with SAhRMs in BT474 cells.   
BT474 cells were treated with (A) TCDD and DIM or (B) TCDD, 6-MCDF, 
UO126 and LY and cell numbers were determined after 2,4 and 6 days as 
described in Materials and methods. Data presented as means of three 
replicate determinations for each treatment group.  Significant inhibition 
(p<0.05) of cell proliferation ± SE (to DMSO) is indicated as “*” in figures (6 
day point). 
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 The Ah-responsiveness of  TCDD, 6-MCDF and DIM was investigated in 
both cell lines by determining the induction of CYP1A1-dependent EROD activity 
which is a well characterized marker of AhR-active compounds (124, 131).  
TCDD (1, 10 and 100 nM) induced EROD activity in MDA-MB-453 (Figure 16A) 
and BT474 (Figure 16B) cells where as 6-MCDF  (168, 184, 376, 377) and DIM  
(378) were inactive as inducers.  These results may be due in part, to the low 
concentrations used in this enzyme induction study.  Figures 16C and 16D show 
that 10 nM TCDD and to a lesser extent 6-MCDF decreased AhR expression 
levels in MDA-MB-453 and BT474  cells respectively and this is consistent with 
the previously reported, ligand activated proteasome dependent degradation of 
the AhR  (370).  In contrast, DIM did not affect AhR expression.  This experiment 
was also repeated in both cell lines treated with the AhR agonists alone or in the 
presence of 5 µM MG132 (proteasome inhibitor) (Figures 16E and 16F) and 
TCDD induced degradation of the AhR was reversed by MG132.  Only minimal 
changes in AhR expression were observed in cells treated with DIM and 6-
MCDF and as a positive control the protease inhibitor calpain II did not effect 
TCDD- induced downregulation of the AhR (data not shown).  Thus the effects 
of TCDD on AhR expression are similar to those observed in ER-positive breast 
cancer cells, and in other cancer cell lines derived from other tumors.  Induction 
of CYP1A1 protein was also determined in BT474 and MDA-MB-453 (Figures 
17A and 17B) and also showed that 10 nM TCDD induced expression of this 
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protein whereas lower but detectable induction was observed for higher 
concentrations  
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Figure 16. Ah-responsiveness of TCDD and SAhRMs DIM and 6-MCDF. 
Induction of CYP1A1 dependent EROD activity in (A) MDA-MB-453 cells 
and (B) BT474 cells.  Cells were treated with TCDD and SAhRMs for 24 hr 
and EROD activity was determined as described in Materials and methods. 
Effects of TCDD and SAhRMs on AhR expression levels in (C) MDA-MB-
453 cells and (D) BT474 cells.  Cells were treated for 24 hr and whole cell 
lysates were analyzed by Western blot analysis as described in Materials 
and methods. Effects of DIM and 6-MCDF on AhR expression and the 
proteasome pathway. 
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Figure 16.  (Continued). (E) and (F)  Analysis of the proteasome pathway in 
MDA-MB453 and BT 474 cells respectively.  Cells were treated with 
different concentrations of compounds for 36 hr and whole cell lysates 
were analyzed by Western blot analysis as described in Materials and 
methods.  In case of MG132 cells were pretreated for 30 min.  Sp1 was 
used as loading control for these experiments. 
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Figure 17. Induction of CYP1A1 by SAhRMs. 
(A) MDA-MB-453 cells were treated with TCDD and different concentrations 
of SAhRMs for 24 hr whole cell lysates were analyzed by Western blot 
analysis as described in Materials and methods. (B) The experiment was 
repeated in BT474 cells.  Sp1 was used as a loading control for these 
experiments. 
 
of both 6-MCDF and DIM after treatment for 24 hr. Induction responses were 
also observed after 96 hr, however, at this later time point the effects of DIM 
were decreased, and this may have been due to metabolism of this compound. 
In cells over-expressing ErbB2 several kinases such as MAPK and PI3K are 
constitutively expressed and contribute to proliferation of these cells(373-375).  
Results in Figure 18A compare the expression of phospho-ERK (pERK) in 
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BT474 cells treated for 12 or 24 hr  with TCDD, 6-MCDF and DIM and the AhR 
agonists did not affect pERK or ERK proteins.  The effects of these compounds 
on AhR protein served as a positive control and Sp1 protein was the loading 
control for this experiment.  This study was repeated in BT474 cells treated with 
the same compounds for 12 and 96 hr (Figure 18B) and the results were similar 
at both the time points.                                                                                          
 A similar approach was used in MDA-MB-453 cells treated with AhR 
agonists for 12 and 24 hr (Figure 19A) or 12 and 96 hr (Figure 19B).  Similar 
results were observed in both cell lines treated with the same AhR agonists for 
12, 24 or 96 hr clearly demonstrating that the MAPK pathway was unaffected by 
these compounds.  As an additional positive control for experiments in Figures 
18 and 19 we showed that pERK was decreased in both cell lines treated with 
the MAPK  inhibitor UO126 but not by the PI3K inhibitor LY294002. 
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Figure 18.Cellular kinase expression and phosphorylation (BT474).  
(A) Phosphorylation of ERK in BT474 cells.  Cells were treated with 
different concentration of compounds for 12 and 24 hr and whole cell 
lysates were analyzed by Western blot analysis as described in Materials 
and methods.   The experiment was repeated in BT474 cells for 12 and 96 
hr (B).  Sp1 was used as loading control for these experiments. 
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Figure 19. Cellular kinase expression and phosphorylation  
MDA-MB-453). (A) Phosphorylation of ERK in MDA-MB-453 cells.  Cells 
were treated with different concentration of compounds for 12 and 24 hr 
and whole cell lysates were analyzed by Western blot analysis as 
described in Materials and methods.   The experiment was repeated in 
MDA-MB-453 cells for 12 and 96 hr (B).  Sp1 was used as loading control 
for these experiments. 
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 The effects of AhR agonists on the PI3K pathway were also investigated 
(Figure 20A) and the results showed that in BT474 cells the pAkt levels were 
unchanged by these compounds. Surprisingly, the PI3K inhibitor LY294002 was 
also inactive in this assay which was repeated several times.  Moreover similar 
results were obtained in MDA-MB-453 cells indicating that AhR agonists did not 
affect pAkt expression.  Moreover levels of cyclin D1 and p27 were also not 
altered by these compounds and FACS analysis indicated that changes in the 
percent distribution of different phases of cell cycle were also unchanged (data 
not shown).  We also showed that these AhR agonists did not affect pERbB2 
expression (Figure 20B) or induction of apoptosis as indicated by the failure to 
observed caspase-dependent PARP cleavage (Figure 20C).                               
 Thus although TCDD, DIM and 6-MCDF inhibit growth of BT474 and 
MDA-MB 453 breast cancer cells, their effects on constitutively active kinase 
pathways, cell cycle progression and cell cycle genes are minimal to non-
detectable (Figures 16-20).  A recent study reported that Hes-1 is induced by 
TCDD in T47D breast cancer cells (379) and this protein has been linked to 
antiproliferative activity in several cell line (379-383).  Treatment of MDA-MB 453 
cells with TCDD, DIM and 6-MCDF induced Hes-1 protein expression (Figure 
21) and this was consistent with results reported in other cell lines and 
represents a potential mechanism for the growth inhibitory action of AhR 
agonists in ER-negative Ah-responsive breast cancer cell lines.  Current studies 
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are focused on fully characterizing Hes-1 induction in these cells and the 
contributions of this protein to the growth inhibitory activity of AhR agonists. 
                  
pErbB2
ErbB2
pErbB2
ErbB2
M
CD
F 
1.
25
 

M
DM
SO
TC
DD
 
10
 
n
M
DI
M
 
1 

M
DI
M
 
5 

M
DI
M
 
10
 

M
M
CD
F 
2.
5 

M
M
CD
F 
5 

M
BT474
-MB-453
B
pAkt
p27
CD1
12 hr 
-
96 hr
DM
SO
TC
DD
 
10
 
n
M
DI
M
 
10
 

M
DI
M
 
20
 

M
M
CD
F 
2 

M
M
CD
F 
5 

M
UO
12
6 
10
 

M
LY
 
10
 

M
Sp1
DM
SO
TC
DD
 
10
 
n
M
DI
M
 
10
 

M
DI
M
 
20
 

M
M
CD
F 
2 

M
M
CD
F 
5 

M
UO
12
6 
10
 

M
LY
 
10
 

M
A
BT474 
 
Figure 20. Cellular kinase expression and phosphorylation. (A) Analysis of 
inhibitory cell cycle genes p27, pAKT, CD1.  BT474 cells were treated with 
different concentrations of compounds for 12 or 48 hr and whole cell 
lysates were analyzed by western blot analysis. (B) Phosphorylation of 
ErbB2 in BT474 and MDA-MB-453 cells.  Cells were treated with different 
concentrations of compounds for 48 hr and whole cell lysates were 
analyzed by Western blot analysis as described in Materials and methods. 
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Figure 20. (continued) (C).  Induction of apoptosis.  BT474 and MDA-MB-
453 cells were treated with different concentration of compounds for 36 hr 
and whole cell lysates were analyzed by Western blot analysis as 
described in Materials and methods Sp1 was used as loading control for 
these experiments.  
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Figure 21. Effects of DIM and 6-MCDF on Hes-1 protein levels.  
MDA-MB-453 cells were treated with different concentration of compounds 
for 96 hr and whole cell lysates were analyzed by Western blot analysis as 
described in Materials and methods. Sp1 was used as a loading control for 
these experiments. 
 
2.4. Discussion 
 Selective receptor modulators have been developed for steroid hormone 
receptors as a new class of mechanism-based drugs for treatment of hormone-
related diseases.  For example tamoxifen is a selective ER modulator (SERM) 
that exhibits tissue-selective ER agonist and antagonist activities and because of 
its antiestrogenic effect in breast tumors, tamoxifen has been used as the major 
drug of choice for treating early stage ER-positive breast cancer in women.  
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Currently several newer SERMs such a raloxifene are also being developed for 
endocrine therapies including treatment of breast cancer (384-387)   Research 
in this laboratory has been investigating an alternative mechanism-based 
strategy for treating breast cancer with SAhRMs (183, 349-351).  AhR agonists 
such as TCDD inhibit E2 dependent gene expression, proliferation of breast 
cancer cell growth and mammary tumor growth in rodent models (143, 145, 146, 
148, 150-152, 154, 155, 157-162, 167, 169, 170, 172, 352-367, 369) .  The 
relatively non-toxic SAhRMs 6-MCDF and DIM also inhibit hormone-dependent 
mammary cell tumor growth and 6-MCDF is slightly more potent than tamoxifen 
in the  carcinogen-induced rat mammary tumor model (168, 184, 376-378).  
Moreover treatment with 6-MCDF plus tamoxifen synergistically inhibited 
mammary tumor growth (184) and this combination therapy is a highly promising 
new approach for treating early stage breast cancer.                                                          
 Vickers and coworkers initially showed that ER-positive breast cancer 
cells were Ah-responsive whereas ER-negative cells were non-responsive to the 
effects of TCDD and related compounds (365).  However, one study reported 
that MDA-MB-468 cells express a functional AhR and TCDD inhibited cell 
growth through an unusual mechanism which involved induction of (TGFα which 
acted as growth inhibitory peptide in this cell line (369).  In this study, we now 
show that two ErbB2 over-expressing breast cancer cell lines BT474 and MDA-
MB-453 cells also express the AhR (Figure 16C) and TCDD induced CYP1A1-
dependent EROD activity in both cells (Figures 16A and 16B).  Not surprisingly 
 119 
DIM and 6-MCDF exhibited minimal activity as CYP1A1 inducers (Figures 16 
and 17) and this correlates to similar results previously observed in ER-positive 
breast cancer cell lines (376-378).  In addition, both TCDD and the SAhRMs 
DIM and 6-MCDF also inhibited BT-474 and MDA-MB-453 cell proliferation 
(Figures 14 and 15) suggesting that ER-negative cell lines may also respond to 
AhR agonists as a new class of drugs for treating these highly resistant later 
stage tumors.                                                                                                      
 The mechanism of AhR-mediated inhibition of ER-negative or ER-
independent cancer cell growth has not been extensively investigated and the 
induction of TGFα by TCDD in MDA-MB-468 cells is the only prior report in ER-
negative breast cancer cells (369).  AhR agonists also inhibited proliferation of 
pancreatic cancer cells and this was associated with induction of p21 expression 
(388).  TCDD and the SAhRMs did not affect p27 or cyclin D1 expression in BT 
474 or MDA-MB-453 cells (Figure 20A).  We also investigated induction of other 
growth inhibitory genes including p21, ATF, NAG1 and KLF 6 and expression of 
these proteins was also unaffected by SAhRMs or TCDD (data not shown).   
 MDA-MB-453 and BT-474 cells over-express the oncogene ErbB2 and 
many ER-negative breast cancer cells also over-express kinases that contribute 
to their highly proliferative and invasive properties (141, 370-375).  Therefore we 
investigated the effects of TCDD and the SAhRMs as potential inhibitors of 
constitutively active kinases.  However, treatment of BT474 cells with these AhR 
agonists did not affect several kinase activities including ErbB2 (Figures 18-20).  
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Recent studies in T47D cells showed that E2 downregulated the HES-1 protein 
and TCDD induced HES-1 expression in the same cell lines (379-381) .  HES-1 
is an antiproliferative basic-helix-loop-helix transcription factor and we therefore 
investigated expression of this gene in BT474 and MDA-MB-453 cells.  The 
results (Figure 21) show that HES-1 protein is induced by TCDD, DIM and 6-
MCDF and this represents a possible mechanism for mediating the growth 
inhibitory effects observed for these compounds.  Current studies are further 
investigating the mechanism of HES-1 induction by AhR agonists in ER-negative 
breast cancer cells and determining the role of HES-1 and other proteins in 
mediating the antiproliferative effects of these compounds in these highly 
proliferative ER-negative cells. 
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CHAPTER III 
 
 
STRUCTURE-DEPENDENT ANDROGEN RECEPTOR 
AGONIST/ANTAGONIST ACTIVITIES AND AR DOWN-REGULATION BY 
DICHLORO AND DIBROMO-SUBSTITUTED 1, 1’-BIS (3-INDOLYL 
METHANES) 
 
3.1 Introduction 
 
 Epidemiological studies have demonstrated that high consumption of 
cruciferous vegetables such as cauliflower, broccoli and Brussels sprouts are 
associated with decreased risks for several cancers (185, 188, 190, 331-333). 
Indole-3-carbinol (I3C) glucosinolates are expressed in high levels in Brassica 
vegetables, and the anticarcinogenic activity of these vegetables or their extracts 
in laboratory animal studies is associated with I3C and related chemoprotective 
phytochemicals (196, 199, 389-394).  I3C conjugates are rapidly hydrolyzed in 
the acidic environment of the gut and converted into structurally diverse 
condensation products including 1,1-bis(3’-indolyl)methane (DIM) (140, 334).  At 
low pH, the percentage conversion of I3C into DIM is minimal; however, in cell 
culture studies at pH 6.6 - 7.5, I3C is primarily converted into DIM (194) and both 
compounds induce many of the same responses in vitro. 
 I3C and DIM exhibit anticarcinogenic activity in several animal models 
(196, 199, 378, 389-395).  For example, in mice bearing mouse TRAMP-C2 
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prostate cancer cells as xenografts, 2.5, 5.0, and 10.0 mg/kg (3X weekly) DIM 
significantly decreased tumor weight/volume and induced apoptosis in the 
prostate tumors (395), and in vitro studies also show that DIM induced apoptosis 
in prostate cancer cells (396).  Results from several laboratories show that 
decreased cancer cell survival after treatment with DIM or I3C may be related to 
activation of multiple and possibly overlapping pathways including modulation of 
cell cycle regulatory proteins, induction of apoptosis and ER stress, and 
decreased mitochondrial membrane potential   (193, 201, 202, 396-402).  
 Le and coworkers (403) reported that DIM is a potent androgen receptor 
(AR) antagonist in LNCaP prostate cancer cells and inhibits dihydrotestosterone 
(DHT)-induced cell proliferation and gene/reporter gene expression.  Their 
results showed that the antiandrogenic activity of DIM was associated with the 
inhibition of DHT-induced AR nuclear translocation, whereas DIM alone did not 
induce accumulation of nuclear AR.  These results were unique for DIM since 
other structural classes of antiandrogens such as casodex induce accumulation 
of nuclear AR, which is transcriptionally inactive. 
 Previous studies in this laboratory have shown that several ring- 
substituted DIMs were more potent than DIM as inhibitors of carcinogen-induced 
mammary tumor growth in Sprague-Dawley rat (330, 404).  The major objective 
of this study was to determine the structure-dependent antiandrogenic activities 
of a series of ring-substituted DIMs and identify potential new antiandrogens for 
treatment of prostate cancer.  A series of symmetrical dichloro- and dibromo 
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DIM isomers were investigated as antiandrogens and androgens in AR-
responsive LNCaP and 22Rv1 prostate cancer cells transfected with the 
androgen-responsive pPB construct, which contains the -288 to +28 region of 
the probasin gene promoter linked to the luciferase gene (405, 406). Most of the 
ring-substituted DIMs exhibited antiandrogenic activity; 7,7’-dichloro- and 7,7’-
dibromo DIMs were only partial AR antagonists, and the compounds alone 
exhibited partial androgenic activity in the transactivation assay.  The 
antiandrogenic/androgenic responses of 4,4'- and 7,7'-dihalo DIMs were further 
investigated by determining their effects on AR levels and expression of the 
androgen-responsive FKBP51 protein in LNCaP cells (335).  The antiandrogenic 
activities of 4,4’-dihalo DIMs were confirmed in these assays; however, both 
7,7’-dibromo- and 7,7’-dichloro DIM uniquely downregulated AR mRNA and 
protein levels after treatment for 48 hr.  
 
3.2  Materials and methods 
3.2.1 Cell lines and reagents.  
 Human prostate carcinoma cell lines LNCaP and 22Rv1 were obtained 
from American Type Culture Collection (Manassas, VA).  Fetal bovine serum 
was obtained from JRH Biosciences, Lenexa, KS.  Cells were maintained in 
RPMI 1640 (Sigma Chemical St. Louis, MO) supplemented with 0.22% sodium 
bicarbonate, 0.011% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% 
FBS, and 10 mL/L of 100x antibiotic antimycotic solution (Sigma).  Cells were 
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maintained at 37°C in the presence of 5% CO2. Antibodies for AR (sc- 816), Sp1 
(sc-59), and FKBP 51(sc-11514) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Reporter lysis buffer and luciferase reagent for 
luciferase studies were purchased from Promega (Madison, WI).  β-
Galactosidase (β-Gal) reagent was obtained from Tropix (Bedford, MA).  
Lipofectamine reagents were supplied by Invitrogen (Carlsbad, CA).  Western 
Lightning chemiluminescence reagents were from Perkin-Elmer Life Sciences 
(Boston, MA).  Dihydrotestosterone was purchased from Sigma.  MG132 was 
obtained from Calbiochem (San Diego, CA) and gliotoxin was kindly provided by 
Dr. Alan Taylor, Atlantic Regional Laboratory, National Research Council 
(Halifax, Canada).  The ring-substituted DIMs were prepared in this laboratory by 
condensation of ring-substituted indoles and formaldehyde or by self-
condensation of ring-substituted indole-3-carbinols;  compounds were >95% 
pure by gas chromatography-mass spectrometry as previously described (330, 
404). All substitute indoles were purchased from the Aldrich Chemical Co. 
(Milwaukee, WI).  
 
3.2.2  Plasmids   
The pPB reporter containing -288 to +28 region of the probasin gene 
promoter was kindly provided by Dr. Robert Matusik (Vanderbilt University 
Medical Center). 
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3.2.3 Transfection and luciferase assay 
 Prostate cancer cells were plated in 12-well plates at 2.5 x 105 cells/well 
in DMEM:Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS.  
After overnight attachment, cells were transfected with 400 ng of pPB and 50 ng 
of β-galactosidase reporter plasmid, using Lipofectamine reagent (Invitrogen) 
according to the manufacturer’s recommended protocol.  Cells were transfected 
and, after 8 - 9  hr, the transfection mix was replaced with 5% charcoal-stripped 
FBS media containing either vehicle (DMSO) or the indicated DIM-isomer and 
incubated for 36 - 38 hr.  Based on results of preliminary studies showing that 
responses were not observed at concentrations ≤ 1.0 µM, concentrations 
ranging from 5 - 15 (for 6,6'-dichloro DIM) or 5 - 20 µM were used.  Cytotoxicity 
was observed at higher doses.  Cells were then lysed with 100 mL of 1x reporter 
lysis buffer, and 30 µL of cell extract were used for luciferase and β-
galactosidase assays.  Lumicount (Parkard, Meriden, CT) was used to 
quantitate luciferase and β-galactosidase activities, and the luciferase activities 
were normalized to β-gal activity.  
 
3.2.4 Western blot analysis 
  LNCaP, and 22Rv1 prostate cells were seeded in 100 mm plates in 
DMEM:Ham’s F-12 media containing 2.5% charcoal-stripped FBS and allowed 
to attach overnight, followed by treatment with either the vehicle (DMSO) or the 
indicated compounds for the desired time points.  Nuclear and cytoplasmic 
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fractionating kit (Pierce Biotechnology, Rockford, IL) was used to obtain the 
nuclear and cytoplasmic lysates.  For whole cell lysates cells were scraped in 
500 µL of lysis buffer [50 mM HEPES, 0.5 M sodium chloride, 1.5 mM  
magnesium chloride, 1 mM EGTA, 10% v/v glycerol, 1% Triton X, and 5 µL/ml of 
Protease Inhibitor Cocktail (Sigma)].  The lysates were incubated on ice for 1 - 
1.5 hr with intermittent vortexing followed by centrifugation at 40,000 g for 10 
min at 4°C.   Protein levels were estimated using Bradford reagent; equal 
amounts of protein were diluted with loading buffer and boiled for 4 min, and 
loaded onto 10% SDS-polyacrylamide gel.  After electrophoresis, gels were 
transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) using 
an electroblotting apparatus overnight at 4°C in transfer buffer containing 48 mM 
Tris-Cl, 29 mM glycine, and 0.025% SDS.  The membranes were blocked with 
TBS [10 mM Tris-HCl (pH 8) and 150 mM sodium chloride] plus 5% milk (blotto-
buffer) for 1 hr, and then incubated in primary antibody at 1:1000 dilution in 
blotto buffer at 4°C  overnight, followed by one min washes (2X) and incubation 
with secondary antibody for 3 - 5 hr at 4°C.  Membranes were then rinsed with 
water and incubated in enhanced chemiluminescence (ECL) reagents (Perkin 
Elmer, Boston, MA) for 1 min, removing excess ECL with paper towelette.  The 
membrane was sealed in plastic wrap and photographed for immunoreactive 
bands using ECL hyperfilm.    
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3.2.5 RNA extraction and cDNA synthesis 
  Total RNA was extracted using Quiagen RNeasy Protect (Quiagen, 
Valencia, CA) according to the manufacturer’s instruction.   RNA was 
quantitated and 5 µg was used for reverse transcription using the SuperScript II 
reverse transcriptase (Invitrogen). 
 
3.2.6 Real-time PCR.   
The cDNA was amplified in a real-time PCR using  SYBR Green PCR 
master mix (Applied Biosystems, Foster City, CA) and 10 pM primers for AR.   
The reactions were performed in an ABI PRISM model 7700 sequence detector 
(Applied Biosciences, Foster City, CA).  The PCR conditions were as follows:  
50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 min, and 60°C for 1 
min.  The sequences for the AR primers were as follows:  forward primer, 5’ gta 
ccc tgg cgg cat ggt 3’; and reverse primer, 5’ ccc att tcg ctt ttg aca ca 3’.  The 
TATA binding protein (TBP) was used as a reference standard for quantitating 
AR mRNA.  The primers for TBP are as follows:  forward primer, 5’ tgc aca gga 
gcc aag agt gaa 3’, and reverse primer, 5’ cac atc aca gct ccc cac ca 3’. 
 
3.2.7 Statistical analysis  
Statistical differences between different groups were determined by 
ANOVA and Scheffe’s test for significance.  The data are presented as mean ± 
SE for at least three separate determinations for each treatment.   
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3.3  Results 
3.3.1 DIM and ring-substituted DIMs:  AR agonist and antagonist activities in  
 transactivation assays 
 Previous studies show that DIM exhibits AR antagonist activity in LNCaP 
cells and inhibits DHT-induced PSA protein and reporter gene activity in cells 
transfected with androgen-responsive constructs (403).  In this study, the 
antiandrogenic activity of DIM has been investigated in LNCaP and 22Rv1 
prostate cancer cells transfected with the androgen-responsive pPB construct 
(Figure 22).  Both cell lines express mutant forms of the AR; however, DHT 
activates the receptor in LNCaP and 22Rv1 cells (407, 408).  The results show 
that DHT but not DIM alone significantly induced luciferase activity in LNCaP 
and 22Rv1 cells transfected with pPB.  In cells cotreated with DHT plus DIM and 
transfected with pPB, hormone-induced luciferase activity was significantly 
decreased at DIM concentrations of 5, 10 and 20 µM.  These results confirm that 
DIM inhibits activation of the androgen responsive pPB construct by DHT in both 
LNCaP and 22Rv1 cells and complements results of a previous report on the 
antiandrogenic activity of DIM (403).   
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Figure 22. Antiandrogenic activity of DIM.   
LNCaP (A) or 22Rv1 (B) cells were transfected with pPB, treated with DHT, 
5 - 20 µM DIM alone or in combination with DHT, and luciferase activity 
determined as described in the Materials and methods.  Results are 
expressed as means ± SE for at least 3 determinations per treatment 
group, and significant (p < 0.05) induction (*) or inhibition (**) in the 
cotreatment groups are indicated. 
 
 
 Ring-substituted DIMs also exhibit potent anticancer activities (330, 404); 
however, the structure-dependent effects of these compounds as antiandrogens 
have not been reported.  This study investigates the AR antagonist and agonist 
activities of symmetrical dihalo DIMs containing substituents in the 4, 5, 6, and 7 
positions of the benzene ring.  The structure-dependent AR antagonist/agonist 
activities of 4,4’-, 5,5’-, 6,6’-, and 7,7’-dichloro- and -dibromo DIMs were 
investigated in LNCaP and 22Rv1 cells transfected with the PB construct 
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(Figures 23 and 24).  The dichloro- and dibromo DIM isomers induce similar 
structure-dependent responses in both cell lines.  The results obtained for the 
dichloro DIM isomers show that 4,4’-, 5,5’-, and 6,6’-dichloro DIM were AR 
antagonists in LNCaP and 22Rv1 cells (Figures 23A and 24B), although their AR 
antagonist activity was more pronounced in the latter cell line.  7,7’-Dichloro DIM 
was a partial AR agonist/antagonist in both cell lines (Figures 23C and 23D), 
whereas the other isomers did not exhibit AR agonist activities.  The pattern of 
antiandrogenic/androgenic activities for the isomeric dichloro DIMs (Figure 23) 
was similar to that observed for the brominated analogs (Figure 24).  4,4’-, 5,5’- 
and 6,6’-Dibromo DIM primarily exhibited antiandrogenic activities in LNCaP and 
22Rv1 cells (Figures 24A and 24B), and 7,7’-dibromo DIM was a partial AR 
agonist/antagonist in both cell lines (Figures 24C and 24D). 
 131 
LNCaP 22Rv1
diClDIMs
diClDIMs + DHT (1 µM)
A
Conc (µM)
0
20
40
60
80
100
120
0 5 10 20
%
 
DH
T 
**
**
**
**
B
Conc (µM)
0
20
40
60
80
100
120
140
0 5 10 20
**
**
**
**
D
Conc (µM)
0
0.5
1
1.5
2
2.5
3
0 5 10 20
l
*
C
Conc (µM)
*
0
1
2
3
4
5
6
7
8
9
0 5 10 20
Fo
ld
 
In
du
c
tio
n
4,4’-diCl
5,5’-diCl
6,6’-diCl
7,7’-diCl 
 
Figure 23.  Antiandrogenic/androgenic activity of isomeric dichloro DIMs in 
prostate cancer cells.  (A, C) LNCaP and 22Rv1 (B, D) cells.  Cells were 
transfected with pPB, treated with DHT, 5 - 20 µM dichloro DIMs alone or in 
combination with DHT, and luciferase activity determined as described in 
the Materials and methods.  Results are expressed as means ± SE for at 
least 3 determinations per treatment group, and significant (p < 0.05) 
induction (*) or inhibition (**) in the 20 µM cotreatment groups are 
indicated. 
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Figure 24. Antiandrogenic and androgenic activity of isomeric dibromo 
DIMs in prostate cancer cells. 
(A, C) LNCaP and 22Rv1 (B, D cells.  Cells were transfected with pPB, 
treated with DHT, 5 - 20 µM dibromo DIMs alone or in combination with 
DHT, and luciferase activity determined as described in the Materials and 
methods.  Results are expressed as means ± SE for at least 3 
determinations per treatment group, and significant (p < 0.05) induction (*) 
or inhibition (**) in the 20 µM cotreatment groups are indicated. 
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3.3.2 Structure-dependent effects of isomeric dihalo DIMs on AR protein 
 expression 
 The antiandrogenic activity of DIM was associated with inhibition of DHT-
induced formation of nuclear AR (403); however, other compounds such as tea 
polyphenols and emodin inhibit androgen responsiveness through 
downregulation of AR protein (409, 410).  We therefore investigated the effects 
of the dichloro DIM (Figure 25A) and dibromo DIM (Figure 25B) isomers on AR 
protein expression in LNCaP cells.  Cells were treated with different 
concentrations of the individual compounds for 24 hr and whole cell lysates were 
analyzed for AR protein by Western blot analysis.  4,4'- and 5,5'-Dichloro DIM 
(up to 20 µM) did not affect AR protein levels; however, AR protein expression 
was decreased by both 6,6'- and 7,7'-dichloro DIM.  Results are shown only for 
15 µM 6,6'-dichloro DIM due to the high cytoxicity of this compound.  Results in 
Figure 25B for the dibromo DIMs gave a similar pattern of isomer-dependent 
responses, namely 4,4'-dibromo DIM had minimal effects on levels of AR 
protein, whereas both 6,6'- and 7,7'-dibromo DIM decreased AR levels.  5,5'-
Dibromo DIM also decreased expression of AR protein but only at the 20 µM 
concentration.  These results demonstrate remarkable differences in the effects 
of 4,4'-/5,5'-dihlo DIMs and 6,6'-/7,7'-dihalo DIMs on AR protein expression in 
LNCaP cells, and these differences were further investigated using the 4,4' and 
7,7'-dihalo DIM as prototypes. 
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 Previous studies showed that nuclear levels of AR increased after 
treatment of LNCaP cells with DHT for 24 hr, and DHT-induced nuclear 
translocation of AR was inhibited after cotreatment with DIM (403).  Figure 26A 
summarizes the effects of 20 µM 4,4’- and 7,7’-dichloro DIM, 20 µM DIM and 10 
nM DHT on cytosolic and nuclear AR levels after treatment for 1 and 24 hr.  
Minimal changes in cytosolic (c) and nuclear (n) 
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Figure 25. Structure-dependent effects of isomeric dihalo DIMs on AR 
protein levels.   
LNCaP cells were treated with different concentrations of isomeric 
dichloro DIMs (A) and dibromo DIMs (B) for 24 hr, and whole cell lysates 
were analyzed for AR and β-actin (loading control) protein by Western blot 
analysis as described in the Materials and methods. 
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Figure 26. Cytosolic (c) and nuclear (n) AR protein in LNCaP cells treated 
with DIM and dihalo DIMs.   
(A) Treatment with DIM, 4,4’- and 7,7’-dichloro DIM.  Cells were treated with 
DMSO, DHT, 4,4’- and 7,7’-dichloro DIM or DIM alone or in combination 
with DHT for 1 or 24 hr, and cytosolic or nuclear fractions were obtained 
and analyzed by Western blot analysis as described in the Materials and 
methods.  The nuclear Sp1 protein was determined as a loading control 
and to determine the efficiency of the isolation of the cytosolic and nuclear 
fractions.  (B)  Treatment with DIM, 4,4'- and 7,7'-dibromo DIM. Cells 
treated with DMSO, DHT, 4,4’ or 7,7’-dibromo DIM alone or in combination 
with DHT for 48 hr, and nuclear and cytosolic fractions were analyzed by 
Western blot analysis as described in the Materials and methods.  Nuclear 
Sp1 protein serves as a control for determining the efficiency of the 
isolated cytosolic and nuclear fractions. 
 
 
 AR levels were observed in all treatment groups (compared to DMSO) 
after 1 hr, and no major changes in AR protein staining in the cytosolic or 
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nuclear fractions were observed.  In cells treated for 24 hr, DHT induced a more 
intense staining of AR in the nuclear fraction and enhanced overall AR staining 
(c+n) compared to cells treated with DMSO alone (c+n).  This was observed in 
replicate experiments and is consistent with results of previous studies showing 
that DHT enhanced AR expression in LNCaP cells (405, 411, 412).  Both DIM 
and 4,4’-dichloro DIM alone also enhanced AR levels in both the cytosolic and 
nuclear fractions; however, in combination with DHT, these compounds did not 
block DHT-induced formation of nuclear AR, and this was in contrast to a 
previous report showing that DIM inhibited this response (403).  In contrast, 7,7’-
dichloro DIM alone decreased nuclear and cytosolic AR levels after treatment for 
24 hr and, in combination (DHT + 7,7’-dichloro DIM), the DHT-induced nuclear 
AR levels were only slightly decreased.  The observed downregulation of AR 
protein in both the cytosolic and nuclear fractions (Figure 26A) complements the 
results observed for AR levels in whole cell lysates from cells treated with 7,7'-
dichloro DIM (Figure 26A).  Sp1 protein served as a loading control for this 
study, and the identification of Sp1 only in the nuclear fraction confirms the 
efficiency of the separation of nuclear and cytosolic fractions. 
 In two separate experiments (1 and 24 hr), the effects of DMSO, DHT, 
4,4’- and 7,7’-dibromo DIM on AR levels were determined in LNCaP cells 
(Figure 26 A and B).  The pattern of effects for the dibromo DIMs alone, and in 
combination with DHT was similar to those observed for the dichloro DIM 
isomers.  DHT and 4,4’-dibromo DIM induced a time-dependent increase in AR 
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levels (compared to DMSO).  Interaction of 4,4'-dibromo DIM with DHT 
decreased the ratio of nuclear/cytosolic levels of AR; however, this could be an 
additive effect since the former compounds alone induced higher cytosolic AR 
levels.  In contrast, cytosolic and nuclear AR protein levels were decreased after 
treatment with 7,7’-dibromo DIM alone for 24 hr.  In cells cotreated with 7,7’-
dibromo DIM plus DHT, AR levels and their distribution were similar to those 
observed for DHT alone.   Both 7,7’-dibromo- and 7,7’-dichloro DIM appeared to 
induce a time-dependent decrease in AR protein, whereas DHT, DIM and 4,4’-
dichloro-, and 4,4’-dibromo DIM increased or stabilized AR protein in LNCaP 
cells.  This was further investigated in LNCaP cells treated for 48 hr with DHT,  
4,4’- and 7,7’-dihalo DIMs followed by Western blot analysis of whole cell 
lysates.  Results in Figure 27A confirm that 7,7’-dichloro- and 7,7’-dibromo DIM 
decreased AR protein expression (compared to DHT),  whereas AR levels after 
treatment with the corresponding 4,4’-dihalo DIMs (Figure 27B) were 
significantly higher than observed in cells treated with the 7,7’-dihalo DIMs 
(Figure 27A).  We also observed that Sp1 protein was also slightly decreased 
only after prolonged treatment with the 7,7’-dihalo DIMs.  
 
3.3.3 Effects of dihalo DIM isomers on AR protein and mRNA levels and their 
antiandrogenic activities in LNCaP cells 
 The potential role of proteasome activation in mediating downregulation 
of AR was investigated.  LNCaP cells were treated with 7,7’-dihalo DIMs for 48  
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Figure 27. Effects of 4,4’- or 7,7’-dihalo DIM on AR expression and 
androgen responsiveness.   
Effects of 7,7’-dihalo DIMs (A) and  4,4’-dihalo DIMs (B) on AR protein 
levels.  LNCaP cells were treated with DMSO,10 nM DHT, 20 µM dihalo 
DIMs for 48 hr, and whole cell lysates were analyzed by Western blot 
analysis as described in Materials and methods.  AR, β-actin (loading 
control) and Sp1 protein were determined.  (C)  Effects of proteasome 
inhibitors on AR protein levels.  LNCaP cells were treated with 20 µM 7,7’-
dichloro- or 7,7’-dibromo DIM alone or in combination with the proteasome 
inhibitor gliotoxin (3 µM) or MG132 (10 µM) for 48 hr, and AR protein levels 
were determined by Western blot analysis as described in Materials and 
methods.  β-Actin served as a loading control.   
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Figure 27. (continued)  (D)Time-dependent effects of 7,7’-dihalo DIMs 
on AR mRNA protein levels.  LNCaP cells were treated with 7,7’-dihalo 
DIMs for 24 hr, and AR mRNA was determined by real-time PCR as 
described in the Materials and methods.  The experiments were carried 
out in triplicate.  Results are expressed as means ± SE, and 
significantly (p < 0.05) decreased AR mRNA is indicated by an “*”.  TBP 
mRNA was also determined and used to normalize the AF mRNA levels.   
 
 
 
hr in the presence or absence of the proteasome inhibitors gliotoxin or MG132 
(Figure 27C).  Western blot analysis of whole cell lysates showed that 7,7’-
dichloro- and 7,7’-dibromo DIM significantly decreased AR protein compared to 
levels observed in solvent-treated cells, and cotreatment with the proteasome 
inhibitors further increased AR degradation.  The proteasome inhibitors alone 
also decreased AR protein, whereas 4,4’-dichloro- and 4,4’-dibromo DIM did not 
affect AR protein.  The data indicated that decreased AR protein in LNCaP cells 
treated with 7,7’-dihalo DIMs is not due to activation of the proteasome pathway.  
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The time-dependent effects of 7,7’-dihalo DIMs on AR mRNA levels was 
determined (Figure 27D), and the results show that mRNA levels are 
significantly decreased within 24 and 48 hr (data not shown).  We also 
investigated the effects of 7,7'-dichloro DIM on AR mRNA stability by pretreating 
cells with DMSO or 20 µM 7,7'-dichloro DIM for 12 hr prior addition of 
actinomycin D.  The results showed an initial 6 - 12 hr increase in AR mRNA 
levels after addition of actinomycin D; however, the subsequent rates of 
degradation of AR mRNA in the DMSO and 7,7'-dichloro DIM treatment groups 
were comparable (data not shown).  These data indicate that 7,7’-dihalo DIMs 
decrease both transcriptional and translational regulation of the AR. 
 Results of transient transfection studies showed that both 7,7’-dibromo- 
and 7,7’-dichloro DIM were partial AR agonists and AR antagonists (Figures 23 
and 24), and the former was observed after treatment for 36 hr.  This AR agonist 
activity of 7,7'-dihalo DIMs is inconsistent with their effects on AR and it is 
possible that 7,7’-dihalo DIM-induced androgenic activity after 36 hr (Figures 23 
and 24) may be due to the relatively slow rate of AR degradation.  We therefore 
investigated the time-dependent effects of 7,7’-dihalo DIMs on androgen-
responsiveness in LNCaP cells transfected with pPB (for 9 hr), and then treated 
with different concentrations of 7,7’-dihalo DIMs for 24, 36 or 48 hr (Figure 28A).  
The results indicated that after 36 hr, 5 - 20 µM 7,7’-dichloro DIM significantly 
induced luciferase activity; however, this response was significantly decreased 
after treatment for 24 or 48 hr and similar results were observed for 7,7’-dibromo  
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Figure 28. AR agonist/antagonist activities of dihalo DIMs.  
 (A) Time-dependent effects of 7,7’-dichloro DIM on transactivation.  
LNCaP  cells were transfected with pPB and, after 9 hr, were treated with 
7,7’-dichloro DIM (5 - 20 µM) for 24, 36 and 48 hr, and luciferase activity 
was determined as described in Materials and methods.  Results are 
expressed as means ± SE for at least 3 determinations for each treatment 
group and significant (p < 0.05) induction (*) is indicated.  (B)  Regulation 
of FKBP51 protein expression.  LNCaP cells were treated with DMSO, 10 
nM DHT, 4,4’-dichloro- or 4,4’-dibromo DIM alone or in combination with 
DHT for 48 hr, and whole cell lysates were analyzed by Western blot 
analysis for FKBP and β-actin (loading control) as described in Materials 
and methods. 
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DIM (data not shown).  The decreased AR agonist activity of 7,7'-dichloro DIM 
after 48 hr is consistent with the effects of this compound on AR protein 
degradation (Figure 27A). 
 A recent study identified a 51 kDa progesterone receptor-associated 
immunophilin, FKBP51, as an androgen-responsive gene in prostate cancer 
cells (335), and the effects of 4,4’-dichloro- and 4,4’-dibromo DIM alone and in 
combination with DHT were investigated in LNCaP cells 48 hr after treatment 
(Figure 28B).  DHT alone enhanced FKBP51 protein expression, whereas 4,4’-
dichloro- and 4,4’-dibromo DIM did not affect levels of FKBP51.  In cells 
cotreated with DHT plus 4,4’-dichloro- or 4,4’-dibromo DIM, the hormone-
induced response was inhibited by both DIM compounds and this was consistent 
with their antiandrogenic activity in transactivation assays (Figures 23 and 24).  
Minimal induction of FKBP51 was observed after treatment with 7,7’-dichloro- or 
7,7’-dibromo DIM (data not shown) and this may be due, in part, to the low levels 
of AR expression in LNCaP cells treatment with these compounds for 48 hr.  In 
summary, these results indicate that ring-substituted DIMs and DIM differentially 
modulate androgenic responses in prostate cancer cells and subtle changes in 
the position of the ring substituents of the dihalo DIMs (i.e. 25 vs. 28) can 
modulate their mechanisms of antiandrogenic action and effects on AR 
expression. 
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3.3 Discussion                                                                                                    
 I3C and DIM inhibit growth of several cancer cell lines through multiple 
mechanisms and these compounds also directly activate receptors.   I3C and/or 
DIM interact with the AhR, the fish ER and AR (140, 334), and ring-substituted 
DIMs also activated the AhR (330, 404).  A recent study showed that DIM 
competitively bound the AR and decreased DHT-induced transactivation/gene 
expression in LNCaP cells (403).  The mechanism of the antiandrogenic activity 
of DIM was novel since this compound inhibited DHT-induced nuclear 
translocation of the cytosolic AR (403), whereas other antiandrogens do not 
block nuclear translocation of the AR but form transcriptionally inactive nuclear 
AR complexes (413, 414).  This study reports the androgenic/antiandrogenic 
activity of a series of symmetrical ring-substituted DIMs to delineate possible 
structure-dependent effects that modulate their activities. 
 Results in Figures 23 and 24 demonstrated that like DIM (Figure 22), the 
symmetrically substituted dichloro- and dibromo DIM isomers also inhibited 
DHT-induced transactivation in LNCaP and 22Rv1 prostate cancer cells.  The 
assay system used the androgen responsive pPB construct, which contains the -
288 to +28 region of the probasin reporter linked to firefly luciferase (405, 406).  
The antiandrogenic activities of the compounds were similar in both cell lines; 
however, with few exceptions their overall potencies were higher in LNCaP than 
22Rv1 cells.  We also investigated the structure-dependent AR agonist activities 
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of ring-substituted DIMs in cells transfected with pPB.  7,7’-Dichloro- and 7,7’-
dibromo DIM were partial AR agonists and partial antagonists in both cell lines 
(Figures 23 and 24), and their androgenic potencies were at least three orders of 
magnitude lower than that of DHT.  In contrast, symmetrical 4,4’-, 5,5’-, 6,6’-
dichloro- and -dibromo DIMs primarily exhibited antiandrogenic activity in this 
transactivation assay in both cell lines.  Other symmetrical ring-substituted 
methyl, methoxy and fluoro DIM analogs also exhibited antiandrogenic activity 
and a few of these isomers were also partial AR agonists; however, these 
activities also depended on cell context and were not further investigated (data 
not shown). 
 The structure-dependent effects of dihalo DIMs on AR expression clearly 
differentiated between the 4,4'-/5,5'- and 6,6'-/7,7'-dihalo DIMs since the latter 
compounds downregulated AR protein, whereas minimal effects were observed 
for 4,4'- and 5,5'-dihalo DIMs (Figure 25).  6,6'-Dichloro DIM exhibited significant 
cytotoxicity at concentrations > 10 µM and, therefore, structure-dependent 
differences in the activities of the dihalo DIM isomers were further investigated 
using 4,4’- and 7,7’-dichloro- and -dibromo DIMs as models in LNCaP cells.  
Previous studies show that DHT stabilizes the AR (compared to DMSO) 
resulting in increased AR expression for at least 24 hr after treatment (405, 411, 
412), and results of this study also showed that treatment with DHT increased 
AR protein (Figures 26 and 27).  We directly compared AR protein levels in 
LNCaP cells treated with DMSO (control), DHT, 4,4’-dichloro-, 7,7’-dichloro-, 
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4,4’-dibromo-, 7,7’-dibromo DIM, DIM alone, and DHT plus the DIMs (in 
combination) for 1 and 24 hr (Figure 26).  The most pronounced changes were 
observed in the 24 hr treatment group, where DHT, DIM, 4,4’-dichloro- and 4,4’-
dibromo DIM stabilized the AR (compared to DMSO).  DHT alone induced 
nuclear translocation of the AR; however, in contrast to a previous report with 
DIM (403), results of this study showed that DIM and 4,4’-dihalo DIMs did not 
markedly inhibit DHT-induced AR translocation and the combined treatments 
tended to give additive effects (Figure 26).  7,7’-Dichloro DIM also had minimal 
effects on DHT-induced translocation of the AR; however, both 7,7’-dichloro- 
and 7,7’-dibromo DIM alone did not stabilize the AR protein after treatment for 
24 hr.   
 Compared to treatment with DHT, DIM or the 4,4’-dihalo-DIMs, 7,7’-
dichloro-, and 7,7’-dibromo DIM significantly decreased AR protein and mRNA 
levels in LNCaP cells (Figure 27).  Down-regulation of AR by these compounds 
was similar to the reported time-dependent decrease of AR protein in LNCaP 
cells after treatment with tea polyphenol epigallocatechin (ECCG) (409).  It was 
hypothesized that the effects of ECCG were due to downregulation of Sp1 
protein, which also plays a role in regulating AR expression.  We also observed 
that the 7,7’-dihalo DIMs slightly decreased Sp1 protein expression after 
treatment for 48 hr (Figures 27A and 27B).  This may contribute, in part, to the 
lower expression of AR in these cells but cannot fully explain the dramatic drop 
in AR protein.  A recent study reported that the phytochemical emodin inhibited 
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AR-dependent transactivation in prostate cancer cells, and this was associated 
with inhibition of AR nuclear translocation and activation of proteasome-
dependent degradation of AR protein (410).  The effects of emodin on AR 
protein in LNCaP cells were blocked by the proteasome inhibitor MG132, and 
emodin did not affect AR mRNA levels.  In contrast 7,7’-dihalo DIM-induced 
degradation of AR protein was not blocked by the proteasome inhibitors gliotoxin 
or MG132 (Figure 27C), and these compounds induced a time-dependent 
decrease in both AR mRNA and protein levels.  We did not observe any 
compound-induced changes in AR mRNA stability (data not shown), suggesting 
a transcriptional mechanism of action which is being currently investigated.  
These results clearly distinguished between the effects of 7,7’-dihalo DIMs with 
other compounds such as emodin and ECCG which also affect AR mRNA and 
protein expression in LNCaP cells. 
 Although the initial in vitro screening assays showed that 7,7’-dihalo DIMs 
exhibited potential AR agonist activity in transactivation assays, we further 
investigated the effects of duration of treatment on their androgenic activity.  
7,7’-Dihalo DIMs induced transactivation in LNCaP cells transfected with pPB 
and treated for 36 hr (Figure 28A).  However, after 48 hr, this response was 
significantly decreased and this was consistent with decreased AR expression at 
this time point, suggesting that the partial androgenic activity of these 
compounds is reversed after longer periods of exposure due to AR 
downregulation. 
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 The AR agonist activity of the 7,7’-dihalo DIMs was also affected by lower 
AR expression since these compounds did not significantly induce FKBP protein 
in LNCaP cells (data not shown).  The androgen-responsive FKBP protein is 
maximally induced by DHT only after treatment for 48 hr, and 4,4’-dichloro- and 
4,4’-dibromo DIM inhibited this response (Figure 28B). 
 In summary, results of this study confirm that DIM and several 
symmetrical ring-substituted DIM isomers exhibit antiandrogenic activity.  In 
addition, some isomers, notably 7,7’-dichloro- and 7,7’-dibromo DIM also exhibit 
partial time-dependent androgenic activity in transfection assays, and these 
results illustrate that subtle changes in the phenyl ring substitution pattern have 
marked effects on the androgenic activity of the dihalo DIMs.  At the 
concentrations used in this study, the antiandrogenic activity of the 4,4’-dihalo 
DIMs was not related to inhibition of DHT-induced nuclear translocation of AR.  
Our results suggest that the antiandrogenic activity of DIM and 4,4’-dihalo DIMs 
may be complex and involve multiple pathways including inhibition of nuclear 
AR-dependent transactivation.  We also observed that 6,6'-dihalo DIMs and 7,7’-
dihalo DIMs decreased AR expression in LNCaP cells, and current studies are 
investigating the potential clinical importance of these and other effects of ring-
substituted DIMs on the growth of prostate cancer cells/tumors in both in vitro 
and in vivo models. 
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CHAPTER IV 
 
INHIBITION OF PROSTATE CANCER CELL GROWTH BY ACTIVATION OF 
PRO-APOPTOTIC PROTEINS NAG-1 AND ATF3 BY SYMMETRICALLY 
SUBSTITUTED DIBROMO AND DICHLORO 1,1’-BIS(3’-
INDOLYLMETHANES) 
 
4.1 Introduction 
 Indole-3-carbinol (I3C) is a phytochemical that is found as an 
isothiocyanate conjugate (glucobrassican) in cruciferous vegetables such as 
cauliflower, brussel’s sprouts and broccoli (333).  Epidemiological studies have 
demonstrated that for several cancers there are lower incidence rates 
associated with high consumption of cruciferous vegetables (185, 188, 190, 331, 
332).  Moreover, there is also evidence in laboratory animal feeding studies that 
rodents consuming diets containing cruciferous vegetables or I3C are more 
resistant to carcinogen-induced tumor formation (196, 199, 389-394).  Although 
the identities of anticarcinogenic compounds in cruciferous extracts have not 
been determined unequivocally, most studies have focused on either I3C or 
sulfurophane, an allylisothiocyanate that exhibits multiple activities (415, 416).   
The induction of glutathione-S-transferase by sulfurophane has been extensively 
investigated and has been shown to play a role in the anticarcinogenic activity of 
this compound due to the enhanced detoxification of toxicants and carcinogens 
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through enhanced formation of glutathione conjugates which are readily 
excreted. 
 I3C has been extensively investigated in laboratory animals and in vitro 
cell culture studies and this compound exhibits multiple activities that are 
associated with the antitumorigenic properties of I3C (193, 397, 398, 417-422).  
For example I3C inhibits several different cell cycle enzymes, induces apoptotic 
pathways and inhibits invasion and migration of cancer cell lines. 
 A major problem in interpreting results from I3C studies is due to its 
instability and rapid formation of various metabolites and rearrangement 
products.  In acidic conditions I3C forms multiple linear and cyclic condensation 
products including 3,3’ DIM and  in vivo studies show that in the acidic 
environment of the gut a wide variety of metabolites are formed (140, 334).  In 
cell culture studies carried out at or near physiological pH I3C is converted to 
DIM and it is therefore difficult to distinguish between the effects of both 
compounds (194).  Research in this laboratory has focused on using DIM as a 
building block for synthesis of both ring- and methylene-substituted DIMs (C-
DIMs) as a novel class of anticancer drugs (330, 404, 423-431).  The selection 
of DIM as a template is due to the relative stability of this compound under acidic 
and basic conditions thereby abrogating the instability problems associated with 
I3C.   
DIM, C-DIM and ring substituted DIMs exhibit some common properties 
including the induction of endoplasmic reticulum (ER) stress and induction of 
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apoptosis in cancer cell lines, however the synthetic analogs were invariably 
more potent than DIM (430).   C-DIMs are triaryl methane analogs that activate 
several orphan receptors including peroxisome proliferator-activated receptor 
γ (PPAR γ) and nerve growth factor induced-B γ (NGFI-B γ, Nur77)(424-429, 
432) whereas the diarylmethane DIM analogs activate or deactivate the aryl 
hydrocarbon receptor (AhR)  (ER) and androgen receptor (AR) (330, 404, 423, 
433).  Recent studies in this laboratory show that symmetrically substituted 
dihalo DIMs exhibit androgenic or antiandrogenic activities in AR-positive 
LNCaP and 22Rv1 prostate cancer cells (433).  Moreover, the 7,7’ 
dichloro/dibromo DIMs but not the corresponding 4,4’dihalo DIM isomers 
preferentially downregulated AR protein expression.  This study further 
investigates the effects of dihalo DIMs on the growth of prostate cancer cells.  
IC50 values for growth inhibition in LNCaP and 22Rv1 cells were 5 µM for the 
4,4’- 5,5’- 6,6’- and 7,7’-dihalo DIMS and the 4,4’- and 7,7’-dihalo DIMs (chloro 
and bromo) induced caspase-dependent apoptosis in LNCaP cells.  The dihalo 
DIMs did not activate ER stress, however these compounds induced both NAG-
1 and activating transcription factor 3 (ATF3), two antiproliferative/proapoptotic 
genes which are responsible in part for the effects of these compounds on the 
proliferation of prostate cancer cells. 
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4.2  Materials and methods 
 
4.2.1  Cell lines and reagents 
Human prostate carcinoma cell lines LNCaP and 22Rv1 were obtained 
from American Type Culture Collection (Manassas, VA).  Fetal bovine serum 
was obtained from JRH Biosciences, Lenexa, KS.  Cells were maintained in 
RPMI 1640 (Sigma Chemical St. Louis, MO) supplemented with 0.22% sodium 
bicarbonate, 0.011% sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% 
FBS, and 10 mL/L of 100x antibiotic antimycotic solution (Sigma).  Cells were 
maintained at 37°C in the presence of 5% CO2.  Antibodies for PARP, GRP-78, 
and ATF-3 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Antibody for NAG-1 was purchased from Upstate Biotechnologies 
(Charlottesville VA). Monoclonal antibody for β-actin was purchased from 
Sigma-Aldrich.  Reporter lysis buffer and luciferase reagent for luciferase studies 
were purchased from Promega (Madison, WI).  β-Galactosidase (β-Gal) reagent 
was obtained from Tropix (Bedford, MA).  Lipofectamine reagents were supplied 
by Invitrogen (Carlsbad, CA).  Western Lightning chemiluminescence reagents 
were from Perkin-Elmer Life Sciences (Boston, MA).  Dihydrotestosterone was 
purchased from Sigma.  MG132  was obtained from Calbiochem (San Diego, 
CA).  Kinase inhibitors LY294002, PD98059, SB203580, SP600125 were 
obtained from Sigma. The ring-substituted DIMs were prepared in this laboratory 
by condensation of ring-substituted indoles and formaldehyde or by self-
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condensation of ring-substituted indole-3-carbinols; compounds were >95% pure 
by gas chromatography-mass spectrometry. 
 
4.2.2  Plasmids 
The pNAG-1 reporter containing -1085/+41 was generated previously 
(336, 434). 
 
4.2.3  Cell proliferation assays 
 LNCaP prostate cancer cells were maintained in RPMI media with phenol 
red and were seeded into 6-well plates at a density of 50,000 cells/well in DME-
F12 plus 5% FBS stripped with dextran-treated charcoal.  After allowing 24 hr to 
attach, cell were treated with test compounds in DMSO (1% final volume) or 
DMSO alone every 48 hr in fresh media.  Cells were harvested every 48 hr by 
trypsinization and counted using a Coulter Z1 cell counter (Coulter Electronics, 
Hialeah, FL).   
 
4.2.4  Transfection and luciferase assay   
Prostate cancer cells were plated in 12-well plates at 2.5 x 105 cells/well 
in DMEM:Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS.  
After overnight attachment, cells were transfected with 100 ng of pNAG-1 and 50 
ng of β-galactosidase reporter plasmid, using Lipofectamine reagent (Invitrogen) 
according to the manufacturer’s recommended protocol.  Cells were transfected 
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and, after 8 - 9  hr, the transfection mix was replaced with 5% charcoal-stripped 
FBS media containing either vehicle (DMSO) or the indicated DIM-isomer and 
incubated for 22-24 hr.  Cells were then lysed with 100 mL of 1x reporter lysis 
buffer, and 30 µL of cell extract were used for luciferase and β-galactosidase 
assays.  Lumicount (Parkard, Meriden, CT) was used to quantitate luciferase 
and β-galactosidase activities, and the luciferase activities were normalized to β-
gal activity.  
 
4.2.5 Western blot analysis   
LNCaP prostate cells were seeded in 100 mm plates in DMEM:Ham’s F-
12 media containing 2.5% charcoal-stripped FBS and allowed to attach 
overnight, followed by treatment with either the vehicle (DMSO) or the indicated 
compounds for the desired time points.    For whole cell lysates cells were 
scraped in 500 µL of lysis buffer [50 mM HEPES, 0.5 M sodium chloride, 1.5 mM  
magnesium chloride, 1 mM EGTA, 10% v/v glycerol, 1% Triton X, and 5 µL/ml of 
Protease Inhibitor Cocktail (Sigma)].  The lysates were incubated on ice for 1 - 
1.5 hr with intermittent vortexing followed by centrifugation at 40,000 g for 10 
min at 4°C.   Protein levels were estimated using Bradford reagent; equal 
amounts of protein were diluted with loading buffer and boiled for 4 min, and 
loaded onto 10% SDS-polyacrylamide gel.  After electrophoresis, gels were 
transferred to polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA) using 
an electroblotting apparatus overnight at 4°C in transfer buffer containing 48 mM 
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Tris-Cl, 29 mM glycine, and 0.025% SDS.  The membranes were blocked with 
TBS (10 mM Tris-HCl (pH 8) and 150 mM sodium chloride] plus 5% milk (blotto-
buffer) for 1 hr, and then incubated in primary antibody at 1:1000 dilution in 
blotto buffer at 4°C  overnight, followed by one min washes (2X) and incubation 
with secondary antibody for 3 - 5 hr at 4°C.  Membranes were then rinsed with 
water and incubated in enhanced chemiluminescence (ECL) reagents (Perkin 
Elmer, Boston, MA) for 1 min, removing excess ECL with paper towelette.  The 
membrane was sealed in plastic wrap and photographed for immunoreactive 
bands using ECL hyperfilm.    
  
4.2.6  Statistical analysis 
Statistical differences between different groups were determined by 
ANOVA and Scheffe’s test for significance.  The data are presented as mean ± 
SE for at least three separate determinations for each treatment.  
 
4.3  Results 
4.3.1  Effects of symmetrical dihalo DIM isomers on LNCaP and 22Rv1 prostate 
 cancer cell proliferation. 
 Previous studies in this laboratory showed that ring substituted DIMs 
inhibited growth of ER-positive and ER-negative breast cancer cells and this was 
due, in part, to induction of apoptosis (330, 404, 423).  We also investigated the 
antiproliferative activity of a series of symmetrical ring-substituted DIMs in AR-
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positive LNCaP prostate cancer cells and the results in Figure 29 illustrate the 
effects of 5, 10 and 20 µM concentrations of 4,4’-, 5,5’, 6,6’-, and 7,7’-, dichloro 
DIMs on LNCaP cell growth.  All symmetrical dichloro DIMs inhibited LNCaP cell 
growth and the lowest concentration and IC50 values were  5 µM for all 
isomers.  A comparable study was carried out for a series of 4,4’-, 5,5’-, 6,6’-, 
and 7,7’-, dibromo DIM isomers and their IC50 values for cell growth inhibition 
were also  5 µM (Figure 30).   Based on direct comparison of their growth 
inhibitory activity at the 5 µM concentration the, 6,6’-, and 7,7’-, dihalo DIMS 
were slightly more potent than the corresponding 4,4’-, 5,5’-dihalo DIMs.  We 
also investigated the growth inhibitory effects of these compounds in AR-positive 
22Rv1 prostate cancer cells and the results were similar to those observed in 
LNCaP cells with some isomer-specific differences.  Among the symmetrical 
dichloro DIMs the IC50 values for growth inhibition was higher for 5,5’- dichloro 
DIM (20 µM) and  5 µM for the other isomers (Figure 31).  Using lower 
concentrations of 5,5’-dichloro DIM (0.1-1 µM) in 22Rv1 cells the IC50 value was 
approximately 1 µM .  The pattern of growth inhibition for the dibromo DIM 
isomers in 22Rv1 cells (Figure 32) was similar to that observed in LNCaP cells.   
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Figure 29. Cell proliferation assays in LNCaP cells with dichloro DIMs.   
LNCaP cells were treated with DMSO or (A) 4,4’-dichloro DIM (B) 5,5’ 
dichloro DIM or (C) 6,6’-dichloro DIM or (D) 7,7’dichloro DIM and cell 
numbers were determined after 2, 4 and 6 days as described in Materials 
and methods.  Data presented as means of three replicate determinations 
for each treatment group.  Significant inhibition (p<0.05) of cell 
proliferation ± SE (to DMSO) is indicated as “*” in figures (6 day point). 
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Figure 30.  Cell proliferation assays in LNCaP cells with dibromo DIMs.   
LNCaP cells were treated with DMSO or (A) 4,4’-dibromo DIM (B) 5,5’ 
dibromo DIM or (C) 6,6’-dibromo DIM or (D) 7,7’dibromo DIM and cell 
numbers were determined after 2, 4 and 6 days as described in Materials 
and methods.  Data presented as means of three replicate determinations 
for each treatment group.  Significant inhibition (p<0.05) of cell 
proliferation ± SE (to DMSO) is indicated as “*” in figures (6 day point). 
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Figure 31. Cell proliferation assays in 22Rv1 cells with dichloro DIMs.    
22Rv1 cells were treated with DMSO or (A) 4,4’-dichloro DIM (B) 5,5’ 
dichloro DIM or (C) 6,6’-dichloro DIM or (D) 7,7’dichloro DIM and cell 
numbers were determined after 2, 4 and 6 days as described in Materials 
and methods.  Data presented as means of three replicate determinations 
for each treatment group.  Significant inhibition (p<0.05) of cell 
proliferation ± SE (to DMSO) is indicated as “*” in figures (6 day point). 
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 Figure 32. Cell proliferation assays in 22Rv1 cells with dibromo DIMs.   
 22Rv1 cells were treated with DMSO or (A) 4,4’-dibromo DIM (B) 5,5’ 
dibromo DIM or (C) 6,6’-dibromo DIM or (D) 7,7’dibromo DIM and cell 
numbers were determined after 2, 4 and 6 days as described in Materials 
and methods.  Data presented as means of three replicate determinations 
for each treatment group.  Significant inhibition (p<0.05) of cell 
proliferation ± SE (to DMSO) is indicated as “*” in figures (6 day point). 
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We also investigated a comparable series of isomeric dimethoxy and dimethyl 
DIMs and their growth inhibitory IC50 values in LNCaP and 22Rv1 cells were in 
the 5-10 µM range (data not shown).  The mechanisms of growth inhibition of 
prostate cancer cells by symmetrical ring substituted DIMs was further 
investigated using the dihalo DIMs as models in LNCaP cells. 
 
4.3.2  Mechanism of action of dihalo DIMs- ER stress 
 Recent studies in this laboratory have demonstrated that DIM, ring 
substituted DIMs and methylene substituted DIMs (C-DIMs) induced apoptosis 
in pancreatic cancer cells through induction of endoplasmic reticulum (ER) 
stress and activation of the extrinsic apoptotic pathways (430).  Using the 4,4’-, 
and 7,7’-, dihalo DIMs as models, treatment of LNCaP cells for 24 hr with 20 µM 
4,4’-, and 7,7’-, dichloro DIMs and 4,4’-, and 7,7’-dibromo DIMs resulted in the 
induction of PARP cleavage which is a hallmark of caspase-dependent 
apoptosis (Figure 33A).  Treatment with 5 µM MG132 also induced apoptosis in 
LNCaP cells and this compound served as a positive control for this experiment.  
Since 5,5’-dibromo DIM induced apoptosis through activation of ER stress in  
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Figure 33. Induction of apoptosis and ER stress by dihalo DIMs. 
(A) Induction of apoptosis. LNCaP cells were treated with 20 µM of 4,4’-, 
7,7’-dihalo DIMs and 5 µM MG132 as positive control for 24 hr and whole 
cell lysates were analyzed by Western blot analysis as described in 
Materials and methods.  (B) Activation of ER stress protein GRP78 in 
LNCaP cells.  Cells were treated with 4,4’-, 7,7’-dihalo DIMs (± 10 µM DHT) 
and 1 µM TG as positive control for 48 hr and whole cell lysates were 
analyzed by Western blot analysis as described in Materials and methods. 
(C) Activation of ER stress protein GRP78 in Panc-1 cells.  Cells were 
treated with 4,4’-, 7,7’-dihalo DIMs and 1 µM TG as positive control for 48 hr 
and whole cell lysates were analyzed by Western blot analysis as 
described in Materials and methods. β-actin  was used as loading control 
for these experiments. 
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pancreatic cancer cells (430) we examined the effects of the 4,4’- and 7,7’-dihalo 
compounds on induction of GRP78, a well known marker of ER stress.  The 
experiment was carried out in the presence or absence of DHT and the results 
(Figure 33B) show that 20 µM concentrations of these dihalo DIMs did not 
significantly induce ER stress in LNCaP cells.  In contrast, thapsigargin (TG), a 
well characterized inducer of ER stress induced approximately a 2-fold increase 
in GRP78 protein.  Thus the dihalo DIMs did not induce ER stress in LNCaP 
cells.  As an additional positive control for this experiment Panc-1 cells were 
treated with 20 µM of the dihalo DIMs and 1 µMTG and Western blot analysis of 
whole cell lysates shows that GRP78 was induced in all treatment groups 
(Figure 33C) Thus the differences in the effects of the 4,4’-, and 7,7’-dihalo DIMs 
on induction of ER stress were cell context dependent and this pathway was not 
activated in LNCaP cells. 
 
4.3.3  Mechanism of action of dihalo DIMs.  Activation of NAG-1 and ATF3 
 DIM and C-DIMs induced the TGFβ-like peptide NAG-1 and ATF3 in 
colon cancer cells and both factors have been linked to  growth inhibition and 
apoptosis (428, 435).  The results in Figure 34 show that 4,4’-, 5,5’-, 6,6’- and 
7,7’-dichloro DIM induce both NAG-1 and ATF3 proteins in LNCaP cells after 
treatment for 24 hr.  Both protein are induced in parallel, however at higher 
concentration of the more toxic 6,6’-dichloro DIM (15 µM) and 7,7’-dichloro DIM  
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Figure 34. Activation of NAG-1 and ATF3. 
(A) Effects of isomeric dichloro DIMs on induction of NAG-1 and ATF3. 
LNCaP cells were treated with isomeric dichloro DIMs for 24 hr and whole 
cell lysates were analyzed by Western blot analysis as described in 
Materials and methods.  (B) Effects of isomeric dibromo DIMs on induction 
of NAG-1 and ATF3. LNCaP cells were treated with isomeric dichloro DIMs 
for 24 hr and whole cell lysates were analyzed by Western blot analysis as 
described in Materials and methods. 
 164 
0
1
2
3
4
- 5   10  15    5   10  15   5   10   5    10  15  10
4,4’-diCl 5,5’-diCl 7,7’-diCl6,6’-diCl
X = 1,1-bis(3’-indolyl)-1-(p-butyl)methane
Positive control
µM
X
C
LNCaP Cells
* *
*
*
*
Fo
ld
 
In
du
ct
io
n
 
 
 
Figure 34 (continued) (C)Transactivation of pNAG-1.  LNCaP cells were 
transfected with pNAG-1luc and treated with the isomeric dichloro DIMs 
and luciferase activity was determined as described in Materials and 
methods.  Results are expressed as means of three replicate 
determinations for each treatment groups   Significant induction (p<0.05) 
of pNAG-1 ±  SE (to DMSO) is indicated by “*” in figure.  
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Figure 34.  (continued) (D)  Effects of kinase inhibitors on induction of 
NAG-1.  LNCaP cells were treated with various kinase inhibitors alone or in 
combination with the 4,4’-, or 7,7’-dichloro DIMs for 24 hr (in case of kinase 
inhibitors cells were pretreated with kinase inhibitors for 2 hr before 
adding the isomeric DIMs) and whole cell lysates were analyzed by 
Western blot analysis as described in Materials and methods.  β-actin  was 
used as loading control for the Western blot experiments. 
 
 
(20 µM) there was a subsequent decrease in NAG-1 protein expression and 
ATF3 was also decreased.  Figure 34B summarizes the effects of 4,4’-, 5,5’-, 
6,6’- and 7,7’ dibromo DIM on induction of NAG-1 and ATF3 and the results 
show that like the dichloro compounds all the isomeric dibromo DIMs enhanced 
expression of both the proteins. Moreover NAG-1 and ATF3 expression 
decreased at the highest concentration of the toxic 6,6’-dibromo DIM isomer.  
The induction of p53 or Egr-1 was not observed in these studies (data not 
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shown).  The induction of NAG-1 protein by the dichloro DIMs was also 
paralleled by induction of reporter gene (luciferase) activity in LNCaP cells 
transfected with pNAG-1 construct which contains the -1084 to +41 NAG-1 gene 
promoter insert (428).  The results showed that 4,4’-, 5,5’-, and 7,7’-dichloro DIM 
compounds significantly induced pNAG-1 whereas the 6,6’-dichloro DIM did not 
induce activity and 1,1-bis (3’indolyl)-1-(p-butylphenyl) methane was used as a 
positive control since this compound has previously been shown induce NAG-1 
in cancer cell lines (428).  Interestingly the only inactive compound was the most 
toxic 6,6’-dichloro DIM isomer which decreased luciferase activity (Figure 34C) 
and NAG-1 protein (Figure 34A).  Using 4,4’- and 7,7’-dichloro DIM as models 
we investigated the effects of kinase inhibitors on induction of NAG-1 since 
previous studies have shown that C-DIMs and other compounds induce NAG-1 
through activation of kinases (428).  Results in Figure 34D show that NAG-1 
protein is induced after treatment of LNCaP cells for 24 hr with 15  4,4’- and 
7,7’-dichloro DIM.  After co-treatment with MAPK (PD98059), PI3K (LY294002), 
JNK SP600125) and p38MAPK (SB203580) inhibitors there was some inhibition 
of 7,7’-dichloro DIM-induced NAG-1 expression in cells co-treated with 
LY294002 and SP600125 and to a lesser extent with the other inhibitors.  In 
contrast, induction of NAG-1 by 4,4’-dichloro DIM was not affected in LNCaP 
cells co treated with these inhibitors.  These results suggest that dihalo DIM-
dependent induction of NAG-1 through kinase pathways is complex and the 
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mechanism of induction may be dependent on the structure of the compounds 
and this is currently being investigated.   
 
4.4  Discussion 
 DIM is a phytochemical metabolite that inhibits cancer cell growth and 
induces apoptosis in cells derived from multiple tumors, however the 
mechanisms of this response are complex and dependent on cell context (193, 
202, 378, 395, 396, 399, 422).  Previous studies in this laboratory have 
described the antitumorigenic effects of symmetrical ring substituted DIM 
derivatives and the results show both some similarities and differences (330, 
404, 423, 430).  DIM and ring-substituted DIMs inhibit growth of breast cancer 
cells and the latter compounds were more active (330, 404, 423).  Results of in 
vivo studies showed that doses of DIM as low as 5 mg/kg/48 hr inhibit growth of 
carcinogen-induced rat mammary tumors (378).  In contrast, several ring 
substituted DIMs, including 4,4’-dichloro-, 6,6’-dichloro-, 5,5’-dibromo-, 1,1’-
dimethyl-, 5,5’-dimethyl and 1,1’,2,2’-tetramethyl DIMs inhibited rat mammary 
tumor growth at doses of   1mg/kg/48 hr and were at least 5 times more potent 
than DIM (330, 404).  Similar differences in potency were observed for induction 
of ER stress in pancreatic cancer cells where 5,5’-dibromo DIM was more potent 
than DIM (430).    
 DIM exhibits antiandrogenic activity in LNCaP prostate cancer cells and 
this was associated with inhibition of dihydrotestosterone (DHT)-induced 
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accumulation  of nuclear AR (403).  In contrast, results from this laboratory using  
DIM and a series of ring substituted isomeric dihalo DIMs gave different results 
in LNCaP and 22Rv1 cells (433).  For example, DIM did not block DHT-induced 
nuclear uptake of AR and the effects of the isomeric dihalo DIMs were structure-
dependent.  In transient transfection studies using an androgen-responsive 
construct containing a probasin promoter insert the 7,7’-dichloro and 7,7’-
dibromo DIMs were partial AR agonists whereas like DIM, the 4,4’-, 5,5’- and 
6,6’-dihalo DIMs were antiandrogens.  We did not observe any effects of DIM or 
dihalo DIMs on DHT induced nuclear uptake of the AR however, 6,6’- and 7,7’-
dihalo DIMs decreased AR expression (protein and mRNA).  However, these 
effects were not observed for DIM or 4,4’- and 5,5’-dihalo DIMS.   
Results in Figures 29-32 show that  4,4’-, 5,5’-, 6,6’- and 7,7’- dihalo DIMs 
all inhibited growth of LNCaP and 22 Rv1 prostate cancer cells.  Over the 
concentrations used in this study (5,10 and 20) the IC50 (growth inhibition) 
values were  5 µM and using lower concentrations the IC50 value for 5,5’-
dichloro DIM was approximately 1 µM in 22Rv1 cells (Figure 31).  Thus despite 
the structure-dependent AR expression in LNCaP cells all of these compounds 
were potent inhibitors of LNCaP and 22Rv1 cell proliferation.  It was apparent 
from the cell proliferation that at doses 5 µΜ there  was considerable induction 
of cell death and results in Figure 33A show that treatment  of LNCaP cells with 
20 µΜ 4,4’-dichloro, 4,4’-dibromo, 7,7’-dichloro and 7,7’-dibromo DIM induce 
caspase-dependent apoptosis.  Similar results were observed in LNCaP cells 
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treated with 5 µΜ MG132, a proteasome inhibitor and know inducer of 
apoptosis.  Since previous studies showed that DIM and ring substituted DIMs 
induce ER stress which leads to activation of apoptosis in pancreatic cancer 
cells (430),  we also investigated activation of ER stress by dihalo DIMs in 
LNCaP cells after treatment for 48 hr.  Treatment with the ring substituted DIMs 
did not enhance expression of the stress protein GRP78, and similar results 
were observed in the co-treatment studies with DHT, whereas TG a known 
inducer of ER stress enhanced GRP78 protein expression.  These experiments 
were also repeated in the presence of DHT and similar results were obtained 
suggesting that stress pathways were not associated with the proapoptotic 
effects of the dihalo DIMs in prostate cancer cells.  In contrast, as a positive 
control for this experiment we showed that like TG, the dihalo DIMs induced ER 
stress in Panc-1 cells (Figure 33C) and this clearly demonstrates the cell context 
dependent differences in the mechanisms of action of these compounds. 
 Previous studies reported that DIM and selected PPARγ-active C-DIMs 
induced the TFGβ-like peptide NAG-1 in colon cancer cells and the latter 
compounds also induced ATF3 (428, 435).  NAG-1 is induced by NSAIDS in 
some colon cancer cell lines and this gene is also enhanced by different drugs, 
PPARγ-agonists, other chemoprotective agents such as genistein, polyphenolics 
and DIM (336-341, 434-438).  Moreover, overexpression of NAG-1 induced 
apoptosis  (436).  ATF-3 is often co-induced with NAG-1 and this gene is also 
associated with growth inhibitory/proapoptotic pathways (439-441).  Results in 
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Figure 34A show that treatment of LNCaP cells with 5-20 µΜ 4,4’-, 5,5’-, 6,6’- 
and 7,7’dichloro DIM induced both NAG-1 and ATF3.  The dose response 
curves were variable particularly with respect to higher concentrations of 6,6’-
dichloro DIM (15 µΜ) and 7,7’-dichlro DIM (20 µΜ) where the induction of NAG-
1 and ATF3 observed at lower concentrations were decreased. The reason for 
these concentration-dependent responses are unknown but have previously 
been observed for other compounds that induce NAG-1 (428).  The effects of 
4,4’-, 5,5’-, 6,6’- and 7,7’-dibromo DIM on NAG-1 and ATF3 expression were 
similar to that observed for the dichloro DIM isomers and expression of both 
proteins was enhanced (Figure 34B). Moreover, induction of luciferase activity 
was also observed in LNCaP cells transfected with pNAG-1 and treated with the 
isomeric dichloro DIMs (Figure 34C) and similar effects have been observed for 
C-DIMs (428).   
 Previous studies with C-DIMs showed that these compounds rapidly 
induced PI3K dependent activation of early growth response gene-1 (Egr-1) 
which in turn activated NAG-1 through the proximal Egr-1 site in the NAG-1 
promoter (428).  Results in Figure 34D show that both 4,4’ and 7,7’ dichloro DIM 
induce NAG-1 expression and these effects are differentially modulated by 
kinase inhibitors. For example, induction of NAG-1 by 4,4’-dichloro DIM was 
inhibited by LY294002 (PI3K inhibitor) and partially inhibited by PD98059 (MAPK 
inhibitor) and SP600125 (JNK inhibitor).  SB203580 (p38 MAPK inhibitor) alone 
induced NAG-1 but also inhibited induction of NAG-1 by 4,4’-dichloro DIM.  In 
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contrast induction of NAG-1 by 7,7’-dichlor DIM was not affected by these 
inhibitors suggesting that although both compounds induce NAG-1 (and ATF3) 
and their mechanism of induction are structure dependent. 
 In summary this study shows that symmetrical ring substituted 4,4’-, 5,5’-, 
6,6’- and 7,7’-dichloro and dibromo DIMs inhibit growth of LNCaP cells and also 
induce caspase dependent apoptosis in this cell line.  The dihalo DIMs induce 
NAG-1 and ATF3 and these responses are related in part to their 
apoptotic/antiproliferative effects.  However mechanistic studies suggest that 
activation of protein kinases by dihalo DIMs may play a role in the activity of 
these compounds, moreover, these effects may be structure-dependent and are 
currently being investigated. 
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
5.1 Inhibition of ER-negative breast cancer cell growth by SAhRMs by  
      induction of pro-apoptotic protein HES-1 
  Selective receptor modulators have been developed for therapeutic uses 
in hormone related diseases. Our laboratory is investigating new mechanism-
based/receptor modulating drugs for the treatment of advanced stage breast 
cancer where cytotoxic chemotherapy is the only current available treatment. 
 It has been reported that SAhRMs are effective for treatment of ER+ 
breast cancers (168, 349) and in this study their effects on ER-negative breast 
cancer cells were investigated.  MDA-MB-453 and BT-474 are ER negative 
breast cancer cell lines that over express epidermal growth factor receptor 2 
EGFR2, erbB2 and exhibit high constitutively active kinase activities. Our results 
showed that treatment of both cell lines with TCDD induced CYP1A1 expression 
and proteasome-dependent degradation of the AhR.  Low but significant 
induction of CYP1A1 was also observed for the SAhRMs 6-MCDF and DIM.  
However these compounds did not downregulate AhR levels.  TCDD (10 nM), 
MCDF (2 and 5 M), and DIM (10 and 20 M) all significantly inhibited MDA-MB-
453 and BT-474 cell proliferation but did not significantly affect the percent 
distribution of the cells in G0/G1, S or G2/M phases of the cell cycle. TCDD and 
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the SAhRMs had minimal effects on the expression of ErbB2 and pErbB2, 
mitogen activated protein kinase 1/2 (MAPK1/2) or phospho-MAPK1/2, whereas 
the MAPK inhibitor UO126 inhibited cell proliferation and phosphorylation of 
MAPK.  These data coupled with results obtained for other activated kinase 
pathways demonstrate that TCDD and SAhRMs uniquely inhibit growth of ER-
negative MDA-MB 453 and BT-474 breast cancer cells through kinase-
independent pathways.  Our study showed that the pro-apoptotic protein HES-1 
is induced by TCDD, DIM and 6-MCDF and this represents a possible 
mechanism for mediating the growth inhibitory effects observed for these 
compounds.  Current studies are further investigating the mechanism of HES-1 
induction by AhR agonists in ER-negative breast cancer cells and determining 
the role of HES-1 and other proteins in mediating the antiproliferative effects of 
these compounds in these highly aggressive ER-negative cells.  
     
5.2  Structure activities of symmetrically substituted DIMs in prostate   
cancer cells                                                                                                                                                                                                           
Ring-substituted DIMs exhibit potent anticancer activities (330, 404), 
however the structure-dependent effects of these compounds as antiandrogens 
have not been reported.  This study investigated the structure-dependent 
androgenic/antiandrogenic activity of several symmetrical dichloro- and dibromo 
DIM isomers.  Initial transactivation studies in LNCaP and 22Rv1 cells 
transfected with an androgen responsive construct (pPB) containing a probasin 
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promoter insert showed that both 7,7'-dichloro- and 7,7'-dibromo DIMs exhibited 
partial androgenic activity.  Most of the other isomeric substituted DIMs, 
including 4,4'-dichloro DIM and 4,4'-dibromo DIM, exhibited antiandrogenic 
activity in the transactivation assay.  Structure-dependent differences were also 
observed for the effects of 4,4'- and 7,7'-dihalo DIMs on AR expression in 
LNCaP cells.  Like DIM, 4,4'-dichloroDIM and 4,4'-dibromo DIM did not affect AR 
protein levels for up to 48 hr and inhibited dihydrotestosterone (DHT)-induced 
responses without affecting cytosolic or nuclear AR distribution.  In contrast, the 
AR agonist activity of 7,7'-dihalo DIMs was significantly decreased after 48 hr, 
and this was due to decreased AR mRNA and protein levels, and the latter 
response was proteasome-independent.  Results of this study demonstrate that 
the antiandrogenic activity of symmetrical dihalo DIMs was structure-dependent 
and the 7,7'-dihalo DIMs exhibited partial AR agonist activity, whereas 4,4'-, 5,5'- 
and 6,6'-dihaloDIMs and DIM were antiandrogens in transactivation assays.  
The mechanisms of action of ring-substituted DIMs were also structure-
dependent since 4,4'- and 5,5'-dihalo DIMs and DIM did not affect AR 
expression, and 6,6'- and 7,7'-dihaloDIMs induced degradation of AR protein 
and AR mRNA levels. 
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5.3  Mechanism of action for the antiproliferative effects of symmetrically  
       substituted dibromo and dichloro DIMs 
 Preliminary results with the dihalo DIMs showed that all the dihalo series 
of compounds inhibited growth of LNCaP and 22Rv1 prostate cancer cells.  
Thus despite the structure dependent effects on AR expression in LNCaP and 
22Rv1 cells all of the compounds were potent inhibitors of cell proliferation.  
Treatment of LNCaP cells with 20 µM 4,4’- and 7,7’-dichloro and dibromo DIMs 
induced caspase dependent apoptosis.  Since previous results showed that DIM 
and ring substituted DIMs induce ER stress which leads to activation of 
apoptosis in pancreatic cells (430) we also investigated the activation of ER 
stress by dihalo DIMs in LNCaP cells after treatment for 48 hr. However, 
treatment with the ring substituted DIMs did not enhance expression of the 
stress protein GRP78 and this clearly demonstrates the cell context dependent 
differences in the mechanism of action of these compounds.  However, the 
dihalo DIMS induced NAG-1 and ATF3, two proapoptotic proteins which could in 
part be responsible for the antiproliferative and pro-apoptotic effects that were 
observed.          
 In summary, this study describes development of new mechanism based 
pharmaceutical agents for treatment of various cancers.  The search for new 
and improved drugs is essential since many of the cancer become drug-resistant 
after prolonged used of a specific compound and development of new agents is 
essential.  Moreover for ER-negative breast cancer, it is very important to find 
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new mechanism based drugs for their treatment since current chemotherapies 
are not highly effective.  
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